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CHAPTER 1
1.1. Introduc  on 
More than two decades ago for the fi rst time an expansion of a repeated microsatellite 
sequence was discovered to be the cause of a disease. A CGG triplet repeat expansion in the 
gene responsible for fragile X syndrome was found (VERKERK et al., 1991). In the same year the 
mutation in fragile X syndrome was identifi ed, a CAG trinucleotide repeat expansion in the AR 
gene was found to be the cause of a X-linked progressive neurodegenerative disorder called 
spinal and bulbar muscular atrophy (SBMA), or Kennedy disease (LA SPADA et al., 1991). The 
CAG trinucleotide repeat expansion in the AR gene results in a mutant androgen receptor (AR) 
with an expanded polyglutamine (polyQ) tract (LA SPADA et al., 1991). Next to SBMA, eight other 
neurodegenerative disorders have since been identifi ed resulting from an expanded polyQ 
protein (Table 1). These disorders are Huntington disease (HD), the spinocerebellar ataxias 
(SCAs) 1, 2, 3, 6, 7, and 17), and dentatorubro-pallidoluysian atrophy (DRPLA) (Table 1). 
This chapter will fi rst introduce a group of inherited disorders caused by a triplet repeat 
expansion and provide a short overview of the main characteristics of polyQ disorders 
(paragraph 1.2). The underlying clinical and molecular genetics of the most prevalent and 
best studied polyQ disorders, HD and SCA3, will be extensively reviewed in paragraph 1.3 
and 1.4. While I will provide a short overview of the disease-causing polyQ proteins and the 
role of known disease mechanisms of the other polyQ disorders; DRPLA, SBMA, and SCAs 1, 2, 
6, 7 and 17, in paragraph 1.5. Next, opportunities for protein lowering approaches of polyQ 
disorders will be discussed (paragraph 1.6). What can we learn from other neurodegenerative 
disorders where genetic therapies are in development or already used as therapy (paragraph 
1.7). The challenges in delivery and cellular uptake of genetic therapies for neurodegenerative 
disorders to the brain and specifi cally neurons will be discussed in paragraph 1.8. Finally, the 
scope and outline of this thesis “developing genetic therapies for polyglutamine disorders” 
will be defi ned.
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11.2. Triplet repeat expansion disorders
Since the early nineties, 14 inherited triplet repeat expansion disorders have been identifi ed. 
Over the years other repeat expansions, such as tetra, penta and dodecanucleotide repeats, 
have also been linked to human diseases (MIRKIN, 2007). In this thesis I will only focus on 
neurological and neuromuscular disorders caused by triplet repeat expansions. These triplet 
repeat disorders are categorised according to their disease mechanism, being (1) functional 
cellular impairment due to loss of function of the gene containing the repeat, (2) cellular 
impairment due to production of RNA containing an expanded CUG tract, or (3) functional 
cellular impairment due to production of a protein containing an expanded polyQ. Here, I will 
provide a short overview of all three categories and successively I will focus on polyQ disorders.
Loss of protein function
As described previously, in 1991 the Human Genome Project led to the discovery of the gene 
responsible for fragile X syndrome (VERKERK et al., 1991). Fragile X syndrome is characterized 
by mental retardation, macroorchidism, and distinct facial features (JACQUEMONT et al., 2007). 
The CGG repeat is located in the 5′ untranslated region (UTR) of the FMR1 gene (KREMER et 
al., 1991; VERKERK et al., 1991). A trinucleotide repeat expansion of over 200 CGGs results in 
decreased FMR1 expression due to hypermethylation at the promoter, decreased fragile X 
mental retardation protein (FMRP) levels and loss of function (PIERETTI et al., 1991; MEIJER et 
al., 1994). The CGG repeat in fragile X syndrome is considered to be highly unstable once it 
exceeds a certain threshold length (RICHARDS AND SUTHERLAND, 1992). This phenomenon where 
the triplet repeat size increases upon the next generation, causing symptoms at an earlier age, 
is called anticipation. The full mutation alleles are derived from meiotically unstable maternal 
premutation alleles, with 55 to 200 CGG repeats (FU et al., 1991). Patients with 45 to 54 repeats 
do not transmit directly to the full mutation, even though these intermediate alleles are slightly 
unstable, particularly when maternally transmitted (ZHONG et al., 1996).
Gain of RNA toxicity
A decade after the discovery of the CGG triplet repeat expansion responsible for fragile X 
syndrome, it was found that carriers with premutation alleles developed a late age of onset 
neurodegenerative disorder called fragile X-associated tremor/ataxia syndrome (FXTAS) 
(HAGERMAN et al., 2001; JACQUEMONT et al., 2003). Although not fully penetrant, especially males 
with premutation alleles containing of more than 70 CGG repeats develop FXTAS with intention 
tremor and cerebellar ataxia (JACQUEMONT et al., 2006). Remarkably, FXTAS patients had close 
to normal FMRP protein levels, ruling out the loss of protein function as shown in fragile X 
syndrome (KENNESON et al., 2001). Peripheral blood leucocytes derived from FXTAS patients 
did show elevated FMRP mRNA levels in (KENNESON et al., 2001). Likewise, post-mortem brain 
tissue showed intranuclear mRNA inclusions (RNA foci) containing the expanded CGG-repeat 
(TASSONE et al., 2004), suggesting RNA-mediated neurodegeneration.
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Originally, the idea for gain of toxic function at RNA level came from myotonic dystrophy 
type 1 (DM1) (DAVIS et al., 1997). DM1 is a member of CTG expansion disorders that derive 
from triplet repeat expansions located in non-coding regions of the corresponding genes. 
Other CTG repeat expansion disorders are HD-like 2 (HDL2), SCA8 and SCA12. DM1 is caused 
by a CTG expansion in the 3’ UTR of the dystrophia myotonica-protein kinase (DMPK) gene 
(BROOK et al., 1992; FU et al., 1992; MAHADEVAN et al., 1992). This unstable CTG triplet repeat 
expansion results in the most common form of adult muscular atrophy. Like other triplet 
repeat expansions, DM1 shows genetic anticipation with an earlier onset and more severe 
phenotype after transmission from one generation to the next (HOWELER et al., 1989). Patients 
with DM1 were shown to have RNA foci with sequestration of the muscleblind-like 1 (MBNL1) 
splicing factor in muscle nuclei (MILLER et al., 2000; FARDAEI et al., 2001). The CUG repeat mRNA 
can form stable hairpin structures which can sequester RNA binding proteins, such as MBNL1. 
This binding of MBNL1 to double stranded CUG RNA is believed to result in depleted MBNL1 
function and consequently misregulation of alternative splicing, resulting in cellular toxicity 
(WHEELER AND THORNTON, 2007).
Gain of toxic polyQ protein function
Since the discovery that an expanded CAG repeat in the AR gene and subsequent 
translation of a mutant polyQ-repeat containing androgen receptor result in SBMA, eight 
other neurodegenerative polyQ disorders have been identifi ed (Table 1). All polyQ disorders 
are caused by a CAG triplet repeat expansion in exons of different genes and are the result 
of a gain of toxic polyQ protein function. These disorders are HD, SCAs 1, 2, 3, 6, 7, and 17, 
and DRPLA (Table 1). PolyQ disorders can be subdivided based on their main clinical feature: 
SBMA is mainly characterized by motor weaknesses, HD by chorea and the other 7 polyQ 
disorders by ataxia. 
It is known that the prevalence of each polyQ disorder signifi cantly varies per country 
and ethnicity. The prevalence of the polyQ SCAs was estimated to be about 3 per 100,000 
individuals in the Netherlands (van de Warrenburg et al., 2005) and for DRPLA 0.1 per 100,000 
individuals in Japan (HIRAYAMA et al., 1994). Worldwide HD (3-5 per 100,000), SBMA (1-2 per 
100,000), and SCA3 (0.5-1 per 100,000) are the most prevalent polyQ disorders (SCHOLS et al., 
2004; BANNO et al., 2012; PRINGSHEIM et al., 2012).
Although the mutations occur in very different genes, polyQ disorders have a lot in common 
(FISCHBECK, 2001). They all result in progressive neurodegeneration with psychiatric, cognitive 
and motor symptoms. Except for SBMA, they are all autosomal dominant and disease onset 
is around midlife. For all disorders the CAG repeat length correlates with the age of onset, 
which means that the longer the CAG repeat, the earlier the disease manifestation (DOYU et 
al., 1992; IKEUCHI et al., 1995; LUND et al., 2001; VAN DE WARRENBURG et al., 2005; ROOS, 2010). All 
polyQ disorders have a CAG repeat threshold, meaning that carriers with a CAG repeat above 
this threshold will certainly develop the disorder (Table 1). PolyQ diseases also have genetic 
anticipation, mainly upon paternal transmission, which means that the next generation will 
likely inherit a longer CAG repeat, resulting in a more severe disease with an earlier age of 
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onset (RUB et al., 2013). 
As described above, the polymorphic polyQ tract consists of CAG repeats. However, polyQ 
is also encoded by CAA codons and usually a combination of both CAG and CAA triplets 
encodes the polyQ tract. In polyQ disease-causing proteins the polyQ tracts are commonly 
composed of long uninterrupted CAG triplets. The polyQ tracts encoded by mixtures of CAG 
and CAA codons seems to be less prone to expansion and more stable upon transmission to 
the next generation (FRONTALI et al., 1999). In accordance, interruption of the CAG repeat by 
CAA (silent) or CAT (missense) mutations results is altered aggregation properties and delay 
the onset age (MENON et al., 2013).
Except for SCA6, polyQ disease-causing proteins are ubiquitously expressed throughout the 
body. Apart from the expanded polyQ repeat, mutant polyQ proteins have no homologous 
sequences or functional domains, assuming that the expanded polyQ repeat is causative 
for the observed pathogenesis (ZOGHBI AND ORR, 2000). It has been suggested that in polyQ 
disorders increasing oxidative stress and inability to protect against free radicals with age 
could lead to mitochondrial dysfunction and cell damage (KIM et al., 2003; GOSWAMI et al., 2006; 
MIYATA et al., 2008; AJAYI et al., 2012).
Table 1: Overview of polyQ disorders and CAG repeat location and number of 
causative genes.
disease gene CAG repeat
repeat 
number
symbol full name symbol full name location wt mut
HD Huntington disease HTT huntingtin exon 1 < 29 ≥ 40
SCA3/ 
MJD
spinocerebellar ataxia type 3/ 
Machado-Joseph disease ATXN3 ataxin 3 exon 10 < 40 ≥ 52
SBMA spinal and bulbar muscular atrophy/Kennedy disease AR androgen receptor exon 1 < 31 ≥ 40
SCA1 spinal and bulbar muscular atrophy/ ATXN1 ataxin 1 exon 8 < 36 ≥ 39
SCA2 Kennedy disease ATXN2 ataxin 2 exon 1 < 31 ≥ 32
SCA6 spinocerebellar ataxia type 6 CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit exon 47 < 18 ≥ 19
SCA7 spinocerebellar ataxia type 7 ATXN7 ataxin 7 exon 3 < 35 ≥ 38
SCA17 spinocerebellar ataxia type 17 TBP TATA box-binding protein exon 3 < 42 ≥ 50
DRPLA dentatorubral-pallidoluysian atrophy ATN1 atrophin 1 exon 5 < 35 ≥ 49
Abbreviations: wt: normal repeat size, mut: full penetrant repeat size
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A prominent pathological hallmark of these diseases is the accumulation of aggregated 
polyQ proteins in the brain (DAVIES et al., 1997). However, the exact role of protein aggregation 
in disease pathogenesis is controversial and whether the aggregates are neurotoxic or 
neuroprotective is still under debate (KLEMENT et al., 1998; SAUDOU et al., 1998; YAMADA et al., 
2006). Probably the smaller soluble polyQ species generated by proteolytic cleavage during 
the aggregation process are the toxic entities and the large SDS-insoluble aggregates may 
likely be less harmful end products of the upstream toxic event (SHAO AND DIAMOND, 2007). 
Misfolding of the expanded polyQ proteins probably results in proteolytic cleavage and altered 
interactions, resulting in neurodegeneration and neuronal loss (SHAO AND DIAMOND, 2007).
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11.3. Hun  ngton disease
HD is an autosomal, dominantly inherited neurodegenerative disorder. HD is rare, but more 
common in Western countries. The prevalence of HD in America is approximately 5 in 100,000 
(SHOULSON AND YOUNG, 2011) and in Europe, the prevalence of HD may be even higher with 
estimates in England and Wales as high as 12 in 100,000 individuals (RAWLINS, 2010). 
Post-mortem studies show that there is a 10-20 percent weight reduction in HD brains 
(VONSATTEL et al., 1985). Neurodegeneration occurs throughout the forebrain and specifi cally 
affects GABAergic medium spiny neurons of the striatum (LEVESQUE et al., 2003). Severe cell loss 
in the striatal complex, the caudate nucleus and putamen, results in striatal atrophy (HALLIDAY 
et al., 1998). This causes an enlargement of the lateral ventricles. The medium spiny projection 
neurons, containing enkephalin, are more susceptible to degeneration than substance P 
containing projection neurons while interneurons seem to be spared (WALKER, 2007). With 
disease progression, degeneration expands throughout the brain and other structures become 
affected (TABRIZI et al., 2009). Cortical atrophy is characterized by thinning of the cerebral cortex 
and the underlying white matter. Neuronal loss is abundant in cortical layers III, V and VI (ROSAS 
et al., 2008) but is also prominent in the Cornu Ammonis (CA1) region of the hippocampus, 
with a reduction of about 9 percent (ROSAS et al., 2003).
Disease onset usually occurs around midlife and is clinically characterized by a combination 
of symptoms: cognitive impairments, movement abnormalities, and emotional disturbances 
(ROOS, 2010). Motor symptoms of HD include chorea and occasionally bradykinesia and 
dystonia (TABRIZI et al., 2009). Choreic movements, recognized as involuntary and unwanted 
movements, start in the distal extremities. During the course of HD these movements become 
more profound and eventually all muscles of the body are affected. These symptoms can 
initially appear as lack of concentration or nervousness and unsteady gait (KREMER et al., 1992). 
Psychiatric symptoms often precede the onset of motor symptoms. Irritability is commonly one 
of the fi rst signs and occurs throughout the course of the disease. Other psychiatric symptoms 
involve anxiety, obsessive and compulsive behaviour while apathy and psychosis can appear 
in advanced stages. However, the most frequent psychiatric symptom is depression (REEDEKER 
et al., 2012). Like psychiatric symptoms, cognitive symptoms can be present prior to the onset 
of the motor symptoms. The cognitive symptoms comprise mainly of impairment in executive 
functions, including abstract thinking, problem solving, and attention (PAULSEN AND LONG, 
2014). Furthermore, the ability to learn new skills is affected (PAULSEN et al., 2001). Altogether 
these symptoms dramatically impede social and professional functioning. Eventually patients 
are incapable to adequately perform daily activities fi nally leading to progressive disability, 
requiring full-time care, followed by death (SIMPSON, 2007). Death generally occurs 15 to 20 
years post diagnosis due to complications such as pneumonia, falls, dysphagia, heart disease 
or suicide (ROOS et al., 1993).
The disease is caused by a CAG trinucleotide repeat expansion in the fi rst exon of the HTT 
gene. The HTT gene was the fi rst autosomal disease locus to be mapped by genetic linkage 
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analysis in 1983 (GUSELLA et al., 1983) on the short arm of chromosome 4 (4p16.3). The huntingtin 
protein (htt) was found to be ubiquitously expressed throughout the body, with highest 
expression in testis and brain (STRONG et al., 1993), however, cells in the brain are specifi cally 
vulnerable to the toxic function of mutant htt. The CAG repeat expansion in the HTT gene 
results in an expanded polyQ repeat in the htt protein (THE HUNTINGTON’S DISEASE COLLABORATIVE 
RESEARCH GROUP, 1993). When the number of CAG repeats exceeds 39, the gene encodes a 
mutated form of the htt protein that is prone to aggregation. Alleles ranging from 36 to 39 
repeats, lead to reduced penetrance of the disease or to a very late onset (KREMER et al., 1992; 
MCNEIL et al., 1997; LOSEKOOT et al., 2013) and both sexes are affected with the same frequency 
(WALKER, 2007). Repeat numbers exceeding 55-60 result in clinical manifestation of the disease 
before the age of 20, known as juvenile HD (ANDRESEN et al., 2007). Intergenerational CAG 
repeat changes are extremely rare on normal chromosomes but on expanded chromosomes 
changes in CAG repeat size take place in approximately 70 percent of meioses and expansion 
is more likely via the paternal line (KREMER et al., 1995). 
There is a strong inverse correlation between repeat numbers and the age of onset of the 
disease. The repeat length accounts for approximately 70 percent of the variance in age of 
onset (ROOS, 2010). The relationship between repeat size is and rate of progression and duration 
of the disease is still under debate (ROSENBLATT et al., 2012). Neuropathological changes, such as 
atrophy and the number of aggregates found in the brain are clearly correlated with the CAG 
repeat number. 
For patients, only symptomatic treatment is available and a treatment to slow down the 
progression or delay the onset of the disease remains elusive.
Huntingtin protein
When the HTT gene was discovered in 1993, the htt protein had an unknown function. 
Since then, enormous research efforts have revealed many functions of the wild-type protein 
(discussed in the present paragraph) and many toxic gain of functions of the mutant protein 
(discussed in the next paragraph) (Figure 1). 
Wild-type htt is mainly localized in the cytoplasm, although a small proportion is present in 
the nucleus (HOOGEVEEN et al., 1993; DE ROOIJ et al., 1996; KEGEL et al., 2002). The protein is known 
to be associated with microtubules, the plasma membrane, Golgi complex, the endoplasmic 
reticulum (ER), and mitochondria. Furthermore htt is associated with vesicular structures, such 
as clathrin-coated and non-coated vesicles, autophagic vesicles, endosomal compartments 
or caveolae (KEGEL et al., 2005; ATWAL et al., 2007; ROCKABRAND et al., 2007; STREHLOW et al., 2007; 
CAVISTON et al., 2011).
Three of the fi rst 17 amino acids at the amino terminus of htt are lysines, which are targets 
for post translational modifi cations that regulate htt half-life and are proposed to be involved 
in targeting htt to various intracellular membrane-associated organelles (KALCHMAN et al., 1996; 
STEFFAN et al., 2004; KEGEL et al., 2005; ATWAL et al., 2007; ROCKABRAND et al., 2007). The polyQ repeat 
starts at the 18th amino acid and is thought to form a polar zipper structure, important for the 
interaction between different polyQ-containing transcription factors (PERUTZ et al., 1994; HARJES 
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1AND WANKER, 2003). The polyQ stretch is followed by a polymorphic polyproline repeat, which is 
thought to be involved in keeping the protein soluble (STEFFAN et al., 2004). Additionally, three 
main HEAT (htt, elongation factor 3, protein phosphatase 2A, and the yeast PI3-kinase TOR1) 
repeat motifs are present which are known to form superhelical structures and are involved in 
protein-protein interactions (TAKANO AND GUSELLA, 2002; LI et al., 2006). Htt is palmitoylated at 
the cysteine residue 214 by htt interacting protein (Hip) 14, which is thought to be involved in 
htt traffi cking (HUANG et al., 2004). Htt has various proteolytic cleavage motifs, with a hotspot 
between amino acid 500 and 600 that are recognized by various proteases, such as caspases 
1, 3, 6, 7 and 8 and calpain (GAFNI AND ELLERBY, 2002; WELLINGTON et al., 2002; KIM et al., 2006). The 
signifi cance of wild-type htt cleavage is not completely clear, but the N-terminal proteolytic 
cleavage products tend to be traffi cked across the nuclear membrane (WARBY et al., 2008). In 
the case of mutant htt, the accumulation of N-terminal proteolytic cleavage products in the 
nucleus has major impact on the pathogenesis (see below).
Mutant huntingtin: gain of toxic function
Although countless toxic gain of functions of the mutant htt have been proposed in the 
last two decades, the exact order of pathogenic events in HD, as well as interactions between 
mutant htt and other cellular proteins, are still poorly understood. Mutant htt is known to 
undergo conformational changes and interferes with various cellular processes, such as cellular 
traffi cking, inhibition of chaperones, proteasomes, and autophagy, causing accumulation of 
htt and other abnormally folded proteins (Figure 1).
The characteristic protein aggregates are located throughout the brain and can already 
be found before the onset of the fi rst symptoms (WEISS et al., 2008). The rate of aggregate 
formation is correlated to the length of the polyQ repeat (LEGLEITER et al., 2010), although there 
is growing evidence suggesting that these aggregates are not good indicators for disease 
onset and progression (WANKER, 2000; VAN ROON-MOM et al., 2006). Whether accumulation 
of these aggregates is neurotoxic or neuroprotective is still under debate but increasing 
evidence suggests that soluble shorter mutant htt, and fragments thereof, are the main toxic 
components (DAVIES et al., 1997; SAUDOU et al., 1998; ARRASATE et al., 2004; SATHASIVAM et al., 2013). 
Mutant htt is more subject to increased caspase activity and proteolytic cleavage of mutant htt 
results in the formation of small toxic N-terminal mutant htt fragments (Figure 1) (COOPER et 
al., 1998). In HD brains, more htt protein fragments are found within the striatum compared to 
control brains, as well as upregulation of caspases, suggesting that cleavage may be disease 
specifi c (MENDE-MUELLER et al., 2001; GRAHAM et al., 2010). Furthermore, strong evidence was 
presented for an important role of htt protein fragments in the pathogenesis of HD, as a HD 
mouse model containing capase-6-resistant expanded htt did not show neuronal dysfunction 
in contrast to the same mouse with caspase-6-sensitve expanded htt (GRAHAM et al., 2006). 
The only difference between these mice was the presence or absence of a 586 amino acid 
caspase-6 cleaved htt fragment containing the expanded polyQ repeat.
Although many genes and proteins have been identifi ed to be involved in the HD 
pathogenesis, there is not one main cellular process affected in HD. Below I will review the 
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best studied cellular processes known to be involved in HD pathology.
Transcriptional deregulation
Like other polyQ disorders, altered gene expression is a prominent molecular hallmark of 
HD. As described above, mutant htt is proteolytically cleaved and N-terminal fragments are 
abundant in the nucleus, where they form aggregates (COOPER et al., 1998). Various transcription 
factors have been found to co-localize with htt aggregates, such as TATA box-binding protein 
(TBP), cAMP response element-binding protein binding protein (CBP) and p53 (STEFFAN et al., 
2000; VAN ROON-MOM et al., 2002). These co-aggregated proteins can no longer assert their 
normal function and could thereby contribute to transcriptional deregulation (NUCIFORA, JR. 
et al., 2001). A large set of genes involved in cellular processes affected have been found to 
be differentially expressed in various cellular and animal models of HD (CHA, 2007) and HD 
patient-derived post-mortem brain (HODGES et al., 2006). In HD, mutant htt binds less effi cient 
to the RE1 silencing transcription factor (REST), causing transcriptional repression of various 
genes, including the brain-derived neurotrophic factor (BDNF) (ZUCCATO et al., 2001; ZUCCATO et 
al., 2007). BDNF is vital for neuronal survival and is involved in synaptic plasticity processes 
(HUANG AND REICHARDT, 2001). Next to reduced gene transcription, mutant htt also disrupts 
vesicular transport and release of BDNF, possibly leading to excitotoxicity (GAUTHIER et al., 2004).
Impaired protein degradation
Protein aggregates in HD patient-derived brain material shows a clear co-localization of htt 
and ubiquitin (DIFIGLIA et al., 1997), suggesting an involvement of the ubiquitin-proteasomal 
protein degradation in the disease. Mutant htt is misfolded, resulting in an aggregation-prone 
conformation (ROUSSEAU et al., 2009). Misfolded, aggregation-prone proteins are generally 
cleared either by the ubiquitin-proteasome system (UPS) (short-lived proteins) or through 
the autophagy-lysosome pathway (long-lived cytoplasmic proteins and protein complexes) 
(RUBINSZTEIN, 2006). Aggregated htt protein and long stretches of Qs are known to impair the 
UPS in vitro and in post-mortem brain tissue (BENCE et al., 2001; VENKATRAMAN et al., 2004; DIAZ-
HERNANDEZ et al., 2006; RASPE et al., 2009; PARK et al., 2013B), resulting in an ineffi cient degradation 
of mutant htt. The UPS is also involved in ER-associated protein degradation (ERAD). In an 
overexpressing cell system mutant htt was found to sequester various ERAD proteins, thereby 
inhibiting their function (DUENNWALD AND LINDQUIST, 2008), which can result in ER stress-induced 
autophagy. To note, the involvement of the UPS in processing of expanded polyQ repeats has 
been the subject of controversy. Overexpressed N-terminal polyQ fragments were found to 
be entirely degraded by cellular proteasomes (JUENEMANN et al., 2013). Also the entrapment of 
components of the UPS in aggregates could not be validated in HD mouse models (BETT et al., 
2009; MAYNARD et al., 2009). Still, UPS activity is known to decrease with age and this reduced 
UPS activity is associated with increasing N-terminal expanded polyQ fragments aggregates in 
an HD knock-in mouse model (ZHOU et al., 2003), suggesting an involvement of UPS impairment 
in the HD pathogenesis.
In HD, two types of autophagy are affected, being macroautophagy and chaperone-mediated 
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1autophagy (CORTES AND LA SPADA, 2014). By macroautophagy cytosolic materials are sequestered 
in double membrane vesicles called autophagosomes. Although in HD cells autophagosomes 
are formed correctly and fused with lysosomes, its cargo recognition is disrupted by mutant 
htt, leading to empty autophagosomes (MARTINEZ-VICENTE et al., 2010). Thus, it seems that the 
in HD reduced macroautophagy is not caused by comprised autophagosomes formation, but 
due to impaired toxic substrate removal. Blockage of macroautophagy results in upregulation 
of chaperone-mediated autophagy (KAUSHIK et al., 2008). Chaperones usually assist target 
substrates, including phosphorylated (mutant) htt, directly to the lysosome (THOMPSON et al., 
2009; QI et al., 2012). In HD, this chaperone-mediated autophagy is impaired, probably by 
reduced phosphorylation of mutant htt (THOMPSON et al., 2009), or by binding of mutant htt 
to chaperone proteins (QI et al., 2012), resulting in a reduced clearance of mutant htt. The 
reduced macroautophagy seen in HD is perhaps initially compensated by chaperone-mediated 
autophagy, but this overcompensation decreases with age, resulting in impaired clearance of 
toxic entities, increased oxidative damage and eventually neuronal cell death (CORTES AND LA 
SPADA, 2014).
Mitochondrial dysfunction
N-terminal mutant htt fragments were found to be associated with the surface of 
mitochondria in transgenic and knock-in HD mice (PANOV et al., 2002; ORR et al., 2008). The 
accumulation of mutant htt on mitochondria increases with age and correlates with disease 
progression. Soluble mutant htt impairs microtubule-based transport of proteins that are 
involved in the transport of mitochondria, which could lead to decreased ATP supply in nerve 
terminals (ORR et al., 2008). Mutant htt is also suggested to be involved in mitochondrial energy 
metabolism defects. Metabolic energy defects could be the result of mutant htt’s capability 
to induce mitochondrial permeability transition pore opening (CHOO et al., 2004). This leads 
to low mitochondrial membrane potential and high glutamate transmission, resulting in 
overactive glutamate receptors (excitotoxicity) (CHOO et al., 2004). Abnormal mitochondrial 
respiratory chain function seen in HD leads to reduced ATP levels and subsequent partially 
depolarized membrane (MILAKOVIC AND JOHNSON, 2005). This voltage change leads to chronic 
calcium infl ux and activation of proteases, causing more reactive oxygen species production 
and eventually oxidative stress. Nevertheless, this respiratory chain impairment is probably not 
caused by mutant htt directly but as late secondary event of autophagy pathway impairment 
and transcriptional deregulation (OLIVEIRA, 2010).
Impaired axonal transport
In HD, axonal transport of mitochondria is impaired (CHANG et al., 2006). Next to transport 
of mitochondria, also transport of other organelles, such as BDNF-containing organelles and 
vesicles that store neurotransmitters and other peptides, exists in synapses (GAUTHIER et al., 
2004; LI et al., 2009). In C. elegans and D. melanogaster HD models, mutant htt overexpression 
resulted in axonal aggregate formation and subsequently impaired axonal trafficking of 
synaptic vesicles and mitochondria (PARKER et al., 2001; GUNAWARDENA et al., 2003; SINADINOS et al., 
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2009). This impaired transport of vesicles is confi rmed by the fi nding that in early stage HD 
patients synaptic vesicle proteins show an altered subcellular location (MODREGGER et al., 2002). 
Finally, various proteins involved in exocytosis are known to have decreased expression levels 
in HD patients. Proteins involved in docking and fusion of vesicles show reduced transcript 
expression, suggesting a defect in the neurotransmitter release machinery in HD patients 
(SMITH et al., 2007). 
To conclude, many cellular processes have been identifi ed that are impaired in HD, making it 
diffi cult to pinpoint offhand which processes are crucial for the disease pathology. Nevertheless, 
the toxic N-terminal polyQ protein fragments are thought to be crucial in the pathogenesis 
of HD. Why certain neuronal populations are more vulnerable to polyQ-containing peptides 
than others, remains elusive.
Loss of wild-type htt function
As described above, the main cause of HD is a gain of toxic mutant htt function. Mutant 
htt can bind and sequester wild-type htt into aggregates, potentially causing loss of wild-type 
htt function (KAZANTSEV et al., 1999; BUSCH et al., 2003). Since wild-type htt has anti-apoptotic 
properties and is important for cell survival in adult brain, loss of wild-type htt function 
could also be involved. Knock-out of the homologous htt mouse gene was found to be early 
embryonic lethal (DUYAO et al., 1995; NASIR et al., 1995; ZEITLIN et al., 1995) and htt inactivation in 
the forebrain and testis of adult mice was shown to result in progressive neurodegeneration, 
sterility and reduced lifespan (DRAGATSIS et al., 2000). Removal of endogenous htt in a D. 
melanogaster HD model was found to exacerbate the neurodegenerative phenotype (ZHANG 
et al., 2009). Htt is reported to be involved in BDNF-mediated neurotrophic support (ZUCCATO 
et al., 2001) and act as protector of brain cells from apoptotic stimuli (RIGAMONTI et al., 2000). 
These neuronal survival pathways are compromised due to mutant htt, once more supporting 
the view that loss of wild-type htt function is also involved in the disease pathogenesis.
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1.4. Spinocerebellar ataxia type 3
SCA3, or Machado-Joseph disease (MJD) (HABERHAUSEN et al., 1995), is the most common 
spinocerebellar ataxia (RANUM et al., 1995; SILVEIRA et al., 1996) and the second most common 
polyQ disease after HD (PRINGSHEIM et al., 2012). Similar to the other polyQ disorders is SCA3 
inherited in an autosomal dominant fashion (COUTINHO AND ANDRADE, 1978), neurodegeneration 
is progressive and is ultimately fatal. Current therapeutic strategies are only able to provide 
symptomatic relief (BAUER AND NUKINA, 2009). SCA3 is clinically heterogeneous, but the main 
feature is progressive ataxia, affecting balance, gait and speech. Other frequently described 
symptoms include pyramidal signs, progressive external ophthalmoplegia, dysarthria, 
dysphagia, rigidity, distal muscle atrophies and double vision (COUTINHO AND ANDRADE, 1978; 
ROSENBERG, 1992; SOONG et al., 1997; TEIVE et al., 2012). Neuropathological studies have detected 
widespread neuronal loss in the cerebellum, thalamus, midbrain, pons, medulla oblongata and 
spinal cord of SCA3 patients, as reviewed by Riess et al., (RIESS et al., 2008). 
SCA3 is caused by an expanded stretch of CAG triplets in the penultimate exon of the ATXN3 
gene on chromosome 14q32.1, encoding the ataxin-3 protein (KAWAGUCHI et al., 1994). Healthy 
individuals have up to 44 CAG repeats, whilst affected individuals have between 52 and 86 
glutamine repeats. A repeat range from 45 to 51 is associated with incomplete penetrance of 
the disease (KAWAGUCHI et al., 1994; DURR et al., 1996; PADIATH et al., 2005). SCA3 patients with 
two mutant alleles show a more severe disease phenotype than those with a single mutant 
allele (CARVALHO et al., 2008). Also, there is a clear correlation between CAG repeat size and 
age of onset, though CAG repeat length only accounts for approximately 50% of the total 
variability in age of onset (MACIEL et al., 1995). The expanded CAG repeat leads to formation 
of an expanded polyQ tract in the C-terminal region of the ataxin-3 protein, leading to a toxic 
gain of function of the protein and formation of characteristic neuronal aggregates (PAULSON et 
al., 1997B). As is the case in HD, the neurotoxic properties of these aggregates are still under 
debate since the number of aggregates does not mirror the level of neurodegeneration or 
ATXN3 CAG repeat length (RUB et al., 2006).
Extensive studies in cell and animal models over the last decade have led to the identifi cation 
of several cellular processes potentially involved in SCA3 pathology. Nonetheless, much remains 
to be elucidated regarding the toxicity resulting from mutant ataxin-3 RNA and protein, and a 
more comprehensive understanding of the many cellular processes involved would be of great 
benefi t for the development of therapeutic strategies.
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The ataxin-3 protein has a molecular weight of approximately 42 kDa, depending on the 
isoform and size of the polyQ repeat. The CAG repeat, located in the penultimate exon, is 
translated into a polyQ repeat located at the C-terminus of the protein. In blood, 56 splice 
variants of ATXN3 have been identifi ed, of which 20 could potentially be translated into a 
functional ataxin-3 protein (BETTENCOURT et al., 2010). Of these 20 isoforms, only two isoforms, 
which differ in their C-terminal tail, have been studied extensively thus far. The isoform of 
ATXN3 most commonly expressed in brain consists of 11 exons, and is translated into an 
ataxin-3 protein consisting of 361 amino acids (SCHMIDT et al., 1998; TROTTIER et al., 1998; HARRIS 
et al., 2010), based on a polyQ repeat length of 13 [Ensembl transcript ID ENST00000393287] 
(Figure 2). 
Ataxin-3 is found throughout the cell and is able to translocate from the cytoplasm to 
the nucleus and back (PAULSON et al., 1997A; SCHMIDT et al., 1998; TAIT et al., 1998; TROTTIER et 
al., 1998; POZZI et al., 2008). Different regions of the ataxin-3 protein infl uence its subcellular 
localisation. It is not yet known if ataxin-3 plays a more important role in the nucleus or the 
cytoplasm, but enzymatically active ataxin-3 has been shown to localise to the nucleus more 
frequently compared to its inactive form (TODI et al., 2007). In silico analysis predicted a nuclear 
localisation signal (NLS) in the proximity of the polyQ repeat at amino acid 273 to 286 (Figure 
2) (TAIT et al., 1998; ALBRECHT et al., 2004; ANTONY et al., 2009; MACEDO-RIBEIRO et al., 2009). This 
NLS showed a weak nuclear import activity in vitro (ANTONY et al., 2009). However, mutating 
or deleting the proposed core NLS sequence from amino acid 282 to 285 had no effect on 
subcellular distribution, thus questioning the importance of the ataxin-3 NLS in its cellular 
localisation (MUELLER et al., 2009; BREUER et al., 2010).
Another region that has been implicated in regulating ataxin-3 cellular localisation lies in 
the fi rst 27 amino acids. Ataxin-3 lacking these fi rst 27 amino acids could not be found in 
the nucleus, though the responsible mechanism involved is still unknown (POZZI et al., 2008). 
Furthermore, ataxin-3 contains six potential nuclear export signals (NES) (ALBRECHT et al., 2004; 
ANTONY et al., 2009; MACEDO-RIBEIRO et al., 2009), of which two (amino acid 77 to 99 and 141 to 
158) (Figure 2), showed signifi cant nuclear export activity (ANTONY et al., 2009; MACEDO-RIBEIRO 
et al., 2009). 
The N-terminus of ataxin-3 contains a large Josephin domain (Figure 2) that is known 
to have a low isopeptidase activity (WINBORN et al., 2008), implicating a role for ataxin-3 in 
the UPS pathway (BURNETT et al., 2003). The Josephin domain, together with the ubiquitin 
interacting motifs (UIM), can either rescue proteins from degradation or stimulate breakdown, 
by the removal of inhibitory poly-ubiquitin chains and by the regeneration of free and 
reusable ubiquitin(BURNETT et al., 2003; WINBORN et al., 2008; DO CARMO et al., 2010). The UPS 
pathway is involved in various cellular processes, such as protein degradation, endocytosis, 
transcriptional regulation and antigen presentation. Ubiquitination is a cascade of processes 
involving activating enzyme E1, transfer to ubiquitin conjugating enzymes E2 and association 
with ubiquitin ligases E3, resulting in addition of ubiquitins via isopeptide linkages to lysines 
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in the targeted protein (FANG AND WEISSMAN, 2004). Ubiquitins can bind individually, or as a 
poly-ubiquitin chain. Polyubiquitin chains linked through lysines 6, 11, 27, 29, 33, and 48 target 
proteins for proteasomal degradation. In contrast, lysine 63 or linear polyubiquitin chains have 
non-proteolytic functions such as activation of kinases and autophagy, where it is proposed to 
be involved in the biogenesis of protein inclusions (LIM AND LIM, 2011). Amino acid cysteine 14, 
histidine 119, and asparagine 134 of the Josephin domain (Figure 2) of ataxin-3 are essential 
for its isopeptidase function and are highly conserved between Josephin and other ubiquitin 
C-terminal hydrolases and ubiquitin-specifi c proteases (MAO et al., 2005; NICASTRO et al., 2005). 
The UIMs mediate selective binding to ubiquitin chains and restrict the types of chains that 
can be cleaved by the Josephin domain. Ataxin-3 is known to recognise poly-ubiquitin chains 
of four or more ubiquitins (BURNETT et al., 2003; BERKE et al., 2005) and binds the poly-ubiquitin 
linkages at lysine 48, lysine 63 and mixed linkage ubiquitin chains, with preference for lysine 
63-tagged ubiquitins (FANG AND WEISSMAN, 2004; WINBORN et al., 2008). Especially the fi rst and 
second UIMs are very important for binding of poly-ubiquitin chains, since mutations of 
leucine 229 and 249 resulted in almost abolished binding to ubiquitins (BURNETT et al., 2003). 
Ataxin-3 has been found to bind the valosin-containing protein (VCP/p97) (Figure 2) 
(WANG et al., 2000; ZHONG AND PITTMAN, 2006). VCP/p97 has numerous functions, of which one 
is the regulation of ERAD (ZHONG AND PITTMAN, 2006; LIU AND YE, 2012). A potential VCP/p97 
binding domain has been mapped to an arginine/lysine-rich motif just prior to the polyQ 
repeat (BOEDDRICH et al., 2006). The ataxin-3-VCP/p97 complex is involved in assisting targeted 
proteins to the proteasome (WANG et al., 2006). Ataxin-3 is also known to interact with the 
human homologues of yeast protein RAD23, hHR23A and hHR23B (Figure 2) (WANG et al., 
2000). hHR23A and hHR23B are involved in DNA repair pathways as well as the delivery of 
ubiquitinated substrates to the proteasome for degradation (WANG et al., 2000). The binding 
site of hHR23B to ataxin-3 is located in the second ubiquitin binding site of the Josephin 
domain, and in concordance, hHR23B was shown to compete with ubiquitin binding (NICASTRO 
et al., 2005). Cell stress resulted in altered interactions with both VCP/p97 and HR23B, which 
were found mainly in the cytoplasm, although no effect on protein degradation was reported 
(LACO et al., 2012A).
Besides the clear role of ataxin-3 in protein degradation, ataxin-3 has been shown to be 
capable of regulating the transcriptional process. Ataxin-3 is, for instance, able to repress 
matrix metalloproteinase-2 (MMP-2) transcription, and improved nuclear localisation of 
ataxin-3 through phosphorylation enhances this transcriptional repression (MUELLER et al., 
2009). Transcriptional regulation by ataxin-3 might arise through different mechanisms, since 
ataxin-3 is known to interact with numerous transcriptional regulators such as TBP-associated 
factor 4 (TAF4) (SHIMOHATA et al., 2000), CBP (MCCAMPBELL et al., 2000; CHAI et al., 2002; LI et al., 
2002), p300 (LI et al., 2002), p300/CBP-associated factor (PCAF) (LI et al., 2002), nuclear receptor 
co-repressor (NCoR1), histone deacetylase (HDAC) 3 and 6 (BURNETT, 2005; EVERT et al., 2006), 
forkhead box O (FOXO) transcription factor FOXO4 (ARAUJO et al., 2011), and RAD23 (WANG et 
al., 2000). Also, direct binding of ataxin-3 to DNA can likely take place through a leucine zipper 
motif located at amino acid 223 to 270 (Figure 2) (EVERT et al., 2006). This basic leucine zipper 
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motif was previously shown to bind to the GAGGAA consensus sequence in DNA (LANDSCHULZ 
et al., 1988). 
In summary, ataxin-3 is a well-established deubiquitinating enzyme, directly regulating 
the UPS machinery. Next to the proteasomal degradation, ataxin-3 is also implicated to be 
involved in regulation of misfolded ER protein degradation and might also directly interact 
with important transcriptional regulators and components of the DNA repair pathway.
Mutant ataxin-3 gain of toxic function
In SCA3, the expanded polyQ stretch in the C-terminus of ataxin-3 most likely leads to 
conformational changes of the protein, in turn resulting in altered binding properties, loss of 
protein function, altered subcellular localisation, aggregation, and perhaps altered proteolytic 
cleavage (JANA AND NUKINA, 2004). Although in the past decade there has been extensive research 
into the SCA3 disease mechanisms, it is still not well understood how the ataxin-3 polyQ 
expansion results in the observed pathology. In brain, the ATXN3 gene expression levels were 
not found to be higher in the predominantly affected brain regions, suggesting that ATXN3 
gene expression levels do not directly correlate with the selective neurodegeneration seen in 
SCA3 patients (SCHMITT et al., 1997). Therefore, other alterations induced by the mutant ataxin-3 
protein are most likely important in SCA3 pathogenesis as well.
One of the fi rst observations made in SCA3 patient derived brain material were the 
intracellular aggregates in neurons of the ventral pons and less frequently in the substantia 
nigra, globus pallidus, dorsal medulla, and dentate nucleus (PAULSON et al., 1997B), a feature 
that was reproduced in cell and animal models overexpressing mutant ataxin-3 (IKEDA et al., 
1996; EVERT et al., 1999; SCHMIDT et al., 2002). Mutant ataxin-3 is known to accumulate in the 
cell nucleus, a property that is required for in vivo toxicity (PAULSON et al., 1997B; SCHMIDT et al., 
1998; BICHELMEIER et al., 2007). In line with this, transgenic SCA3 mice show a decrease of soluble 
mutant ataxin-3 protein in the cerebellum during disease progression, whilst aggregate 
formation increases and the disease phenotype progresses (NGUYEN et al., 2013). The nuclear 
environment has been suggested to promote the formation of nuclear aggregates, and 
additional proteins, such as TBP and CBP, were found to be recruited to the aggregates in 
human brain (van Roon-Mom et al., 2005) and SCA3 animal models (PEREZ et al., 1998). Indeed, 
reducing nuclear localisation of mutant ataxin-3 led to a reduction in nuclear inclusions (FEI et 
al., 2007; MUELLER et al., 2009). The intranuclear aggregates only arise when ataxin-3 contains 
the expanded polyQ tract (PAULSON et al., 1997B). 
In SCA3, proteolytic cleavage of mutant ataxin-3 is thought to lead to generation of cytotoxic 
and aggregation prone shorter soluble fragments containing the expanded polyQ toxic entity 
(BERKE et al., 2004; HAACKE et al., 2006; TAKAHASHI et al., 2008; KOCH et al., 2011). In a mouse model, 
ataxin-3 derived cleavage fragments were shown to contain expanded polyQ-containing 
protein fragments C-terminal of amino acid 221 (GOTI et al., 2004). Interestingly, in the two 
SCA3 brains tested, the ataxin-3 C-terminal fragments were enriched in disease-relevant brain 
structures, such as the cerebellum and substantia nigra, compared to an unaffected brain 
region or control brain material (GOTI et al., 2004). In subsequent studies, several caspase and 
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1calpain proteolytic enzymes were identifi ed that could be responsible for the generation of the 
potentially toxic ataxin-3 fragments. These mutant ataxin-3 fragments are highly susceptible 
to aggregation (HUBENER et al., 2012), and capable of inducing both aggregation and toxicity to 
a larger extent than full length mutant ataxin-3 (IKEDA et al., 1996; TEIXEIRA-CASTRO et al., 2011).
In the past decade there has been extensive research into the SCA3 disease mechanisms, 
and various cellular processes, which I will review below, were found to be altered in SCA3.
Impaired protein degradation
Though ubiquitin chain proteolytic activity does not appear to vary between wild-type and 
mutant ataxin-3 (WINBORN et al., 2008), a widespread reduction of protein deubiquitination 
was reported in a mutant ataxin-3 cell model (WINBORN et al., 2008). This potential loss of 
deubiquitination function in SCA3 might in part be explained by trapping of ataxin-3 and 
various other components of the proteasomal machinery in the large ubiquitin-rich aggregates 
(PAULSON et al., 1997B; CHAI et al., 1999). Mutant ataxin-3 binds the ERAD-mediated protein 
degradation component VCP/p97 more effi ciently than wild-type ataxin-3, possibly because 
of conformational changes (HIRABAYASHI et al., 2001; ZHONG AND PITTMAN, 2006; LACO et al., 2012A). 
In spite of this more effi cient binding, mutant ataxin-3 seems to interfere with the degradation 
of target substrates (DOSS-PEPE et al., 2003; LACO et al., 2012A). Additionally, N-terminal ataxin-3 
fragments of 259 amino acids lacking the VCP/p97 binding domain were found to result in 
ER stress and impaired ER mediated unfolded protein response when expressed in a mouse 
model, though ERAD component levels appeared unchanged (HUBENER et al., 2011).
Not only ER degradation is altered in SCA3 but also autophagy, in which the degradation 
of cellular components through the lysosomal machinery, is impaired (Figure 3). Aggregates 
of mutant ataxin-3 were found to contain molecular components involved in autophagy. For 
instance, beclin-1, a protein crucial in the autophagy pathway was found to be trapped in 
protein aggregates in SCA3 brains (NASCIMENTO-FERREIRA et al., 2011). In a rat model overexpressing 
mutant ataxin-3, increased beclin-1 expression resulted in clearance of the mutant protein 
(NASCIMENTO-FERREIRA et al., 2011). This observation is in accordance with impairments in 
autophagy seen in other neurodegenerative disorders (WONG AND CUERVO, 2010), and the fact 
that stimulation of autophagy was found to alleviate symptoms in vivo (RAVIKUMAR et al., 2004).
These observations suggest that the SCA3 pathology may partly be the result of loss of 
function of ERAD machinery as well as compromised autophagy, together resulting in impaired 
protein degradation, accumulation of ubiquitinated proteins, and cellular stress.
Mitochondrial dysfunction
A cell model overexpressing mutant ataxin-3 with 78 CAGs showed reduced antioxidant 
enzyme levels, increased mitochondrial DNA damage, and reduced energy supply, which 
indicates impaired mitochondrial function (YU et al., 2009). Recently, mitochondrial DNA 
damage was also seen in SCA3 transgenic mice expressing full length ataxin-3 with 98 to 104 
glutamines (KAZACHKOVA et al., 2013). In the disease affected pontine nuclei of these transgenic 
SCA3 mice less mitochondrial DNA copies were seen, as compared to the unaffected 
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hippocampus (KAZACHKOVA et al., 2013). Additionally, less mitochondrial DNA copy numbers 
were observed in the mutant cells and SCA3 patient samples, implying mitochondrial DNA 
damage due to oxidative stress (YU et al., 2009). In line with this, the antioxidant enzyme 
superoxide dismutase was found downregulated in pontine brain tissue of SCA3 patients 
(ARAUJO et al., 2011), suggesting diminished antioxidant enzyme function.
Additionally, mitochondrial dysfunction was verifi ed by the fi nding that the mitochondrial 
respiratory chain complex II activity was somewhat compromised in SCA3 (LACO et al., 2012B). 
As damaged mitochondria will not be able to scavenge free radicals and prevent cell energy 
impairment as effectively, this process may therefore further increase oxidative stress in the 
cell. Oxidative stress is then able to interfere with vital cellular functions, potentially resulting 
in activation of apoptosis or excitotoxicity, two of the main causes of neuronal death (EMERIT et 
al., 2004).
Above described fi ndings indicate that, like other polyQ disorders, defects in the cellular 
defence mechanism against oxidative stress could play a role in the pathogenesis of SCA3.
Transcriptional deregulation
Since ataxin-3 has DNA-binding properties and interacts with transcriptional regulators, 
transcriptional deregulation has been suggested to play a central role in the SCA3 pathogenesis 
(RILEY AND ORR, 2006). In SCA3 and other polyQ disorders, transcription factors, together 
with polyQ proteins, are sequestered into nuclear aggregates, resulting in deregulation of 
their function as transcriptional co-repressor or activator (PEREZ et al., 1998; VAN ROON-MOM 
et al., 2005). Transcription of genes involved in infl ammatory processes, cell signalling, and 
cell surface-associated proteins were found to be altered in SCA3 cell and mouse models, 
suggesting transcriptional deregulation in SCA3 (EVERT et al., 2001; EVERT et al., 2003; CHOU et al., 
2008). Likewise, some corresponding proteins like MMP-2, amyloid-β precursor protein (APP) 
and interleukins were found to be signifi cantly increased in SCA3 patient brain material (EVERT 
et al., 2001). However, thus far no gene expression studies have been performed on SCA3 
patient material to replicate above described fi ndings.
Ataxin-3 was shown to inhibit histone acetylase activity. When mutated, this inhibition 
of histone acetylase is impaired, and increased acetylation of total histone H3 was indeed 
observed in mutant ataxin-3 overexpressing cells and human SCA3 brain material, resulting in 
an increase of transcription in SCA3 cells (EVERT et al., 2006). This transcriptional upregulation 
was supported by the discovery that in cells overexpressing mutant ataxin-3, MMP-2 was 
found upregulated (EVERT et al., 2003).
Although in SCA3 changes in gene expression have not been as extensively studied as the 
impaired protein degradation, the discovery of altered transcription of many genes suggests a 
role of transcriptional deregulation in SCA3 pathogenesis.
29





1Loss of wild-type ataxin-3 function
Although the ataxin-3 protein has been well studied, it is still uncertain to what extent 
ataxin-3 is an essential protein for normal cellular functioning. In support of an essential 
role for ataxin-3, depletion of ataxin-3 using small-interference RNA (siRNA) in cultured 
non-neuronal human and mouse cells resulted in accumulation of ubiquitinated material in 
the cytoplasm, cytoskeletal disorganisation, loss of cell adhesion and increased cell death 
(RODRIGUES et al., 2010). Likewise, knock-out of ataxin-3 was found to result in lower levels of 
stress-induced chaperone proteins in mouse brain, proposing an signifi cant role for ataxin-3 in 
cellular homeostasis (REINA et al., 2012). Other evidence however suggests that ataxin-3 is not 
necessary for normal cellular functioning. First, ataxin-3 knock-out in C. elegans did not alter 
the lifespan (RODRIGUES et al., 2007), and remarkably resulted in resistance to stress (RODRIGUES 
et al., 2011). In mice, local knock-down of endogenous ataxin-3 in the striatum for 2 months 
did not show any toxicity (ALVES et al., 2010). Likewise, ataxin-3 knock-out mice, loss of ataxin-3 
did not affect viability or fertility (SCHMITT et al., 2007; BOY et al., 2009; SWITONSKI et al., 2011). 
However, these mice did show a mild behavioural phenotype with increased anxiety, as well 
as increased levels of ubiquitinated proteins, particularly in cells that are known to express 
high levels of ataxin-3 in wild-type mice (SCHMITT et al., 2007). Furthermore, ataxin-3 has also 
been proposed to serve as a neuroprotectant, since in fl ies expressing mutant polyQ proteins 
overexpression of ataxin-3 was found to alleviate neurodegeneration (WARRICK et al., 2005). In 
contrast, double transgenic mice, co-expressing mutant and wild-type ataxin-3, did not show 
any phenotypic improvement as compared to single transgenic SCA3 mice, suggesting that 
ataxin-3 may not act as neuroprotectant (HUBENER AND RIESS, 2010)
Whilst absence of ataxin-3 thus does not appear to be directly detrimental to cellular vitality 
in most studies, the subtle phenotypes observed in rodent ataxin-3 knock-out models and the 
fact that ataxin-3 contains several well conserved regions amongst different species (ALBRECHT 
et al., 2003) indicate that the protein may not be completely dispensable.
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1.5. Clinical and molecular gene  cs of other polyQ 
disorders
Spinal and bulbar muscular atrophy
SBMA is X-linked and females typically exhibit a reduced pathology (BANNO et al., 2012). Next 
to lower motor weakness, males affected by SBMA suffer from muscle cramps, gynecomastia 
with abdominal obesity, and progressive loss of libido (KATSUNO et al., 2012). There is marked 
degeneration of anterior horn cells, bulbar neurons, and dorsal root ganglion cells (ORR AND 
ZOGHBI, 2007). Patients with 40 or more CAGs in the fi rst exon of the AR gene will develop SBMA 
(LA SPADA et al., 1991).
The AR protein is a well characterized nuclear hormone with the polyQ repeat located in 
its N-terminal transactivation domain. Next to this transactivation domain, the AR contains 
a DNA binding domain and an androgen binding domain. Binding of android to the AR in 
the cytoplasm results in translocation into the nucleus, where it dimerizes and subsequently 
stimulates transcription of androgen responsive genes. AR is essential for male foetus 
development, male sexual characteristics and spermatogenesis maintenance (BRINKMANN, 2011). 
The main pathological mechanisms leading to SBMA are altered protein-protein interactions 
and transcriptional deregulation. Intranuclear aggregates have been found to sequester AR 
binding partners (BEITEL et al., 2013). Other known polyQ gain of function mechanisms like 
mitochondrial deregulation, autophagy, and impaired transport were also suggested to be 
involved in SBMA (BEITEL et al., 2013).
Spinocerebellar ataxia type 1
SCA1 is clinically characterized by dysphagia, oculomotor disturbance, pyramidal and 
extrapyramidal disease signs, sensory deficits as well as mild cognitive decline (SASAKI et al., 
1996). SCA1 is caused by a repeat expansion of 39 or more CAGs in the fi rst coding exon (exon 
8) of the ATNX1 gene, resulting in severe cerebellar and brain stem atrophy (ORR et al., 1993). 
In healthy individuals, when the repeat is longer than 21 CAGs, it is interrupted by one to three 
histidine-encoding CAT triplets. Loss of one of these CAT codons results in an uninterrupted 
CAG repeat which is instable upon transmission (MENON et al., 2013). There is a clear inverse 
correlation between the pure CAG repeat number and the age of onset (MENON et al., 2013). 
Patients with 70 or more CAG repeats will develop a juvenile form of SCA1 (DONATO et al., 2012).
The function of the ataxin-1 protein is largely unknown, although various domains and 
phosphorylation sites have been identifi ed that are involved in protein-protein interactions, 
cellular localisation and stability (CHEN et al., 2003; LA SPADA AND TAYLOR, 2010). Ataxin-1 is able to 
translocate from the cytoplasm to the nucleus where it can interact with various transcription 
factors (ORR, 2012). Mutant ataxin-1 can still translocate to the nucleus, but transport back to 
the cytoplasm is impaired (IRWIN et al., 2005).
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1Spinocerebellar ataxia type 2
Compared to SCA1, patients with SCA2 show slower eye movements and more pronounced 
hyporefl exia and tremor (GIUNTI et al., 1998). SCA2 is characterized by olivopontocerebellar, 
spinal and cortical atrophy (GESCHWIND et al., 1997A). SCA2 is caused by a CAG repeat expansion 
in the fi rst exon of the ATXN2 gene which is translated into an expanded polyQ containing 
ataxin-2 protein (IMBERT et al., 1996). The CAG repeat is interrupted by one or two CAA triplets 
and loss of one of the CAA triplets makes the repeat very unstable upon transmission to the 
next generation. SCA2 is an unique polyQ disorder as it does not show reduced penetrance. 
Patients with 32 or more CAGs will develop SCA2, whereas individuals with 31 do not (MAGANA 
et al., 2013).
Though no reduced penetrance has been reported for SCA2, an expansion between 27 
to 33 CAGs in ATXN2 has been associated with sporadic and familial amyotrophic lateral 
sclerosis (ALS). In these cases, an altered interaction between ataxin-2 and the ALS related TAR 
DNA-binding protein (TARDBP) is thought to result in cytoplasmic aggregations in neurons 
derived from ALS patients (ELDEN et al., 2010). The ataxin-2 protein is thought to be involved 
in transcriptional regulation via its interaction with mRNA metabolism complexes (ORR, 2012).
Spinocerebellar ataxia type 6
SCA6 is a slow progressing pure cerebellar ataxia with mainly cerebellar atrophy mild 
peripheral neuropathy (SCHOLS et al., 1998). Patients show pronounced oculomotor disturbance 
and problems with the vestibulo-ocular refl ex (YABE et al., 2003). SCA6 is the only non-fatal polyQ 
disease, probably because the brain stem is not affected (ZHUCHENKO et al., 1997; GESCHWIND et 
al., 1997B). The CAG repeat located in the 3’UTR of the CACNA1A gene on chromosome 19p13 
was found when mapping the gene responsible for familial hemiplegic migraine (FHM) and 
episodic ataxia type-2 (EA-2) (OPHOFF et al., 1996). SCA6 is the result of an expansion of 20 till 
33 CAG repeats, usually located in the 3’UTR of the CACNA1A gene (RIESS et al., 1997). However, 
in SCA6 alternative splicing leads to an alpha 1A subunit of the voltage-dependent P/Q type 
calcium channel (Cav2.1) isoform containing the toxic polyQ repeat at its C-terminus. This 
alternative splicing disrupts the reading frame at the 3’ end of the CACNA1A transcript due to 
a GGCAG pentamer read-through at the intron 46 and exon 47 boundary (TSUNEMI et al., 2008). 
The pathogenic polyQ expansion in the encoded C-terminus of Cav2.1 is by far the smallest 
of all polyQ disorders and within the range of normal repeats in other polyQ disease-causing 
proteins. Cav2.1 is highly expressed in the cerebellar cortex and is expressed in only a few 
neuronal specifi c cell types. The pathology of SCA6 is thought to be a straightforward 
channelopathy, although SCA6 knock-in mice, which displayed aggregation of mutant Cav2.1, 
did not show an electrophysiological phenotype, suggesting that the polyQ repeat itself does 
not affect the intrinsic electrophysiological properties of the channels (WATASE et al., 2008). 
Proteolytic processing is implicated in disease pathogenesis, because C-terminal fragments 
and cytoplasmic protein aggregates have been reported in SCA6 post-mortem brain tissue 
(ISHIKAWA et al., 1999; KUBODERA et al., 2003).
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Spinocerebellar ataxia type 7
Next to ataxia and dysarthria, the clinical presentation of SCA7 consists of oculomotor 
disturbance, pyramidal disease signs, and visual loss due to pigmentary retinopathy (ENEVOLDSON 
et al., 1994). This clinical presentation resulting from the olivopontocerebellar atrophy is highly 
variable and depends on the length of the CAG repeat in exon 3 of the ATXN7 gene (DAVID et 
al., 1997). Individuals with 36 or more CAG repeats will certainly develop the disease around 
midlife and in the case of more than 100 repeats the disease manifests itself in infancy or early 
childhood (VAN DE WARRENBURG et al., 2001). Intermediate alleles of 28 to 35 CAG repeats are 
meiotically unstable and were shown to result in pathological repeat lengths after paternal 
transmission (STEVANIN et al., 1998).
The ataxin-7 protein is part of various transcription regulating complexes, where it functions 
as transcriptional repressor via histone acetylation (STROM et al., 2005). The pathogenic role of 
expanded ataxin-7 is still not exactly known and expanded ataxin-7 overexpression systems 
showed confl icting results on its histone acetylation activation (MARTIN, 2012). Although its 
gain of function mechanism is thus far unidentifi ed, proteolytic cleavage and entrapment 
of truncated and full-length ataxin-7 in nuclear aggregates are part of the disease process 
(HOLMBERG et al., 1998; GARDEN et al., 2002). 
Spinocerebellar ataxia type 17
SCA17 was the last identifi ed polyQ disorder. In SCA17 patients the repeat size correlates 
with clinical characteristics; patients with 43 to 50 repeats display a reduced penetrance and 
show an HD-like phenotype (ROLFS et al., 2003), patients with 50 to 60 Qs show intellectual 
disability, dystonia and pyramidal signs, whereas patients with over 60 Qs have early childhood 
onset with rapid progression (CLOUD AND WILMOT, 2012). The expanded CAG repeat, interspersed 
by CAAs, is located in exon 3 of the TBP gene (NAKAMURA et al., 2001). Because the CAG repeat 
is interrupted by CAA codons, the expanded repeat is quite stable upon inheritance, and 
anticipation is rare in SCA17.
The expanded mixed repeat encodes a polyQ expansion in the transcription initiation factor 
TBP. TBP has the longest pure glutamine stretch in the healthy human proteome and can 
contain up to 42 Qs. An homozygous expanded polyQ repeat in TBP does not impair normal 
function during development, ruling out loss of function in SCA17 (ZUHLKE et al., 2003; TOYOSHIMA 
et al., 2004). Although transcriptional deregulation has been suggested, the exact mechanism 
by which expanded TBP cause neurotoxicity is not yet known (FRIEDMAN et al., 2008).
Dentatorubro-pallidoluysian atrophy
DRPLA is characterized by progressive ataxia, dementia, choreoathetosis, myoclonus, and 
epilepsy (NAITO AND OYANAGI, 1982). It is caused by an expanded CAG repeat in exon 5 of the 
atrophin-1 (ATN1) gene, resulting in degeneration of the dentatorubral and pallidoluysian 
systems of the central nervous system (CNS) (NAITO AND OYANAGI, 1982). Patients with a repeat of 
49 or more will develop symptoms (NAGAFUCHI et al., 1994). Patients with a repeat number of 65 
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1or more will develop myoclonic epilepsy during childhood, whilst infantile onset with severe 
atrophy was reported in patients with more than 90 CAGs (SHIMOJO et al., 2001).
Although the exact function of atrophin-1 is still unknown, it was suggested to act as 
transcriptional co-repressor (ZHANG et al., 2002). Mutant atrophin-1 is prone to proteolytic 
cleavage and N-terminal fragments accumulate in nuclei of neurons (NUCIFORA, JR. et al., 2001). 
This transcriptional deregulation is thus far the only pathogenic mechanism proposed to 
contribute to the neurodegeneration in DRPLA.
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1.6. Protein lowering approaches for polyQ disorders
Most therapeutic strategies for polyQ diseases under investigation are targeting one of 
the many altered cellular processes caused by toxic mutant polyQ protein. To date, several 
clinical trials with small patient numbers have been carried out for polyQ disorders as 
symptomatic treatment to reduce depression, chorea, parkinsonian phenotype, restless leg 
syndrome, and sleepiness (OGAWA, 2004; BETTENCOURT AND LIMA, 2011; SCOTT, 2011). Clearly, there 
is demand for polyQ disorder therapies directed at preventing or slowing the progression of 
neurodegeneration. Targeting a single cellular process might be inadequate to be clinically 
benefi cial. A more effective approach would be to reduce the expression of the mutant gene 
and thereby inhibiting all downstream toxic effects. Since polyQ disorders are monogenic 
and are the result of a gain of toxic polyQ protein, reducing the expression of the CAG repeat 
expansion containing gene should ideally halt the disease progression. However, for most of 
the polyQ disorders, the exact function and importance of the polyQ-containing protein is not 
fully understood, and therefore specifi c lowering of the mutant polyQ protein levels, leaving 
wild-type levels unchanged, would be favoured over a generic downregulation (MILLER et al., 
2003; RODRIGUEZ-LEBRON AND PAULSON, 2006). For instance, TBP haploinsuffi ciency was already 
shown to cause cognitive defi cits in mice, indicating that complete knockdown of TBP cannot 
be used as potential therapy for SCA17 (ROOMS et al., 2006).
For SCA2 and SCA17, no reports are available that use oligonucleotide-mediated modulating 
therapeutics as potential treatment, although if there would be therapies existing for these 
disorders, rodent models that nicely mimic phenotypic characteristics, are available to test 
these protein lowering strategies (KELP et al., 2013; MAGANA et al., 2013). For the remaining polyQ 
disorders, there have been reports on protein lowering strategies, which will be shortly outlined 
below. I will fi rst in short describe the basic principles of oligonucleotide-mediated therapies. 
Next I will focus on studies showing non-allele-specifi c lowering of total polyQ protein levels 
(Figure 3a and b), followed by different approaches for allele-specifi c lowering of mutant 
polyQ proteins (Figure 3c), than oligonucleotide-mediated modulating therapeutics targeting 
the common denominator of polyQ disorders, being the expanded CAG repeat (Figure 3d), 
and fi nally I will discuss lowering polyQ protein levels by targeting its binding partner.
Basic principles of antisense oligonucleotide-mediated therapies
Oligonucleotide-mediated therapies are widely used to manipulate the expression of specifi c 
disease-causing genes, as well as modulating splicing to rescue protein expression. Nowadays, 
there are many types of nucleic acid molecules that can interfere at the RNA level, such as 
double stranded RNAs (siRNAs, short hairpin RNAs (shRNA), and microRNAs (miRNA or miR)) 
(MAXWELL, 2009) or single stranded RNAs (single-stranded silencing RNA (ss-siRNA)) (YU et 
al., 2012), that promote selective degradation of homologous cellular mRNAs through the 
RNA-induced silencing complex. In this thesis I will mainly focus on antisense oligonucleotides 
(AON), which are small pieces of modifi ed RNA or DNA that can hybridize to RNA. They can 
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1generate different effects depending on the AON chemistry and target site (Figure 3 and 4).
Initially, AONs were used to induce gene knockdown (DIAS AND STEIN 2002). This can be achieved 
through RNase H, a ubiquitous enzyme that cleaves RNA:RNA or RNA:DNA hybrids. The AONs 
used for this application are generally modifi ed with a phosphorothioate (PS) backbone, 
which increases AON stability and enhances uptake of the AON across cell membranes. AONs 
modifi ed further containing DNA molecules with 2’sugar moieties at the wings (DNA gapmers) 
will, upon binding to target mRNA, recruit RNase H to this RNA:DNA heteroduplex, resulting in 
cleavage and degradation of the target by nucleases (WU et al., 2004) (Figure 3a).
Suppressing RNA translation into protein is also achieved by AONs targeting the translation 
start site by sterically blocking the binding of RNA binding protein complexes, such as 
ribosomal subunits (KOLE et al., 2012) (Figure 3b). Here, AONs can be modifi ed further to 
render them RNase H resistant by addition of a methyl (Me) or methoxyethyl (MOE) group to 
the 2’O sugar ribose, which is the target cleavage site of the RNase H enzyme. The 2’ sugar PS 
AONs targeted at pre-mRNA splicing elements can also block the access of proteins involved 
in the splicing machinery, causing exon skipping or inclusion (Figure 4).
Alternatively, nucleotides have been modifi ed even further, e.g. using phosphorodiamidate 
morpholino oligomers (PMO), peptide nucleic acids (PNA) or locked nucleic acids (LNA). PMOs 
have been widely used for developmental studies in zebrafi sh embryos (NASEVICIUS AND EKKER 
2000; NASEVICIUS et al., 2000). Multiple RNase H-dependent AONs are in clinical trials including 
one against high-grade glioma in phase IIb (trabedersen (BOGDAHN et al., 2011), and one has 
even been registered as a drug for cytomegalovirus induced retinitis (vitravene) (MARWICK 1998).
Lowering total polyQ protein levels
For HD, various synthetic oligonucleotides with different modifi cations and backbones have 
been used in rodents to lower htt expression (SAH AND ARONIN, 2011). A partial reduction of 25 
to 35% of both normal and mutant htt by using shRNAs was well-tolerated in wild-type rats up 
to 9 months without signs of toxicity or striatal degeneration (DROUET et al., 2009). Non-allele-
specifi c reduction of htt transcripts up to 75% by using shRNAs (MCBRIDE et al., 2008; BOUDREAU et 
al., 2009; GRONDIN et al., 2012) and chimeric MOE PS AONs (Figure 3b) (KORDASIEWICZ et al., 2012) 
was found to be well tolerated in HD rodents and non-human primates. Intracerebroventricular 
(ICV) infusion of MOE PS AONs in transgenic HD mice for two weeks targeting both the human 
HTT transgene and endogenous murine htt resulted in reduced toxicity, extended survival, 
and improved motor performance up to 3 months post treatment (KORDASIEWICZ et al., 2012). 
Interestingly, the observed phenotypic improvement was comparable to the mice who were 
treated with exclusively the human HTT-specifi c AON, suggesting that the therapeutic reversal 
is caused by total lowering of htt protein levels (KORDASIEWICZ et al., 2012). Since htt lowering 
strategies will be most benefi cial for patients when administered over many years, the long-
term safety needs to be assessed.
Reducing AR protein expression using siRNAs was shown to reduce truncated mutant 
AR-induced toxicity in mutant AR overexpressing D. melanogaster and human cell models of 
SBMA (CAPLEN et al., 2002). However, no follow-up studies have been published since showing 
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an in vivo effect of reduced AR protein expression levels.
In a transgenic mouse model of SCA1, it also has been shown that ataxin-1 is an essential 
protein for cellular functioning (BURRIGHT et al., 1995). Depletion of endogenous ataxin-1 resulted 
in learning defi cits and decreased hippocampal paired-pulse facilitation. This suggests that 
complete knockdown of ataxin-1 is not favourable (MATILLA et al., 1998). The fi rst attempt to use 
oligonucleotides as treatment for SCA1 was performed in a SCA1 transgenic mouse model, 
where injection of lentiviral shRNAs into the cerebral ventricles resulted in reduced mutant 
ataxin-1 protein expression, causing improved neuropathology and motor coordination (XIA 
et al., 2004). Silencing of mutant ataxin-1 in vivo was also achieved with miRNAs (KEISER et al., 
2013). However, these shRNAs or miRNAs are uniquely attacking the transgenic human 82 
CAGs-containing ATXN1 gene, whereas the endogenous ataxin-1 is left untouched, limiting 
its value as a model for the human intervention where all the ataxin-1 protein will probably be 
affected.
As potential gene silencing treatment for SCA3, non-allele-specifi c downregulation of all 
ataxin-3 transcripts has been tested in both wild-type and SCA3 rats (ALVES et al., 2010). Striatal 
knock-down of endogenous ataxin-3 by injection of lentiviruses encoding shRNAs into the 
brain of wild-type rats did not show any toxicity (ALVES et al., 2010). Interestingly, in SCA3 rats, 
this non-allele-specifi c silencing of ataxin-3 in the striatum for a 2 month period resulted in 
locally reduced neuropathology (ALVES et al., 2010).
Lowering specifi cally mutant polyQ protein
Suppression of human mutant htt by 50% to 80%, for 4 months in transgenic rodent models 
of HD (expressing one human mutant htt and two wild-type murine htt transcripts) was found 
to improve motor and neuropathology abnormalities and prolonged longevity in HD mice 
(HARPER et al., 2005; WANG et al., 2005). These studies showed that allele-specifi c lowering mutant 
htt without reducing wild-type htt levels, result in an improved pathology. Various studies have 
shown that a pronounced decrease of mutant htt levels with only minor reduction in wild-type 
htt is feasible using allele-specifi c oligonucleotides (KROL et al., 2007; VAN BILSEN et al., 2008; HU 
et al., 2009B; LOMBARDI et al., 2009; PFISTER et al., 2009; CARROLL et al., 2011). One way to design 
a molecule that can distinguish between the wild-type and polyQ disease-causing allele is to 
target a single nucleotide polymorphism (SNP) that is unique to the mutant transcript (MILLER 
et al., 2003). SNPs are DNA sequences in which a single nucleotide is different between the 
two alleles of a gene. The fi rst study showing allele-specifi c silencing in HD using SNP-specifi c 
siRNAs was obtained in human cells overexpressing an additional copy of HTT containing 
the targeted SNP (SCHWARZ et al., 2006). The fi rst proof of principle of endogenous mutant htt 
silencing using this approach was shown in fi broblasts derived from HD patients (van Bilsen et 
al., 2008). Next to siRNAs, SNP-targeting RNase H-dependent AONs (Figure 3c) were shown 
to allele-specifi cally reduce mutant htt expression in patient-derived cells and a humanized HD 
mouse model (CARROLL et al., 2011; OSTERGAARD et al., 2013). Subsequent genotyping revealed a 
group of 22 SNPs that are highly associated with mutant htt alleles in a European HD cohort 
(WARBY et al., 2009). Since then, various groups have shown that the vast majority of the HD 
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1patient population could be treated in this way using 5 (75% of HD patients) or 7 (85% of the 
HD patients) different siRNAs (LOMBARDI et al., 2009; PFISTER et al., 2009). The most promising 
SNP is located in exon 67 of the HTT gene. This SNP is strongly associated with the mutant 
allele while 48% of the total Western HD population was heterozygous at this site (PFISTER et al., 
2009). Although the allele specifi city obtained from above described SNP targeting siRNAs are 
very promising, there are some limitations. The diversity of SNPs within patient populations 
would make it necessary to develop multiple oligonucleotides. Furthermore, for HD patients 
that do not exhibit heterozygosity at any of the most frequent SNPs this approach is not 
applicable. 
A cre-recombinase conditional knock-out SCA1 mouse model proved that removal of 
mutant ataxin-1 at an early stage of the disease results in clearance of nuclear inclusions 
and reversal of disease symptoms (ZU et al., 2004). To date, there is only one report on allele-
specifi c silencing of mutant ataxin-1 by targeting a heterozygous SNP. Using SNP-specifi c 
siRNAs in SCA1 patient-derived fi broblasts, only a moderate reduction of the mutant ataxin-1 
transcript was achieved, whereas the normal ataxin-1 allele was also somewhat reduced (FISZER 
et al., 2012).
Whilst absence of ataxin-3 does not appear to be directly detrimental to cellular vitality in 
most studies, subtle phenotypes were observed in rodent ataxin-3 knock-out models (SCHMITT 
et al., 2007; BOY et al., 2009; SWITONSKI et al., 2011). The fact that ataxin-3 contains several well 
conserved regions amongst different species (ALBRECHT et al., 2003), together with its important 
function in protein degradation, transcription and possibly DNA repair, suggests that a strategy 
which reduces mutant ataxin-3 protein toxicity, whilst maintaining wild-type ataxin-3 protein 
levels, would be a preferable approach for therapeutic application in SCA3. Allele-specifi c 
silencing was achieved using shRNAs directed against a SNP unique to the mutant ataxin-3 
transcript (ALVES et al., 2008). This targeted SNP at the 3’ end of the ATXN3 gene was found 
to be present in over 70% of SCA3 patients (GASPAR et al., 2001). The SNP-specifi c shRNA was 
able to specifi cally silence mutant ataxin-3 and was found to be neuroprotective in SCA3 
mouse and rat models (ALVES et al., 2008; NOBREGA et al., 2013), thus showing good promise of 
allele-specifi c reduction for clinical implementation in SCA3 patients.
In the case of SCA6, complete removal of the Cav2.1 protein would probably result in 
cerebellar dysfunction due to Purkinje cell loss (SAITO et al., 2009). However, mice with one 
functional CACNA1A allele are phenotypically normal (FLETCHER et al., 2001). Therefore, an 
allele-specifi c, or even better, a specifi c reduction of the Cav2.1 isoform containing the toxic 
polyQ repeat at its C-terminus would be preferred. This splice isoform-specific knockdown 
of polyQ-containing Cav2.1 was performed in vitro in transiently transfected human cells 
using siRNAs, as well as in human neuronal cells using miRNAs targeting a specifi c sequence 
encoding the polyQ-containing C-terminus of Cav2.1 (TSOU et al., 2011).
Recently, conditional knockdown of mutant ataxin-7, one month after onset of motor 
symptoms, resulted in reversal of aggregation and alleviated some behavioural defi cits in 
a tamoxifen-inducible SCA7 transgenic mouse model (FURRER et al., 2013). They concluded 
that a 50% downregulation of the mutant ataxin-7 protein expression already would show 
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major impact on the SCA7 phenotype. On the other hand, complete removal of the ataxin-7 
homolog in D. melanogaster was shown to be lethal at the larval stage (MOHAN et al., 2014). 
Furthermore, knockdown of ataxin-7 in D. melanogaster resulted in reduced deubiquitinase 
activity, pronounced neurodegeneration, reduced locomotion, and decreased life span (MOHAN 
et al., 2014), suggesting that complete removal of ataxin-7 is not a proper strategy for SCA7. 
Thus far only one potential treatment for SCA7 showed to some extent an allele-specifi c 
reduction of mutant ataxin-7. Using shRNAs, a reduction of mutant ataxin-7 was achieved 
by targeting an expanded CAG repeat-linked SNP located in the last coding exon of ATXN7 
(SCHOLEFIELD et al., 2009; SCHOLEFIELD et al., 2014). In a heterozygous wild-type and mutant ataxin-
7 overexpressing cell model it was found that using this SNP-specifi c shRNA a 97% and 26% 
reduction of respectively mutant and wild-type ataxin-7 was achieved, which ameliorated the 
SCA7 phenotype (SCHOLEFIELD et al., 2009). However, in patient-derived fi broblasts this allele-
specifi c reduction of mutant ataxin-7 transcript levels was less pronounced and was only found 
at very low doses of SNP-specifi c shRNAs (SCHOLEFIELD et al., 2014), questioning the allele-
specifi city of this particular small RNA, especially at higher dosage or of more realistic (less 
favourable) agent : target ratios.
PolyQ expansion-specifi c protein lowering
Another approach to achieve allele-specifi c silencing targets the common denominator of 
all polyQ disorders; their expanded CAG repeat (Figure 3d). Here selective silencing is either 
based on the hypothesis that there are structural differences between wild-type and mutant 
HTT mRNA, or based on the larger number of CAGs in the expanded repeat and subsequent 
more binding possibilities of CAG-targeting oligonucleotides. The fi rst proof for allele 
discrimination by targeting the CAG repeat was achieved in HD human fi broblasts using an 
siRNA with 7 consecutive CUG nucleotides (KROL et al., 2007). Further studies with CAG repeat 
targeting siRNAs showed a low selectivity for the mutant allele, making siRNAs unsuitable for 
CAG repeat-directed allele-specifi c silencing (HU et al., 2009B). Other chemical modifi cations 
and oligomers show much higher specifi city for expanded CAG repeat transcripts. Single 
stranded PNAs, LNAs and 2OMePS AONs targeting CAG repeats (Figure 3d) have been used 
to specifi cally reduce expanded HTT transcripts in vitro in patient-derived fi broblasts (Hu et 
al., 2009b; chapter 3). Other endogenous CAG repeat containing transcripts with important 
cellular functions were unaffected by the tested CUG oligonucleotides (Hu et al., 2009b; chapter 
3). To note, PNA selectivity was less pronounced in CAG repeat lengths (40 to 45 CAGs) that 
occur most frequently in the HD patient population. The allele-specifi c reduction with 2OMePS 
AONs and LNAs with 7-mer CUG repeats was more pronounced in the average HD CAG repeat 
length, making these 2OMePS AONs and LNAs more suitable for polyQ expansion-specifi c 
protein lowering. 
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Figure 3. AON-mediated therapeutic approaches for lowering polyQ protein levels. Two different 
polyQ protein lowering strategies used for polyQ disorders are: 1) Lowering total polyQ protein levels 
by (a) using 2’-O-modifi ed-phosphorothioate (PS) AONs blocking translation from both transcripts or (b) 
using (chimeric 2’-O-modifi ed-PS) DNA AONs resulting in a RNA:DNA hybrid, which activates RNase 
H. RNase H will cleave the mRNA and prevents the translation into a protein. 2) Specifi cally lowering 
mutant polyQ protein by (c) targeting a unique heterozygous SNP linked to the mutant transcript and 
subsequently RNase H-induced cleavage of the mutant mRNA or (d) targeting the expanded CAG 
repeat by using CUG triplet AONs complementary to the CAG repeat, resulting in polyQ expansion-
specifi c protein lowering.
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Lowering polyQ protein levels by targeting its modulating partner
Next to targeting the (mutant) transcript directly, targeting binding partners to lower polyQ 
protein levels have been recently proposed as potential therapeutic intervention for various 
polyQ disorders. For SBMA, a possible approach to lower AR protein levels that does not 
directly target the AR, but targets a binding partner of AR, acts through miRNAs. Exploration 
of miRNA expression differences in the spinal cords of mice expressing full length wild-type 
AR and mutant AR resulted in the identifi cation of upregulated miR-196a (MIYAZAKI et al., 2012). 
This miR-196a regulated CUGBP Elav-like family member 2 (CELF2). CELF2 recognizes the AR 
exon 1-internal CUGCUGCUG sequence and by binding increases AR mRNA stability (MIYAZAKI 
et al., 2012). Lentiviral miR-196a injection in the hind limb skeletal muscle of SBMA mice 
resulted in reduced levels of the polyQ-specifi c antibody 1C2-positive aggregate formation in 
the spinal cord and improved motor symptoms (MIYAZAKI et al., 2012).
For SCA1, it was recently found that multiple components of the cell-signalling RAS–MAPK–
MSK1 pathway infl uence ataxin-1 protein expression levels (PARK et al., 2013A). Pharmacological 
inhibition of this pathway was found to decrease ataxin-1 protein levels and knockout of MSK1 
rescued both behavioural and pathological phenotypes in SCA1 mice (PARK et al., 2013A). These 
results suggest that components of this pathway are potential target for oligonucleotide-
mediated lowering of mutant ataxin-1 protein levels.
In summary, most research has been performed on protein lowering treatments for HD and 
SCA1 and SCA3. Concerning the rarer polyQ disorders, less is known about the importance of 
the wild-type functions of polyQ proteins and the gain of toxic pathological mechanisms of the 
expanded polyQ proteins. For none of the polyQ disorders, much data is available elucidating 
the levels of mutant and wild-type transcript and protein present in the brain. Knowledge of 
wild-type and mutant polyQ protein levels are required to allow researchers to better assess 
the impact of non-allele-specifi c reduction of wild-type htt protein. Knowledge on these basal 
levels, together with better understanding of the signifi cance of the polyQ protein for normal 
cellular functioning, will eventually defi ne which protein lowering strategy to follow; an allele-
specifi c or general reduction.
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11.7. An  sense oligonucleo  des in therapy for other 
neurodegenera  ve diseases
Like polyQ disorders, many other neurodegenerative diseases originate from a mutation in 
a single gene, resulting in a loss- or gain of one or more toxic functions, eventually initiating 
disease onset. There are several neurodegenerative disorders where the use of AONs is a 
promising therapeutic strategy. I will show some examples where AON treatment resulted 
in therapeutic benefi t in animal models and/or clinical trials. In neurodegenerative diseases 
such as polyQ disorders, multiple sclerosis (MS), ALS and Alzheimer disease (AD), the aim of 
AON treatment can be to reduce transcript levels of disease-causing proteins. Alternatively, 
the deleterious allele can be reduced or knocked-out using allele-specifi c approaches or the 
mutated element can be eliminated by modulating pre-mRNA splicing events. The latter 
approaches are being followed for HD (chapter 4), SCA3 (chapter 5), and spinal muscular 
atrophy (SMA). In SMA, altering splicing can also be used to restore the expression of a gene 
or increase expression of a particular isoform.
Prevent translation of mutant protein in neurodegenerative diseases
ALS is a progressive neurodegenerative disorder caused by degeneration of motor neurons 
in the brain and spinal cord. This eventually leads to muscle weakening, twitching, and an 
inability to move the arms, legs, and body (AL-CHALABI AND LEIGH, 2000). Only 5% of ALS cases are 
familial and about 20% of all familial cases result from a specifi c genetic defect that leads to 
mutation of the enzyme known as superoxide dismutase 1 (SOD1) rendering the protein toxic 
and prone to aggregation (BOSSY-WETZEL et al., 2004). The AONs that have been used in ALS 
were designed to lower mRNA levels of the SOD1 transcripts and were PS modifi ed chimeric 
nucleotides with fi ve MOE modifi cations on both the 5’ and 3’ ends and 10 deoxynucleotides 
in the center to support RNase H activity. Continuous ventricular infusion reduced levels of 
mutant SOD1 in a rodent model of ALS and signifi cantly slowed disease progression (SMITH 
et al., 2006). A phase I study to test the safety of this AON in subjects with familial ALS with a 
SOD1 mutation showed no serious adverse side effects after intrathecal injection into the CSF 
(MILLER et al., 2013).
MS is an autoimmune disease of the CNS where multifocal infi ltration of autoreactive T 
lymphocytes across the blood brain barrier (BBB) takes place. Lymphocytes in MS patients 
display high levels of α-4 integrin on their surface (CANNELLA AND RAINE, 1995) and this plays an 
important role in lymphocyte migration to sites of infl ammation (ROSE et al., 2007). Decreasing 
leukocyte traffi cking into various organs has been successful using monoclonal antibodies 
against α-4 integrin (LOBB AND HEMLER, 1994). In a commonly used mouse model of MS, the 
experimental autoimmune encephalomyelitis model, AON-induced blocking of α-4 integrin 
expression reduced the incidence and severity of paralytic symptoms (MYERS et al., 2005). The 
20-mer AONs with MOE modifi cations and a PS backbone were designed to target a sequence 
just 3’ of the translation start site of the murine α-4 integrin mRNA to block its translation. 
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Subcutaneous daily injections reduced α-4 integrin surface expression. Although the site of 
actions of this particular AON is unknown, it is thought that α-4 integrin levels are reduced 
in peripheral lymphoid tissue and this prevents traffi cking of activated mononuclear cells into 
brain and spinal cord (MYERS et al., 2005). 
AD is the most common form of dementia, in which AONs are considered in yet another 
mode. Cleavage of amyloid β precursor protein (APP) at the β-secretase and γ-secretase 
site causes elevated levels of β-amyloid peptide (Aβ). This is considered a key event in the 
pathogenesis of AD (VAN BROECK et al., 2007). Point mutations near the β-secretase site in the 
human gene for APP lead to a dominantly inherited form of AD (SELKOE AND KOPAN 2003). In a 
transgenic mouse model of AD containing this mutated β-secretase site, translation of the 
APP-mRNA was blocked by AONs that bind specifi cally to the mutated β-secretase site. The 
AONs used in this study had a MOE group and capped at 5’- and 3’-ends with a PS backbone. 
Repeated injections into the third ventricle (once a week for 4 weeks) reduced the levels of 
toxic Aβ and increased the levels of soluble α-cleaved APP indicating that this could be a 
possible strategy to treat familial AD (CHAUHAN AND SIEGEL, 2007).
Modulating pre-mRNA splicing neuromuscular diseases
Other AON applications that do not induce the lowering of transcript levels are gaining 
more interest. The best-known application is the manipulation of splicing. Using AONs 
that target splice sites or exonic/intronic inclusion signals, exons can be hidden from the 
splicing machinery, resulting in skipping of the target exon (Figure 4). This can have multiple 
applications, e.g. switching from one isoform to another, skipping an aberrantly introduced 
exon to restore the normal transcript, removing disease-causing mutations from genes, or 
introducing an out-of-frame deletion that results in knock down expression of a gene. The latter 
approach is an alternative approach to AON-induced knockout through RNAse H-dependent 
cleavage of RNA:DNA hybrids (AARTSMA-RUS et al., 2009).
The most advanced clinical application of exon skipping is the exclusion of an exon allowing 
the production of an internally deleted, partially functional protein. This has been extensively 
studied as a therapeutic approach for Duchenne muscular dystrophy (DMD). Protein restoration 
has been shown in patient-derived cell cultures and in animal models this led to a rescued 
phenotype (AARTSMA-RUS et al., 2006; HEEMSKERK et al., 2009; HEEMSKERK et al., 2010). The results 
in phase I and I/II clinical trials were very encouraging (LU et al., 2003; ALTER et al., 2006; VAN 
DEUTEKOM et al., 2007; KINALI et al., 2009; GOEMANS et al., 2011). Although the primary endpoint in 
a recently conducted phase III clinical trial was not reached (FLANIGAN et al., 2014), a very clear 
phenotypical improvement in young children was seen (PRESS RELEASE JANUARY 16TH 2014, PROSENSA 
HOLDING N.V.), indicating that exon skipping is successful in DMD patients.
Intron splicing silencers can also be targeted resulting in exon inclusion. This can be used 
to restore expression of a gene or inducing expression of a particular isoform. Here, the most 
prominent application is rescue of SMA by AON mediated stimulation of the expression of 
a functional homologue. SMA is an autosomal recessive neuromuscular disorder caused by 
dysfunction and loss of motor neurons in the anterior horn of the spinal cord and lower brain 
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stem. The underlying cause of SMA is a homozygous deletion of survival motor neuron 1 
(SMN1). SMN1 depletion is viable because of the presence of the almost identical SMN2 gene. 
However, the majority of SMN2 mRNA transcripts lack exon 7, due to a silent mutation within 
this exon. This reduces the inclusion of exon 7 which results in a truncated protein and reduced 
expression of functional SMN protein (LORSON et al., 2010). Current therapeutic strategies are 
aimed at modulation the splicing of SMN2 by blocking exonic splicing silencers (ESE) or intronic 
splicing silencers (ISS), thereby increasing exon 7 inclusion. Transfecting fi broblasts with an 
AON (termed ISS-N1) blocking an ISS in intron 7 of SMN2 was found to result in inclusion of 
SMN2 exon 7 (SINGH et al., 2006). Improved effi cacy of the AON was achieved by incorporation 
of a uniform MOE chemistry and a single injection of this AONs into the cerebral ventricles in a 
severe mouse model of SMA showed increased exon 7 inclusion and SMN protein levels in the 
spinal cord resulting in increased muscle size and strength (PASSINI et al., 2011). An increased 
exon 7 inclusion could also be achieved by targeting the 3’ splice site region of exon 8 with 
2OMe and PS backbone modifi ed AONs (LIM AND HERTEL, 2001). These 2OMePS AONs were 
found to result in exon 7 inclusion and elevated SMN protein expression levels in vivo (WILLIAMS 
et al., 2009; HUA et al., 2010). 
Recently, a phase I clinical trial has been completed evaluating the safety of a MOE-modifi ed 
AON which aims at exon 7 inclusion and increased SMN protein levels (CLINICALTRIALS.GOV, 2011). 
The so called ISIS-SMNRx was intrathecally injected in 4 increasing doses in children with 
SMA. In this open label safety tolerability dose-escalating study, the MOE-modifi ed AON was 
well tolerated with no signifi cant safety or tolerability fi ndings after a single dose up to 9 mg. 
The intrathecal injection procedure was well tolerated and all SMA patients who participated 
completed the study. In the high dose treated patients, the SMN protein levels in the CSF 
more than doubled in the two highest dose cohorts and that those children continued to 
show increases in muscle function scores up to 14 months after a single injection of the MOE-




of pre-mRNA splicing. 
2’OH modifi ed RNase 
H-resistant or alternative-
ly modifi ed AONs com-
plementary to the target 
pre-mRNA can result in: 
1) inclusion of an exon 
by binding to the exonic 
splicing silencers (ESSs) 
or intronic splicing silenc-
ers (ISSs). 2) exclusion 
of an exon by binding to 
the 3’ or 5’ splice sites or 
exon-internal sequences, 
resulting in an in-frame transcript and translation of a shorter partly functional protein. Full lines indicate 
possible splicing events while dashed lines indicate non-possible events.












modifi ed AON (RIGO et al., 2012). Currently a phase II trial is ongoing with 6 mg or 12 mg doses 
of MOE-modifi ed AON administered intrathecally on days 1, 15 and 85. The interim results 
reported that the MOE-modifi ed AON was well tolerated (CLINICALTRIALS.GOV, 2012).
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11.8. Drug delivery to the brain, how to cross the blood 
brain barrier?
One major challenge of AON-mediated therapies for neurodegenerative disorders is 
delivery of the AON to the brain. In this paragraph I will describe in short the BBB function 
and how this impairs the uptake of peripherally administered drugs. I will focus in particular on 
the limitations and possibilities of AON delivery to the brain and specifi cally neurons, and will 
speculate on future clinical applications. 
Blood Brain Barrier
A unique feature of the brain is that it is separated from the blood by the BBB. This is a 
monolayer of endothelial cells forming tight junctions through the interaction of cell adhesion 
molecules (PALMER, 2010). Astrocytes with their processes surrounding the endothelial cells, 
pericytes located between the endothelial cells and astrocytes, macrophages, and the 
basement membrane, form the other structural components of the BBB. Endothelial cells of 
the BBB are characterized by only few fenestrae and pinocytic vesicles, limiting transport to 
and from the brain. In this respect, it should be noted that the BBB also largely separates 
the immune system from the brain. Despite this gate-controlling system, essential nutrients, 
such as glucose, are permitted to pass (BERNACKI et al., 2008). In neurodegenerative diseases, 
including HD, disruption of the BBB is common (TOMKINS et al., 2007; PALMER, 2010). Interestingly, 
in animal models, this can even lead to neurodegenerative changes itself (TOMKINS et al., 2007). 
The BBB has been already noticed in the work of Paul Ehrlich, Nobel Prize winning 
bacteriologist in the late 19th century. Injected dyes stained all organs except the brain and 
spinal cord. However, he did not attribute this phenomenon to the presence of a barrier but 
to dye characteristics. His student showed later that staining of the brain was possible when 
the dye was injected directly into the brain (PALMER, 2010). Subsequent studies using electron 
microscopy allowed to directly visualize the BBB. 
While essential to protect the brain, the BBB is a major challenge in CNS drug development. 
When a drug is administered to the body, a fraction will be bound to proteins (e.g. serum 
albumin, lipoprotein etc.) and a fraction will be free. The free fraction is the pharmacologically 
relevant fraction, since it is, in principle, available to cross the BBB (PALMER, 2010), depending 
on its physiochemical properties. After crossing the BBB, the drug will enter the interstitial fl uid 
and go to the target (proteins, receptors, transporters etc.). Subsequently, the interstitial fl uid 
drains to the CSF, which is produced at a rate of 500 ml/day in humans, while the ventricle 
system can house only 100-150 ml. This means that there is a continuous dehydration as well, 
making up for at least a threefold CSF circulation, allowing a continuous drainage of the brain’s 
interstitial fl uid. 
In the process of drug discovery, the aim is to fi nd a substance which is potent, selective and 
preferably bioavailable. In addition, it needs to be able to cross the BBB, and reach the target 
at a suffi cient concentration (ALAVIJEH et al., 2005). The following mechanisms are available 
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to cross the BBB. The fi rst one is simple diffusion. Small lipophilic substances which have 
a hydrogen bond are more likely to pass the BBB (GEREBTZOFF AND SEELIG, 2006). The second 
mechanism is via active transport mediated by transporter molecules. The most well-known is 
glucose with its glucose transporter 1 (GLUT1), which is the most widely expressed of the GLUT 
family (13 isoforms) (GUO et al., 2005; PALMER, 2010). Other carriers are for instance lactate and 
amino acids. A well-known drug transported via this way is levodopa (COTZIAS et al., 1967). The 
third mechanism to cross the BBB is via receptor-mediation. Receptor-mediated endocytosis 
allows macromolecules to enter the brain, such as transferrin, insulin, leptin, and insulin-like 
growth factor 1 (PARDRIDGE, 2007). 
Besides systemic mechanisms to cross the BBB, there are also techniques to bypass the BBB by 
direct infusions into the subdural space, the brain’s ventricle system, or the brain parenchyma. 
These infusions can be single, repeated, or continuous depending on the methodology, using 
either simple or sophisticated pump systems. It is possible to use one probe or more probes 
for infusion. Using the subdural and ventricle compartments, diffuse delivery of the drug into 
the brain can be achieved, while using intraparenchymal delivery, a local, but well-targeted 
delivery can be realized.
When a substance has successfully entered the brain, there are mechanisms preventing 
adequate functioning. One mechanism is active transport to remove the substance, also 
known as resistance. A superfamily of multidrug resistance proteins, belonging to the 
adenosine triphosphate (ATP)-binding cassette transporters, drives substances out by an ATP-
dependent process (PALMER, 2010). One of the most abundant proteins is the P-glycoprotein. 
This mechanism is responsible for the failure of some anticancer drugs. Another relevant family 
of egress transporters is the organic anion transporting proteins.
In the fi eld of HD, efforts are ongoing to deliver innovative drugs to the brain via the 
systemic route and drugs are designed to use any of the three mechanisms to cross the BBB, 
as explained earlier. For instance, Lee and associates described the use of a peptide nucleic 
acid as an antisense which was able to access endogenous transferrin transport pathways 
(receptor mediated endocytosis) and reach the brain in a transgenic mouse model (LEE et al., 
2002). However, there are also efforts to bypass the BBB, and to deliver the drug using either 
the ventricle system or intraparenchymally.
Cellular delivery and associated safety of oligonucleotide-mediated therapeutics
In all instances of oligonucleotide-mediated therapeutics targeting the brain, delivery is an 
issue. In vivo manipulation of gene expression with shRNA very often depends on the use of 
viral vectors (DI BENEDETTO et al., 2009; EHLERT et al., 2010; KUBO et al., 2010), as do cre-recombinase 
mediated gene excision (KOLBER et al., 2008) or gene overexpression models (ULUSOY et al., 2010; 
WOLDBYE et al., 2010). However, after reaching the brain, AONs are readily taken up by neurons, 
and are therefore independent of viral transduction of neurons (KORDASIEWICZ et al., 2012). The 
ease of delivery of the present day modifi ed AONs seems to be linked with a lack of any major 
adverse side effects, making AONs suitable candidates as potential treatment for the polyQ 
disorders.
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1Associated safety of oligonucleotide-mediated therapeutics 
Delivery of viral vectors has been associated with toxicity in the brain, mainly depending 
on viral type used. For example, adeno-associated virus (AAV) vectors have been shown to 
induce neurotoxicity when delivered to the CNS (EHLERT et al., 2010; JAYANDHARAN et al., 2011), 
although serotypes may differ in that aspect (SANCHEZ et al., 2011). Other viral types, such as 
retrovirus, show milder toxicity, but they are not suitable for investigation of long term effects 
and due to their tropism for mitotically active cells have limits in the applicability to postmitotic 
neurons (KAPLITT et al., 1998). Lentivirus causes less infl ammatory and immune response, but 
still share the disadvantage that pre-existing immunity to parental wild-type virus may cause 
an accentuated immune response. Furthermore, toxicity could also be triggered due to the 
lack of dosage regulation of virally-mediated shRNAs since they tend to produce an all-or-
nothing effect, particularly when cre-recombinase systems are used (KOLBER et al., 2008; PFEIFER 
et al., 2001). 
Although AONs have a longer half-life than, for instance, siRNAs (SMITH et al., 2006), 
eventually they are degraded allowing gene expression to return to basal levels, offering the 
possibility to discontinue treatment (SMITH et al., 2006). Obviously, in instances where long-
term manipulation is the goal, viral delivery may be desirable (HUA et al., 2010). The lack of viral 
vectors makes that AON administration allows better dosage control while reducing potential 
toxic effects (SMITH et al., 2006; HEEMSKERK et al., 2010; HUA et al., 2010). For 2’-O-modifi ed-PS 
AONs only very mild toxicity has been reported, which did not interfere with their desired 
effects after delivery in the brain via the ventricles (LIEBSCH et al., 1999; HUA et al., 2010), or in 
cultured neuronal cells (MULLER et al., 2000). Although it has been shown that PS AONs can 
have an immunostimulatory effect via toll-like receptors, appropriate 2’-O modifi cations, such 
as 2OMe can suppress these effects (ROBBINS et al., 2007; HAMM et al., 2010; MA et al., 2011). It 
is important to mention that possible toxic and immunostimulatory effects of 2OMePS AONs 
may also be a function of dosage, concentration, or duration of treatment (HUA et al., 2010).
Cellular delivery of AONs
Single stranded AONs have a very rapid uptake within minutes to hours (PITTS et al., 2009; 
MA et al., 2011). A typical AON used to modulate splicing is negatively charged and has a 
PS backbone. There are diverse chemical modifi cations to strengthen binding to the target 
mRNA and to improve pharmacokinetics by reducing nuclease-induced degradation. Most 
chemistries have modifi cations of the 2’O sugar ribose (such as 2OMePS and MOE), which 
is the target cleavage site of the RNase H enzyme, and thus have increased resistance to 
degradation. Other oligonucleotide chemistries, such as PNAs, LNAs, PMOs, are even more 
resistant to nuclease degradation. 
Conjugating arginine-rich peptides to 2OMePS and PMOs (PPMO) have been shown 
to improve cellular uptake (MOULTON et al., 2009; JIRKA et al., 2014). This is not required for 
neurodegenerative disorders when locally administered, since 2OMePS and MOE AONs are 
readily taken up by neurons and translocate to the nucleus where splicing events take place 
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(KORDASIEWICZ et al., 2012; ZALACHORAS et al., 2013). Furthermore, ICV injected PMOs resulted 
in increased SMN protein expression in the spinal cord and total brain of severe SMA mice 
(MITRPANT et al., 2013). Nevertheless, these “naked” AONs do not cross the BBB and therefore 
need to be administered into the CSF.
Interestingly, a PPMO against ataxia-telangiecatasia causing out-of-frame splicing mutations 
did cross the BBB after intravenous injections (DU et al., 2011). The PPMOs were widely 
distributed throughout the brain of wild-type mice (DU et al., 2011). Although remarkable, 
thus far no follow-up studies have been published showing an in vivo restoration of normal 
splicing and protein production in ataxia-telangiecatasia mice. Unfortunately, two PPMOs 
are abandoned as therapeutic agent since repetitive intravenous bolus injections of PPMOs 
caused lethargy and weight loss in rats (AMANTANA et al., 2007) and tubular degeneration in the 
kidneys of monkeys (MOULTON AND MOULTON, 2010).
To conclude, most in vivo data on splicing modulation or protein reduction in brain disorders 
make use of MOE PS and as described in chapter 3 to 5, 2OMePS AONs. While AONs for use 
in the CNS cannot be administered systemically, they have excellent entry into cells once they 
passed the BBB. For several chemistries, it has been shown that local injection and distribution 
via the CSF seem to be devoid of any major toxicity, making these oligonucleotide chemistries 
suitable candidates as potential treatment for the polyQ disorders.
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11.9. Scope and outline of the thesis
Although polyQ disorders are caused by CAG triplet repeat expansions in different genes, 
they all result in gain of toxic polyQ protein function and subsequently neurodegeneration. 
The polyQ disorders have a monogenic cause and thus far no therapies are available to delay 
the age of onset or slow the disease progression. Because of the well-defi ned nature of the 
primary mutation and its direct consequence on toxic polyQ protein function, reducing the 
expression of the CAG repeat expansion-containing gene should in principle contribute 
signifi cantly to halting the disease progression. Therefore, much effort has been put in reducing 
the expression of the mutant gene and thereby inhibiting all downstream toxic polyQ effects. 
Preclinical results during the course of this PhD research using oligonucleotide-mediated 
therapies for polyQ disorders, particularly HD, look promising. Despite the fact that for several 
neurodegenerative disorders oligonucleotide-mediated therapies moved from preclinical to 
clinical testing, for polyQ disorders we are not there yet.
While much research has been done on the underlying polyQ disease mechanisms, 
knowledge on mRNA and protein regulation and expression levels are limited. In Chapter 2, 
htt expression levels in adult-onset HD and juvenile HD patient-derived fi broblasts and post-
mortem brain are studied. Subtle differences in htt mRNA and protein expression between 
adult-onset and juvenile HD are described.
By targeting the polyQ-encoding transcripts, translation of mutant polyQ protein is 
reduced, inhibiting all downstream toxic polyQ effects. Chapter 3 describes the reduction of 
polyQ disease-causing proteins by specifi cally targeting expanded CAG repeat transcripts. By 
targeting the common denominator of all polyQ disorders, using CUG triplet-repeat AONs, 
mutant polyQ transcript and protein levels in several polyQ disorders were found to be reduced. 
Chapter 4 describes a novel therapeutic approach for HD through removal of cleavage 
motifs that are implicated in the formation of toxic htt polyQ fragments. In HD, expanded 
polyQ htt is known to undergo proteolytic processing, which results in toxic polyQ-containing 
htt protein fragments. Preventing the formation of these toxic polyQ htt fragments is achieved 
by AONs that induce exon skipping of HTT pre-mRNA. Thus by modifying the htt protein, 
cleavage motifs are removed and less toxic polyQ htt fragments are formed.
Chapter 5 describes the removal of the CAG repeat-encoding exon from SCA3-causing 
mutant ATXN3 pre-mRNA. This AON-mediated skipping results in the removal of the toxic 
polyQ repeat from the ataxin-3 protein. A modifi ed ataxin-3 protein is formed that lacks the 
toxic polyQ repeat, but maintains important wild-type functions of the protein. 
Chapter 6 provides a general discussion of the thesis, reviewing the main fi ndings, followed 
by recent developments and its implications for the genetic therapies proposed in this thesis 
and fi nally discussing future perspective.
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Huntington disease (HD) is an autosomal dominant neurodegenerative disorder, 
characterized by motor, psychiatric and cognitive symptoms. HD is caused by a CAG repeat 
expansion in the fi rst exon of the HTT gene, resulting in an expanded polyglutamine tract 
at the N-terminus of the huntingtin protein. Typical disease onset is around mid-life (adult-
onset HD) whereas onset below 21 years is classifi ed as juvenile HD. While much research has 
been done on the underlying HD disease mechanisms, little is known about regulation and 
expression levels of huntingtin RNA and protein.
In this study we used a unique collection of human post-mortem HD brain tissue and 
fi broblast cells to investigate huntingtin mRNA and protein expression, as well as huntingtin 
antisense isoforms. In adult-onset HD brain samples, there was only a small but signifi cant 
lower expression of mutant huntingtin mRNA compared to wild-type huntingtin mRNA, while 
protein expression levels were equal. Juvenile HD subjects did show a lower protein expression 
of mutant huntingtin compared to wild-type huntingtin protein. Additionally, in brain tissue we 
did not fi nd any evidence for a reduced expression of huntingtin antisense with an expanded 
CTG repeat, as we showed HTTAS_v1 expression in a homozygous HD patient. Finally, we have 
identifi ed a novel huntingtin antisense isoform and named it HTTAS_v2.2.
Our results highlight subtle differences in huntingtin RNA and protein expression with less 
mutant huntingtin mRNA, but equal wild-type and mutant huntingtin protein levels in adult-
onset HD. In juvenile HD mutant huntingtin protein levels were lower compared with wild-type 
huntingtin. This indicates subtle differences in huntingtin protein expression between adult-
onset and juvenile HD.
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2.2. Introduc  on
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder, 
characterized by motor, psychiatric and cognitive symptoms (ROOS, 2010). HD is caused by 
a CAG repeat expansion in the fi rst exon of the HTT gene on chromosome 4p16, resulting in 
an expanded polyglutamine (polyQ) tract at the N-terminus of the huntingtin (htt) protein. 
Carriers of 40 or more CAG repeats will develop HD, whereas people with 36 to 39 repeats 
show reduced penetrance (KREMER et al., 1992; LOSEKOOT et al., 2013). The mean disease onset 
lies between 30 and 50 years of age (adult-onset HD). HD patients with onset below 21 years of 
age ( juvenile HD), typically carry more than 55 polyQs (ROOS, 2010). The major neuropathology 
in HD occurs in the striatum and cerebral cortex but degeneration is seen throughout the brain 
as the disease progresses (VONSATTEL AND DIFIGLIA, 1998) and insoluble protein aggregates in the 
nucleus and cytoplasm of cells are a hallmark of the disease (DIFIGLIA et al., 1997).
Knowledge on regulation of htt RNA and protein expression is limited and inconsistent. 
Upregulation of mutant HTT mRNA translation in HD was suggested by interaction of the 
expanded CAG repeat with the MID1-PP2A complex (KRAUSS et al., 2013). Upregulation of 
mutant HTT mRNA translation was also suggested by HTT antisense transcript regulation 
(CHUNG et al., 2011). Two natural HTT antisense transcripts (HTTAS_v1 and v2) were identifi ed at 
the HTT locus, of which HTTAS_v1 contains a CTG repeat. Overexpression of HTTAS_v1 resulted 
in reduced HTT transcript levels, whereas HTTAS_v1 knockdown increased HTT transcript levels 
(CHUNG et al., 2011). Furthermore, in post-mortem HD brain no HTTAS_v1 with expanded CTG 
repeat could be detected. From these observations, it was suggested that HTTAS_v1 negatively 
regulated HTT transcript expression (CHUNG et al., 2011). Contrasting, in patient-derived 
lymphoblasts, no CAG repeat-related effect on total HTT mRNA was observed (LEE et al., 2013), 
suggesting that there is no difference in wild-type and mutant HTT RNA expression. To our 
knowledge, levels of wild-type and mutant htt RNA and protein in human HD tissue have not 
been assessed systematically.
In this study we have investigated htt mRNA and protein levels in a unique collection of 
human post-mortem HD brain tissue and fi broblasts. For post-mortem adult-onset HD brain 
tissue we detected a small, but signifi cant, decrease in mutant HTT mRNA levels compared 
to wild-type HTT mRNA. Moreover, both brain tissue and fi broblasts from adult-onset HD 
patients did not show difference in wild-type and mutant htt protein expression levels. In 
contrast, juvenile HD fi broblasts and brain tissue showed a small, but signifi cant, lower level 
of mutant htt protein compared to wild-type htt protein. Furthermore, similar HTTAS levels in 
(homozygous) HD and controls were found. Additionally, we identifi ed a novel HTTAS isoform 
and named it HTTAS_v2.2.
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2.3. Materials & Methods
Patient-derived fi broblasts and human brain samples
Fibroblasts derived from HD patients and controls were purchased from Coriell Cell 
Repositories, Camden, USA (Table 1). Fibroblasts were cultured at 37°C and 5% CO2 in Minimal 
Essential Medium (Gibco Invitrogen, Carlsbad, USA) with 15% heat inactivated fetal bovine 
serum (Clontech, Palo Alto USA), 1% Glutamax (Gibco) and 100 U/ml penicillin/streptomycin 
(Gibco).
Post-mortem human brain tissue was obtained from the Neurological Foundation of New 
Zealand Human Brain Bank 
in the Centre for Brain 
Research, University of 
Auckland, and the brain 
bank from the department 
of Neurology, Leiden 
University Medical Center. 
Tissue was obtained with 
the families full consent and 
with the ethical approval 
of the various institutional 
Ethics Committees. For a 
complete list of samples 
and corresponding clinical 
information, see Table 2.
CAG repeat sizing
Genomic DNA samples were isolated from patient-derived fi broblasts and human brain using 
the Wizard Genomic DNA Purifi cation Kit (Promega) according to manufacturer’s instructions 
and diluted to 50 μg/ml. The number of CAG repeats in the HTT gene was determined by PCR 
using primers “HD-1” and “HD-3” as described previously (WARNER et al., 1993), followed by 
fragment analysis on an ABI 3130 Automated Capillary DNA Sequencer (Applied Biosystems, 
Life Technologies Corporation, Carlsbad, USA). The exact PCR conditions are available on 
request. The 3’ CAA and following CAG are not counted. For the polyQ repeat the CAA and 
CAG triplet are counted and the polyQ repeat is therefore 2 units longer than the CAG repeat 
size.
RNA and genomic DNA analysis
Post-mortem brain tissue was homogenized using ceramic MagNA Lyser beads (Roche, 
Mannheim, Germany) by grinding in a Bullet Blender (Next Advance, Averill Park, USA) according 
Table 1. Patient-derived fi broblasts.





GM02173 44 17 HD 52 NA F
GM04022 44 18 HD 28 NA F
GM04855 48 20 HD 11 26 M
GM04857 50 40 homozygous HD 23 28 F
GM04281 71 17 juvenile HD 20 14 F
GM05539 97 22 juvenile HD 10 2 M
GM09197 179 18 juvenile HD 6 NA M
GM04204 18 17 control 81 NA M
Samples ranked on CAG repeat size of the longest allele. 
M: male, F: female, NA: not assessed.
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Total RNA was 
isolated from fi broblast 
cells and brain tissue 
using the Aurum Total 
RNA Mini Kit (BioRad, 
Hercules, USA), with 
an on-column DNase 
treatment for 30 min. 
RNA was eluted in 40 μl 
elution buffer and cDNA 
was synthesized from 1 
μg total RNA using the 
Transcriptor First Strand 
cDNA Synthesis Kit with 
oligo (dT) primers at 
55°C for 90 min (Roche). 
PCR was performed 
using 1 μl cDNA or 
genomic DNA, 10x 
Expand High Fidelity 
buffer with 15 mM MgCl2 (Roche), 200 μM dNTPs (Roche), 1 M Betaine (Sigma-Aldrich, St. 
Louis, USA), 15 pmol of both forward primer HttCAGFw: 5’- ATG GCG ACC CTG GAA AAG CTG 
AT -3’ and reverse primer HttCAGRev: 5’- TGA GGC AGC AGC GGC TG -3’ (Eurogentec, Liege, 
Belgium), 3 U Expand High Fidelity enzyme mix (Roche), and PCR grade water to a fi nal volume 
of 30 μl. The PCR program started with a 2 min initial denaturation at 94°C, followed by 35 
cycles of 15 sec denaturation at 94°C, 30 sec annealing at 60°C, 1 min elongation at 72°C, after 
which a fi nal elongation step was performed at 72°C for 7 min. 
PCR products were loaded on a 2% agarose gel diluted in Tris/Borate/EDTA buffer (TBE). 
DNA gel electrophoresis was performed for 1 hour at 100 V. Intensities of DNA bands were 
quantifi ed using ImageJ software. Intensity of the HTT mRNA band was divided by the 
corresponding genomic DNA band to normalize for differences in PCR effi ciency between 
wild-type and mutant HTT due to CAG repeat length.
SNP genotyping and SNP linkage by circularization (SLiC)
The procedure for SNPs rs362273 genotyping and SNP linkage by circularization on human 
brain tissue was adapted from Liu et al. (LIU et al., 2008). One μg of DNase-treated total RNA, 
together with oligo (dT) primers, was used for cDNA synthesis using SuperScript III First-Strand 
Synthesis System (Invitrogen). To improve reverse transcription of long cDNA templates, 2 M 
Betaine and 0.6 M Trehalose (both Sigma-Aldrich) were added to the reaction mixture (SPIESS 
Table 2. Post-mortem human brain tissue.





HC103 40 19 MTG 11 1 41 35 M
HC105 42 15 MTG 9 1 67 47 F
HD166 42 17 FC 32 2 80 > 70 M
HC102 43 17 MTG 10 3 64 40 M
HC107 43 19 MTG 3 3 75 58 M
HD193 44 9 FC 18 3 68 44 M
HD188 44 16 FC NA 3 64 44 M
HD195 44 22 FC 8.5 3 61 NA F
HD159 47 17 FC 42 3 41 26 F
HC114 47 21 MTG 12 NA 53 30 F
HD192 52 18 FC 62 4 37 NA M
HC104 53 18 MTG 15 3 40 15 M
HD86 84 17 FC/STR 20 3 20 16 F
HD29 84 20 FC 11 NA 11 8 F
H121 23 18 MTG 6 control 64 control F
Samples ranked on CAG repeat size of the longest allele. MTG: middle 
temporal gyrus, FC: frontal cortex, STR: striatum, PMD: post-mortem de-




AND IVELL, 2002). cDNA synthesis was performed at 42°C for 2.5 hours, followed by RNase H 
treatment at 37°C for 20 min. Next, 5 μl cDNA was used as template for long-range PCR and 
SLiC.
Taqman SNP assay
Quantitative PCR was performed using the LightCycler 480 II (Roche), according to 
manufacturer’s instructions, using a mixture containing 45 ng cDNA, 1xTaqMan® Universal 
PCR Master Mix, no AmpErase®UNG (Applied Biosystems), 1xTaqMan® SNP Genotyping 
Assay (Applied Biosystems), and nuclease-free water (Ambion) in a 20μl reaction volume. ACTB 
(Applied Biosystems, cat#Hs99999903_m1) was included as reference gene. A standard curve 
was generated using pooled equal amounts of cDNA from all samples. Quantifi cation of the 
dual-color hydrolysis of both allele-specifi c fl uorescent reporter dyes, FAM (“G” allele) and 
VIC (“A” allele), was performed with the LightCycler® 480 SW 1.5.1 software using the 2nd 
derivative method, according to manufacturer’s instructions. 
HTT antisense determination
RNA isolation as described above. PCR was performed using 1.5 μl cDNA, 10x PCR buffer 
with 20 mM MgCl2 (Roche), 200 μM dNTPs (Roche), 6 pmol primer, for HTTAS_v1, forward: 
5’-CAC CGG GGC AAT GAA TGG-3’, reverse: 5’- GTG CGG ATG GCA AGG ACA G -3’; and for 
HTTAS_v2.1/2.2, forward: 5’-GAA GGC GCG GGG CTC AAC-3’, reverse: 5’- TGC AGT GCG GAT 
GGC AAG GA -3’, 2 U FastStart Taq DNA Polymerase (Roche), 1 M ethylene glycol (Sigma-
Aldrich, St. Louis, USA), and PCR grade water to a fi nal volume of 30 μl. The PCR program 
started with a 3 min initial denaturation at 95°C, followed by 40 cycles of 10 sec denaturation 
at 95°C, 10 sec annealing at 60°C, 10 sec elongation at 72°C, after which a fi nal elongation step 
was performed at 72°C for 7 min.
PCR products were loaded on a 3% TBE agarose gel and bands were extracted using the 
NucleoSpin Gel & PCR Clean-up kit (Machery Nagel, Düren, Germany). To identify the sequence 
of the novel HTTAS isoform, PCR products were cloned into a pGEM-T Easy vector (Promega) 
and analyzed by Sanger sequencing using a T7-specifi c forward primer.
Protein isolation
Fibroblasts were detached from the culture surface with a 0.5% Trypsin/EDTA solution. After 
washing twice with HBSS, cells were resuspended in 200 μl ice cold lysis buffer, containing 15 
mM HEPES, pH 7.9, 200 mM KCl, 10 mM MgCl2, 1% NP40, 10% glycerol, 20 μg/ml BSA, and 
1 tablet Complete mini protease inhibitor EDTA free (Roche) per 10 ml buffer. Next, samples 
were sonicated 3 times 5 sec using ultrasound with amplitude 60 at 4°C. After 1 hour head-
over-head incubation at 4°C, extracts were centrifuged for 15 min at 10,000 x g and 4°C and 
supernatant was isolated. 
For brain homogenates, slices from frozen unfi xed human brain tissue were collected using 
a sliding microtome (Leica SM 2010 R.). Tissue was homogenized using ceramic MagNA Lyser 
beads (Roche) by grinding in a Bullet Blender (Next Advance) for 3 min at strength 8 in lysis 
57






buffer as described previously (HU et al., 2009). Homogenates were incubated for 1 hour in a 
head-over-head rotator at 4ºC, and centrifuged for 15 min at 10,000 x g at 4ºC. 
Protein concentrations were determined with the bicinchoninic acid kit (BCA) (Thermo Fisher 
Scientifi c, Waltham, USA) using Bovine Serum Albumin (BSA) as a standard. After addition of 
5% glycerol, samples were aliquotted, snap frozen and stored at -80°C.
Western blotting
SDS-PAGE separation of proteins was performed according to the “shorter CAG repeats” 
protocol as described previously (HU et al., 2009). Proteins were transferred to a 0.2 μm 
nitrocellulose membrane (Bio-Rad, #170-4159.) using the Trans-blot Turbo (BioRad) at 2.5A 
(constant)/25V for 10 min. Membranes were blocked for 15 min in tris buffered saline (TBS) 
containing 5% non-fat milk (Nutricia, Schiphol, the Netherlands). Next, membranes were 
incubated with primary rabbit antibody EPR5526 (Abcam, Cambridge, UK) that recognizes 
the N-terminus of the htt protein, diluted 1:5000 in blocking buffer, followed by secondary 
incubation with rabbit IRDye800 (LI-COR, Lincoln, USA) diluted 1:5000 in blocking buffer. Blots 
were analyzed on an Odyssey reader (LI-COR). Protein bands corresponding to wild-type and 
mutant htt were quantifi ed using the Odyssey software version 3.0 (LI-COR). Background 
correction was performed by sampling an empty area of the blot of the same size as the area 
that contained the positive protein band. Wild-type and mutant htt protein expression levels 
relative to total htt protein expression were calculated by dividing wild-type and mutant htt 
band intensities with total htt band intensity (wild-type + mutant).
Dot blot assay
Brain homogenates were prepared in 150 mM sucrose, 15 mM HEPES pH 7.9, 60 mM KCl, 5 
mM EDTA, 1 mM EGTA and 1 tablet Complete mini protease inhibitor EDTA free (Roche) per 10 
ml buffer. Tissue was homogenized using ceramic MagNA Lyser beads (Roche) by grinding in 
a Bullet Blender (Next Advance) for 3 min at strength 8. Next, Triton X-100 (Sigma) was added 
to a fi nal concentration of 1%. Homogenates were incubated in a head-over-head rotator 
for 1 hour at 4ºC and extracts were centrifuged for 10 min at 10,000 x g. Protein pellets were 
washed three times in 60 mM Tris and centrifuged for 10 min at 10,000 x g. Next, pellets 
were resuspended in 15% SDS and incubated overnight at 95ºC. Protein concentrations of the 
resulting pellet suspensions were determined by BCA. Per well, 100 μg of pellet suspension was 
applied to in 0.2% SDS pre-wetted cellulose acetate pore size 0.2 μm (Schleicher and Schuell, 
St. Louis, USA) membranes by vacuum application using the Bio-dot manifold (Bio-Rad). Wells 
were washed twice with 0.2% SDS and membrane was fi xed in 0.5% glutaraldehyde for 20 
min. The fi xed membrane was blocked in TBS containing Tween-20 (TBST) and 5% non-fat 
milk (Nutricia). First incubation was performed with rabbit EPR5526 antibody diluted1:5,000 
in TBST containing 5% non-fat milk. Secondary incubation was performed with mouse anti 
rabbit antibody conjugated with horse radish peroxidase (Santa Cruz, Dallas, USA), diluted 
1:10,000 in TBST containing 5% non-fat milk. Membranes were incubated with enhanced 




GraphPad Prism version 6.02 was used for statistical analysis. Typically, signifi cance was 
determined using the two-tailed paired Student’s t-test after testing for normal distribution. 
Data presented as bar graphs (means + standard deviation (SD)), whisker boxplots (whiskers = 
10-90 percentile), or scatter dot plot (line = mean).
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No diff erence in wild-type and mutant HTT mRNA levels in HD patient-derived 
fi broblasts
To measure both wild-type and mutant HTT mRNA levels we performed a PCR with primers 
fl anking the CAG repeat that separated on gel electrophoresis due to differences in their CAG 
repeat length (Figure 1a). In total four HD patient-derived fi broblasts of which 1, GM04857, 
contained a homozygous CAG repeat expansion were analyzed. For more information, see 
Table 1. Genomic DNA (gDNA) was taken along to control for differences in PCR amplifi cation 
effi ciencies across the CAG repeat. Furthermore, reverse transcription without reverse 
transcription enzyme was taken along, verifying that there was no gDNA contamination in our 
RT-PCR (Figure 1b). The two PCR products for each cell line were quantifi ed and individual 
wild-type versus mutant HTT mRNA expression ratios were calculated. Next, the average 
expression levels of wild-type and mutant HTT mRNA in the adult-onset HD fi broblasts were 
calculated. No signifi cant difference (P = 0.5168) between wild-type and mutant HTT mRNA 
















































































Figure 1. Wild-type and mutant HTT mRNA levels in HD patient-derived fi broblasts. Wild-type and 
mutant HTT mRNA PCR products were separated on gel electrophoresis by differences in their CAG 
repeat length. (a) RT-PCR products from 3 HD (GM02173, GM04022, GM04855) and one homozygous 
HD (GM04857) fi broblasts. Allelic CAG repeat sizes are indicated below each lane. gDNA was taken 
along to control for differences in PCR amplifi cation effi ciencies across the CAG repeat. (b) RT-PCR 
products with input: cDNA (+RT), cDNA lacking reverse transcriptase (-RT) and gDNA of 1 control 
(GM04204). (c) Scatter boxplot of RT-PCR from HD patient-derived fi broblasts, comparing wild-type 
and mutant HTT mRNA expression levels, relative to gDNA. Line = mean, data were evaluated using 
two-tailed student-t test, n = 3.
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More wild-type than mutant HTT mRNA in human post-mortem HD brain material
Next, we investigated HTT mRNA expression levels in post-mortem brain tissue from HD 
patients with a wide range of repeat lengths. RNA was isolated and PCR was performed with 
primers fl anking the CAG repeat. PCR products were separated by gel electrophoresis due 
to differences in their CAG repeat length (Figure 2a). Individual bands were quantifi ed and 
normalized against PCR products from gDNA (Figure S1). 
After calculating average expression, wild-type and mutant HTT mRNA levels were compared 
(Figure 2b). Although the PCR approached the plateau phase, we still found a small, but 
signifi cant, lower average mutant HTT mRNA expression 0.89 (±0.19) versus 1.15 (±0.25) of 
wild-type mRNA in post-mortem brain tissue from HD patients.
To validate the semi-quantitative RT-PCR gel electrophoresis analysis, we performed a SNP-
Figure 2. Wild-type and mutant HTT mRNA levels in HD human post-mortem brain material. Wild-
type and mutant HTT mRNA PCR products were separated on gel electrophoresis by differences in their 
CAG repeat length. (A) RT-PCR products from brain tissue derived from 10 HD patients. Allelic CAG 
repeat sizes are indicated below each lane. gDNA was taken along to control for differences in PCR 
amplifi cation effi ciencies across the CAG repeat. (B) Whisker boxplot of HD RT-PCR data, comparing 
wild-type and mutant HTT mRNA expression levels, relative to gDNA. Whiskers = 10-90 percentile, data 
were evaluated using a two-tailed student t-test, **** P < 0.0001, n = 10. (C) Scatter boxplot of SNP 
rs362273-specifi c quantitative RT-PCR on HD post-mortem brain material, comparing wild-type and 
mutant HTT mRNA expression levels, normalized to β-actin (ACTB). Line = mean, data were evaluated 
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specifi c TaqMan quantitative PCR, using probes for SNP rs362273 located at exon 57 of HTT. 
Of our post-mortem brain samples, 6 out of 14 were heterozygous for SNP rs362273. Next, 
SNP linkage by circularization (SLiC) was successfully performed to determine which allele 
has the guanine and which allele the adenine in exon 57 (LIU et al., 2008). Due to the variable 
RNA quality of brain tissue, SLiC was only possible in 4 out of 6 samples. The SNP-specifi c 
TaqMan quantitative (q)RT-PCR showed a consistent trend towards wild-type HTT. Due to the 
smaller number of brain samples that we could use for this SNP-specifi c TaqMan assay, the 
difference did not reach signifi cance. However, it confi rmed the higher expression of wild-type 
HTT mRNA compared to mutant HTT mRNA in HD post-mortem brain (Figure 2c).
No diff erence in wild-type and mutant htt protein levels in HD fi broblast and post-
mortem brain
We examined levels of SDS-soluble wild-type and mutant htt protein levels in patient-
derived fi broblasts by Western blot (Figure 3a). In the homozygous HD fi broblast GM04857, 
only one protein band was visible because the difference in protein size between the htt 
protein expressed from the two alleles is too small to separate by Western blot. For the other 
samples, the separated wild-type and mutant htt protein bands were quantifi ed and individual 
wild-type versus mutant htt protein ratios were calculated (Figure S2). Next, we averaged all 
data from individual measurements and compared wild-type and mutant htt protein levels. 
No signifi cant difference between wild-type and mutant htt protein levels in patient-derived 
fi broblasts was found (Figure 3c). 
We then analyzed SDS-soluble wild-type and mutant htt protein levels in post-mortem 
human HD brain homogenates (Figure 3b). As with the HD fi broblasts, there was no difference 
in wild-type and mutant htt levels in HD brains (Figure 3d and Figure S2). We also examined 
aggregation of mutant htt in our post-mortem human HD brain tissue by investigating SDS-
insoluble htt using a dot blot assay. We found comparable levels of SDS-insoluble htt for 
subjects HC105 and HD166, which had the same polyQ stretch of 44, and more insoluble htt 
for subject HC107 which had a slightly longer polyQ stretch of 45 (Figure 3e).
Soluble wild-type and mutant htt protein levels are similar in both fi broblasts and brain, 
while in fi broblasts it is known that mutant htt protein does not aggregate (SATHASIVAM et al., 
2001). We found more htt protein aggregation in the brain sample with the longer polyQ 
repeat, but there was no decrease in mutant htt protein levels on Western blot.
More wild-type than mutant htt protein in juvenile HD fi broblasts and post-mortem 
brain
Next, we used Western blot to analyze SDS-soluble levels of wild-type and mutant htt protein 
in juvenile HD samples. Analysis of juvenile HD fi broblast cell lines showed a signifi cant higher 
level of wild-type htt protein compared to mutant htt (0.55 versus 0.45 (±0.05)) (Figure 4a and 
c). Western blot analysis of post-mortem juvenile HD brain lysates also showed a signifi cantly 
higher level of wild-type htt protein with respect to mutant htt (0.53 versus 0.47 (± 0.06)) 
(Figure 4b and d). 
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Figure 3. Wild-type and mutant htt protein levels in HD fi broblasts and post-mortem brain tissue. 
PolyQ repeat lengths are indicated below each lane. The lower band represents wild-type htt protein, the 
upper band mutant htt protein. (a) Western blot analysis of total protein lysates from human fi broblasts 
from three heterozygous HD (GM02173, GM04022, GM04855) and one homozygous HD subject 
(GM04857). (b) Western blot analysis of cortical brain homogenates from six HD subjects. (c) Whisker 
box plots comparing wild-type and mutant htt levels normalized against total htt in HD fi broblasts (n = 3) 
and (d) HD post-mortem brain tissue (n = 6). Whiskers = 10-90 percentile, data were evaluated using a 
two-tailed student t-test. (e) Dot blot assay of SDS-insoluble htt protein fractions of human control (H121) 























































































































































We also looked at aggregation of post-mortem juvenile HD brain lysates from subjects 
HC104 and HD29 using the dot blot assay (Figure 4e). As expected, when compared with the 
HD brain lysates, juvenile HD brain lysates clearly showed more aggregated SDS-insoluble 
mutant htt protein.
Figure 4. Wild-type and mutant htt protein levels in patient-derived juvenile HD fi broblasts and 
post-mortem brain tissue. (a) Western blot analysis of total protein lysates from human fi broblasts 
derived from three juvenile HD subjects. PolyQ repeat lengths are indicated below each lane. (b) Post-
mortem cortical brain tissue from three juvenile HD subjects (GM04281, GM05539, GM09197). The 
lower band represents wild-type htt, the upper band mutant htt. (c) Whisker box plots comparing wild-
type and mutant htt levels normalized against total htt in juvenile HD fi broblasts and (d) juvenile HD post-
mortem brain tissue. Whiskers = 10-90 percentile, data were evaluated using a two-tailed student t-test, 
n = 3, * P > 0.05, ** P > 0.01. (e) Dot blot assay of SDS-insoluble htt protein fractions of human control 
(H121) and juvenile HD brain homogenates (HC104 and HD29). Dot intensity indicates level of insoluble 




















































































































To conclude, in adult-onset HD samples, wild-type and mutant htt protein levels are equal, 
regardless of mutant htt protein aggregation. In juvenile HD there is a consistent lower level of 
mutant htt protein expression, in both brain and fi broblast samples.
Identifi cation of novel HTT antisense isoform in patient-derived fi broblasts and 
brain tissue
In previous studies in post-mortem HD brain it was suggested that the HTTAS_v1 with an 
expanded CTG repeat was not expressed (CHUNG et al., 2011). To validate this a homozygous HD 
patient-derived fi broblast GM04857 was included since it has two expanded CAG repeats and 
therefore should not have any HTTAS_v1 expression. Unexpectedly, we also found HTTAS_v1 
in fi broblasts obtained from an HD patient homozygous for the CAG repeat expansion (Figure 
5a). The HTTAS_v1 expression level of the homozygous HD patient was comparable to that of 
the heterozygous patient samples, suggesting that there is expression of HTTAS_v1 with the 
expanded CTG repeat.
Next, we designed HTTAS isoform-specifi c primers to examine the expression of HTTAS_v1 
and v2 in: (I) fi broblasts derived from a control, (II) an HD patient, and (III) a juvenile HD patient 
(Figure 5a), as well as post-mortem ( juvenile) HD brain tissue (Figure 5b). Similar levels of 
HTTAS_v1 in all brain and fi broblasts samples were shown. Interestingly, the primers specifi c 
for HTTAS_v2 gave an additional band, slightly bigger than the expected PCR amplicon. Sanger 
sequencing confi rmed that this was a novel HTTAS isoform, which we named HTTAS_v2.2 
(Figure 5c). This HTTAS_v2.2 has an additional 69 nucleotides at the 3’end of HTTAS exon 2. 
In sum, similar HTTAS expression levels in (homozygous) HD and controls were found, 
suggesting that the observed variations in wild-type and control HTT transcript levels in post-
mortem brain are probably not caused by changes in HTTAS expression levels. Furthermore, 
we have identifi ed a novel HTTAS isoform, which we named HTTAS_v2.2.
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Figure 5. HTT antisense (HTTAS) identifi cation in HD patient-derived fi broblasts and post-mortem 
brain tissue. HTTAS_v1 and HTTAS_v2 were amplifi ed using strand- and HTTAS isoform-specifi c 
primers. (a) Gel electrophoresis of HTTAS_v1 and HTTAS_v2 RT-PCR of patient-derived fi broblasts 
from a control (GM04204), an HD patient (GM02173), an HD patient homozygous for the CAG repeat 
expansion (GM04857) and a juvenile HD patient (GM05539). (b) Gel electrophoresis of HTTAS_v1 and 
HTTAS_v2 RT-PCR of post-mortem brain tissue from a control (H121), an HD patient (HC105), and 
2 juvenile HD patients (HD192 and HD86). Allelic CAG repeat sizes below each lane. (c) Schematic 
representation of HTTAS_v2.1 and the novel identifi ed HTTAS_v2.2. Sanger sequencing of the exon 
2 - exon 3 boundaries of both HTTAS_v2 isoforms are shown. The novel HTTAS_v2.2 has an additional 




In the current study we found that in adult-onset HD patient-derived fi broblasts, the levels 
of wild-type and mutant HTT mRNA did not signifi cantly differ. This is in concordance with 
results found in patient-derived HD lymphoblasts (LEE et al., 2013). By analyzing microarray 
probes that detect both wild-type and mutant HTT mRNA, it was shown that the expanded 
CAG repeat did not affect HTT mRNA expression (LEE et al., 2013). CAG repeat-induced RNA 
toxicity has recently also been proposed to be involved in the HD pathogenesis (WOJCIECHOWSKA 
AND KRZYZOSIAK, 2011). The size of the CAG repeat is thought to be critical for the contribution 
of RNA toxicity (WANG et al., 2011). Juvenile fi broblast cells with mutant htt alleles containing 
either 68 or 151 CAGs exhibited aggregation of mutant HTT mRNA (DE MEZER et al., 2011). 
Our results show that there is no difference in wild-type and mutant HTT mRNA levels in 
fi broblasts, suggesting that there is no detectable effect of mRNA aggregation on mRNA levels 
in adult-onset fi broblast samples. However, in post-mortem brain tissue we did fi nd a small but 
signifi cant lower level of mutant than wild-type HTT mRNA, highlighting subtle differences 
between post-mortem brain tissue and patient-derived fi broblasts.
Wild-type and mutant htt protein levels did not signifi cantly differ in either patient-derived 
fi broblasts or post-mortem brain samples. Soluble htt has a half-life of approximately 24 
hours (PERSICHETTI et al., 1996) and we hypothesize that with Western blot analysis we detect 
soluble htt that is present in the cells. Aggregated htt is less effi ciently cleared (GUTEKUNST et al., 
1999). This SDS-insoluble accumulated htt protein is detected by dot blot assay. Since protein 
aggregation is an important feature in HD brain tissue, but does not occur in HD fi broblasts 
(SATHASIVAM et al., 2001), our results show that protein aggregation does not affect the levels 
of soluble htt protein. Although htt protein levels did not differ, in human brain samples we 
did fi nd less mutant HTT mRNA. A possible explanation could be an enhanced translation of 
mutant HTT, resulting in equal htt protein levels. Recently, increased translation of mutant 
htt by binding of the MID1-PP2A translational complex was shown (KRAUSS et al., 2013). Cells 
overexpressing N-terminal htt fragments with a normal and mutant polyQ repeat showed 
an enhanced protein synthesis of htt fragments with an expanded polyQ repeat. This more 
effi cient translation of mutant HTT mRNA was proposed to be caused by enhanced binding 
of the MID1-complex to the expanded CAG repeat and mediated by mTOR and S6K kinases 
(KRAUSS et al., 2013). However, this cannot be a general expanded polyQ mechanism, since we 
only found a difference in wild-type and mutant HTT mRNA in brain tissue samples and not in 
fi broblast cells. Another possible explanation for the differences in HTT mRNA levels between 
human fi broblasts and brain could be the nature of the tissue where RNA was isolated from; 
dividing living cells versus brain material with post-mortem delay and subsequently autolysis. 
Nevertheless, our results show subtle differences in htt protein levels between post-mortem 
brain tissue and patient-derived fi broblasts. This has to be considered when interpreting 
results obtained from patient-derived HD fi broblasts or other peripheral tissue with respect to 
disease processes in HD.
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In juvenile HD samples we consistently found that the levels of wild-type htt protein were 
higher than mutant htt protein in both patient-derived fi broblasts and post-mortem brain 
tissue. This is in contradiction with previous studies in knock-in HD mice carrying one or two 
repeats with 111 CAGs (KRAUSS et al., 2013), which showed increased mutant htt protein levels. 
It is known that reverse transcriptase and polymerase chain reactions across CG-rich regions 
are notoriously diffi cult (STINE et al., 1995), this combined with a reduced RNA quality in our 
juvenile HD samples, is why we could not reliably quantify mutant HTT mRNA levels in juvenile 
HD subjects. It is conceivable that the lower mutant htt protein level in juvenile HD is caused 
by an equivalent lower level of mutant HTT mRNA. Clearly, our results indicate that expression 
of wild-type and mutant htt in juvenile HD are different compared to that of adult-onset HD.
Recently it has been suggested that in polyQ disorders bidirectional RNA transcription could 
play a role in the disease pathology by deregulation of the sense transcript (CHUNG et al., 2011; 
SOPHER et al., 2011). In HD, two natural HTTAS transcripts (HTTAS_v1 and v2) were identifi ed at the 
HTT locus, of which HTTAS_v1 contained the CTG repeat (CHUNG et al., 2011). It was shown that 
overexpression of HTTAS_v1with an wild-type repeat resulted in reduced HTT sense transcript 
levels, whereas knockdown of HTTAS_v1 increased HTT sense transcript levels. Based on these 
fi ndings, it was hypothesized that HTTAS_v1 negatively regulated htt transcript expression 
(CHUNG et al., 2011). Also, when the CTG repeat in HTTAS_v1 was expanded, expression was 
strongly reduced in HD brains. However, our results show expression of HTTAS_v1 in human-
derived fi broblasts homozygous for the CAG repeat expansion, suggesting that there is an 
HTTAS_v1 with expanded CTG repeat transcribed. Unfortunately we did not have post-mortem 
material from a homozygous HD patient to validate this HTTAS_v1 expression in human 
homozygous HD brain. Furthermore, we have identifi ed a novel HTTAS_v2 isoform, which has 
an additional 69 nucleotides at the 3’end of HTTAS exon 2, which we named HTTAS_v2.2. Future 
research will have to determine the role of these antisense transcripts in HTT expression.
Recent advances have shown the potential of reducing mutant htt levels with oligonucleotide-
based therapeutics. Reduction of both wild-type and mutant htt up to 70% was well tolerated in 
HD rodent models and non-human primates (KORDASIEWICZ et al., 2012). Long-term suppression 
of wild-type and mutant htt might not be desirable because of htt’s anti-apoptotic function 
(RIGAMONTI et al., 2000) and importance for cell survival in the adult brain (DRAGATSIS et al., 2000; 
ZHANG et al., 2003). A different approach would be an allele-specifi c reduction of mutant htt. 
This could be achieved with oligonucleotides directed against SNPs unique to the mutant 
htt transcript, or by targeting the expanded CAG repeat directly (APPL et al., 2012). Showing 
that the basal levels of mutant HTT mRNA and mutant htt protein are equal or lower when 
compared to wild-type, provides feasibility for oligonucleotide therapeutics that are not 
completely specifi c for the mutant HTT allele.
Our results highlight subtle differences in htt RNA and protein expression with less mutant 
HTT mRNA, but equal wild-type and mutant htt protein levels in adult-onset HD. In juvenile HD 
mutant htt protein levels were lower compared with wild-type htt, indicating subtle differences 
in htt protein expression between adult-onset and juvenile HD. Differences between post-
mortem brain tissue and patient-derived fi broblasts have to be taken into account when 
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interpreting results obtained from HD patient-derived fi broblasts. Furthermore, differences 
in htt levels between adult-onset HD and juvenile HD samples should be taken into account 
when using HD tissue and animal models with juvenile polyQ repeat lengths.
2.6. Acknowledgements
We thank David F. Fischer (BioFocus, a Galapagos company, Leiden, The Netherlands) and 
Michela A. Tessari (Galapagos B.V., Leiden, The Netherlands) for the TaqMan SNP assay. We 
thank Marika Eszes and Ingrid Hegeman for providing us with the relevant clinical information.
This work was supported by the Center for Biomedical Genetics (the Netherlands), the 
Prinses Beatrix Spierfonds (the Netherlands), and Integrated European Project in Omics 
Research of Rare Neuromuscular and Neurodegenerative Diseases (Neuromics). The funders 
had no role in study design, data collection and analysis, decision to publish, or preparation 
of the manuscript.
69



























































































































































Figure S1. Wild-type and mutant HTT mRNA levels in individual HD patient-derived fi broblasts 
and post-mortem brain material. Wild-type and mutant HTT alleles were separated by differences in 
CAG repeat length. Allelic CAG repeat sizes below each bar. gDNA was taken along to control for the 
PCR reaction over the CAG repeat. Wild-type and mutant HTT RNA expression levels were calculated 
by dividing the intensity of the gDNA normalized wild-type HTT band by the mutant HTT band. (a) Gel 
electrophoresis quantifi cation of 4 HD fi broblasts. Bars represent mean values with standard deviation 
(n = 3). (b) Gel electrophoresis quantifi cation of brain tissue derived from 10 HD patients. Bars represent 
mean values with standard deviation. Data were evaluated using two-tailed student-t test, * P > 0.05, ** 


































































































































































Figure S2. Analysis of wild-type and mutant htt ratio’s in individual subjects. Wild-type versus 
mutant htt ratio for individual subjects was calculated by dividing wild-type htt band intensity with mutant 
htt band intensity. Individual polyQ tracts are indicated below each subject. (a) Individual patient-derived 
HD fi broblast cell lines (left), or individual post-mortem cortical brain lysates (right). (b) Individual patient-
derived juvenile HD fi broblast cell lines (left), or individual post-mortem cortical juvenile HD brain lysates 
(right). Bars represent mean values with standard deviation (n ≥ 3). Data were evaluated using two-tailed 
student-t test, * P < 0.05.
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To date there are 9 known diseases caused by an expanded polyglutamine repeat, with the 
most prevalent being Huntington’s disease. Huntington’s disease is a progressive autosomal 
dominant neurodegenerative disorder for which currently no therapy is available. It is caused by 
a CAG repeat expansion in the HTT gene, which results in an expansion of a glutamine stretch 
at the N-terminal end of the huntingtin protein. This polyglutamine expansion plays a central 
role in the disease and results in the accumulation of cytoplasmic and nuclear aggregates. 
Here, we make use of modifi ed 2’-O-methyl phosphorothioate (CUG)n triplet-repeat antisense 
oligonucleotides to effectively reduce mutant huntingtin transcript and protein levels in 
patient-derived Huntington’s disease fi broblasts and lymphoblasts. The most effective 
antisense oligonucleotide, (CUG)7, also reduced mutant ataxin-1 and ataxin-3 mRNA levels 
in spinocerebellar ataxia 1 and 3, respectively, and atrophin-1 in dentatorubral-pallidoluysian 
atrophy patient derived fi broblasts. This antisense oligonucleotide is not only a promising 
therapeutic tool to reduce mutant huntingtin levels in Huntington’s disease but our results in 
spinocerebellar ataxia and dentatorubral-pallidoluysian atrophy cells suggest that this could 
also be applicable to other polyglutamine expansion disorders as well.
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3.2. Introduc  on
Polyglutamine (polyQ) diseases are a group of disorders caused by CAG triplet repeat 
expansions in the coding region of the genome. The disease causing proteins in these polyQ 
diseases are very different, but in each case the expanded stretch of glutamines results in a 
toxic-gain-of function of the protein and this leads to neurodegeneration. To date, a total 
of 9 polyQ disorders have been described: dentatorubral-pallidoluysian atrophy (DRPLA), 
Huntington’s disease (HD), spinal bulbar muscular atrophy (SBMA), and spinocerebellar ataxias 
(SCA1, 2, 3, 6, 7, and 17) (CUMMINGS AND ZOGHBI, 2000; NAKAMURA et al., 2001). Of these polyQ 
disorders, HD and SCA3 have the highest prevalence worldwide (BAUER AND NUKINA, 2009). The 
expanded repeats in these polyQ diseases are unstable resulting in anticipation; a more severe 
and earlier onset of disease in following generations (RANEN et al., 1995). There is an inverse 
correlation of disease onset and polyQ length in the protein; the longer the CAG repeat, the 
earlier the age of onset of the disease (CUMMINGS AND ZOGHBI, 2000). Protein aggregates are 
found in the nucleus and cytoplasm of cells, indicating that protein misfolding is a common 
feature of these disorders. Currently no treatment is available to delay onset or even slow 
progression of polyQ diseases. 
In HD, the expanded CAG repeat is located in the fi rst exon of the HTT gene on chromosome 
4p16. The expanded CAG transcript is translated into a mutant huntingtin (htt) protein with an 
expanded polyQ tract at the N-terminus. Patients with 40 or more CAG repeats will develop the 
disease, whereas people with 35 to 39 repeats show reduced penetrance (MCNEIL et al., 1997). 
The disease is characterized by motor, psychiatric and cognitive impairments and the typical 
age of onset lies between 30 and 50 years (ANDREW et al., 1993). The major neuropathology 
occurs in the striatum but degeneration is seen throughout the brain when the disease 
progresses. Various other proteins have been found to co-localize with htt aggregates, i.e. 
TATA box binding protein (TBP), CREB binding protein (CBP) and several molecular chaperones 
(HUANG et al., 1998; STEFFAN et al., 2000; MUCHOWSKI et al., 2002; ROON-MOM et al., 2002). When 
the mutation for HD was found, htt was a protein of unknown function but extensive research 
over the past decade has revealed numerous functions for htt. Also many affected cellular 
processes have been identifi ed in HD, such as transcriptional de-regulation, mitochondrial 
dysfunction, and impaired vesicle transport (BAUER AND NUKINA, 2009; ROSS AND TABRIZI, 2011).
SCAs are genetically and clinically distinct autosomal dominant CAG-expansion diseases, 
numbered by the order of gene description. Patients with SCA exhibit cerebellar degeneration 
resulting in ataxia and oculomotor defi cits, often followed by general brain atrophy (MANTO, 
2005; SCHOLS et al., 2004). The fi rst SCA identifi ed, SCA1, is caused by a CAG repeat expansion 
of 41 or more in exon 8 of the ATXN1 gene (BAUER AND NUKINA, 2009). ATXN1 is translated 
into the 98 kDa protein ataxin-1, which is involved in transcriptional regulation and RNA 
metabolism (MATILLA-DUENAS et al., 2008). Mutated ataxin-1, by entering the nucleus, causes 
cellular dysfunction (KLEMENT ET AL., 1998). In SCA3, the expanded CAG repeat is located in 
exon 10 of the ATXN3 gene which is translated into mutant ataxin-3 (KAWAGUCHI et al., 1994). 
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Patients develop the disease when the number of CAGs exceed 51, while there is reduced 
penetrance when the number of repeats is between 45 and 51 (PADIATH et al., 2005). The 42 
kDa ataxin-3 protein is suggested to be involved in proteasomal degradation and transport 
of ubiquitinated proteins (RIESS et al., 2008). DRPLA is a rare autosomal dominant disorder, 
characterized by dementia, ataxia, chorea, myoclonic epilepsy, and psychiatric disturbances. 
The disease is caused by a CAG repeat expansion in exon 5 of the ATN1 gene, which encodes 
the 200 kDa atrophin-1 protein. Atrophin-1 is a known transcriptional co-regulator although 
its exact function is not well understood (SHEN AND PETERSON, 2009). Patients with a repeat of 49 
or more glutamines will develop the disease (NAGAFUCHI et al., 1994). 
Most therapeutic strategies under investigation for polyQ disorders are aimed at 
counteracting one of the many cellular processes that are altered due to expression of the 
mutant protein. For instance, in all of these neurodegenerative diseases the formation of 
fragmented protein products by proteolytic cleavage is an important step in the pathogenic 
process (BAUER AND NUKINA, 2009). It has been shown that altering proteolysis of the mutant 
htt protein can be benefi cial, as an HD mouse model lacking the caspase 6 cleavage site 
had reduced neuronal dysfunction and neurodegeneration (GRAHAM et al., 2006). Reducing 
mutant polyQ protein levels and thereby inhibiting all downstream toxic effects would be 
much more effective than targeting a single cellular process. One way to achieve this would be 
to enhance the degradation of mutant polyQ proteins through activation of the proteasome 
(SEO et al., 2007) or through upregulation of the autophagic pathway (METCALF et al., 2010). 
Another strategy would be to inhibit the formation of mutant polyQ proteins by gene 
silencing or transcript degradation (SCHOLEFIELD AND WOOD, 2010). RNAi is increasingly used as a 
potential therapeutic tool to reduce expression of target transcripts (RAO et al., 2009). RNAi is 
an endogenous cellular defense mechanism against exogenous viral components and is also 
involved in transcriptional regulation (DING AND VOINNET, 2007). Specifi c knock down of target 
sequences is achieved by introducing exogenously modifi ed oligonucleotides (e.g. short 
hairpin RNA (shRNA) and short interfering RNA (siRNA)) that bind to the target transcript, 
which is subsequently degraded or its translation blocked. Recently an siRNA targeting both 
normal and mutant htt was found to be well-tolerated in wild-type rats (DROUET et al., 2009). 
However, endogenous htt expression is important for normal cellular function, as underlined 
by the fi nding that conditional knockout of murine htt in forebrain and testis resulted in 
loss of function and progressive neurodegeneration (DRAGATSIS et al., 2000). Total loss of the 
endogenous htt homolog in a Drosophila HD model expressing the human fi rst exon of the 
HTT gene with 93 Qs enhanced the HD pathogenesis (ZHANG et al., 2009A). These studies show 
that a specifi c reduction of mutant htt levels, leaving as much wild-type htt protein as possible, 
would be the optimal outcome of a therapy aimed at htt knockdown. Specifi c reduction of the 
mutant htt transcript was shown by allele-specifi c siRNAs directed against a single nucleotide 
polymorphism (SNP) in htt exon 50 (van Bilsen et al., 2008). In a recent study on the cleavage 
of triplet repeat hairpins by ribonuclease dicer it was shown that an siRNA with 7 consecutive 
CUG nucleotides specifi cally reduced the expression of the mutant htt transcript containing 
44 CAG repeats in HD human fi broblasts (KROL et al., 2007). Although off-target effects and 
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interference with endogenous RNAi processes remains to be assessed (MCBRIDE et al., 2008), 
these results are encouraging.
Another RNA based therapy approach to knock down gene or protein expression is the use 
of single stranded antisense oligonucleotides (AON). One of the most promising examples of 
AON treatment in a neurodegenerative disease is aimed at amyotrophic lateral sclerosis (ALS). 
In ~2% of ALS patients, the disease is caused by a mutation in superoxide dismutase 1 (SOD1) 
(ROBBERECHT, 2000). Continuous intraventricular infusion of AONs successfully down regulated 
SOD1 mRNA and protein levels in the brain and signifi cantly slowed disease progression in an 
animal model of ALS (SMITH et al., 2006). A clinical trial is currently ongoing in ALS patients with 
SOD1 mutations and results are expected this year (CLINICALTRIALS.GOV, 2009).
For glutamine-expansion disorders, peptide nucleic acid (PNA) and locked nucleic acid 
(LNA) antisense oligomers targeting CAG repeats have been used to reduce expanded HD and 
SCA3 transcripts in vitro (HU et al., 2009A; HU et al., 2009B; GAGNON et al., 2010; HU et al., 2011). 
However, although PNA transfection effi ciently reduced mutant protein levels with very long 
glutamine expansions, the reductions on polyQ lengths that occur most frequently in the HD 
patient population were less pronounced (HU et al., 2009A; HU et al., 2009B). In the current we 
make use of 2’-O-methyl (2OMe) modifi ed RNA AONs with a phosphorothioate (PS) backbone 
carrying different CUG numbers. We examine the effect of (CUG)n AONs on mRNA level in cell 
lines derived from HD, SCA1, SCA3, and DRPLA patients with CAG expansions that occur most 
frequently in the patient population. A signifi cant reduction in expanded transcript levels was 
found in patient derived fi broblast from HD, SCA1, SCA3, and DRPLA. Furthermore a signifi cant 
reduction of mutant htt protein was seen in the HD cells. For htt, a reduction in wild-type htt 
transcript levels was observed as well, but this reduction was less pronounced than for the 
mutant transcript. Lowering the AON concentration increased the specifi city for the mutant 
transcript. These results show that one single antisense oligonucleotide could be a promising 
therapeutic treatment for all polyQ disorders.
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3.3. Materials & Methods
Cell culture and transfection
Patient derived fi broblasts from HD (GM04022), SCA3 (GM06151), SCA1 (GM06927), and 
DRPLA (GM13716) (purchased from Coriell Cell Repositories, Camden, USA); and control 
fi broblasts FLB73 (kind gift from Dr. M.P.G. Vreeswijk, LUMC) were cultured at 37°C and 5% 
CO2 in Minimal Essential Medium (Gibco Invitrogen, Carlsbad, USA) with 15% heat inactivated 
fetal bovine serum (Clontech, Palo Alto USA), 1% Glutamax (Gibco) and 100 U/ml penicillin/
streptomycin (Gibco). Human Epstein Barr Virus transformed lymphoblasts HL2.42 and HL2.93 
were a kind gift from Prof. E. Bakker (Laboratory of Diagnostic Genome Analysis (LDGA), LUMC). 
Cells were cultured at 37°C and 5% CO2 in RPMI 1640 medium (Gibco), containing 15% FBS, 1% 
glutamax and 100 U/ml P/S.
AON transfection was performed with 3.3 μl ExGen 500 polyethylenimine (PEI) (MBI 
Fermentas, Vilnius, Lithuania) per μg AON. AON and PEI were diluted in 150 mM NaCl to a total 
volume of 100 μl and mixtures were prepared according to the manufacturer’s instruction. 
Four different transfection conditions were used: 1) transfection with 1-100nM (CUG)7, 100nM 
(CUG)3, 100nM (CUG)12, 2) transfection with 10-100nM h40AON2 directed against exon 40 
of the DMD gene (5’- UCC UUU CAU CUC UGG GCU C -3’) (Control AON) (AARTSMA-RUS et al., 
2002), 3) transfection without AON (Mock II), and 4) NaCl only (Mock I). Mixtures were added 
to a total volume of 2 ml of medium with 5% FBS. Four hours after transfection, medium 
was replaced with fresh medium and a second identical transfection was performed 24 hours 
after the fi rst transfection. All AONs consist of 2’-O-methyl RNA and contain a full-length 
phosphorothioate backbone (Prosensa B.V. Leiden, the Netherlands). 
RNA Isolation and RT-PCR
Forty eight hours after the fi rst transfection cells were harvested by trypsinization and 
washed twice with Hanks buffered salt solution (HBSS) (Gibco). Total RNA was isolated from 
the cells using an RNeasy Mini Kit (QIAgen, Venlo, The Netherlands), with an on-column DNase 
treatment for approximately 30 minutes. RNA was eluted in 50 μl elution buffer and cDNA 
was synthesized from total RNA using the Transcriptor First Strand cDNA Synthesis Kit with 
Random Hexamer primers at 65°C (Roche, Mannheim, Germany).
PCR was performed using 1 μl cDNA, 10x PCR buffer with 1.5 mM MgCl2 (Roche), 2mM 
dNTPs, 10 pmol forward primer, 10 pmol reverse primer, 1U FastStart Taq DNA Polymerase 
(Roche), 1M Betaine (Sigma-Aldrich, St. Louis, USA), and PCR grade water to a fi nal volume 
of 20 μl. PCR was performed with primers for HTT, ATXN1, ATXN3, and ATN1 (all fl anking the 
CAG repeat), ACTB, and RPL22 (for sequences, see Table S1). The PCR program started with a 
4 min initial denaturation at 95°C, followed by 35 cycles of 30 sec denaturation at 95°C, 30 sec 
annealing at 60°C (56°C for ATXN3), 45 sec elongation at 72°C, after which a fi nal elongation 
step was performed at 72°C for 7 min. 
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Lab-on-a-Chip was performed on the Agilent 2100 Bioanalyzer (Agilent Technologies, 
Waldbronn, Germany), using the Agilent DNA 1000 Kit. Expression levels were normalized 
for β-actin levels and relative to transcript levels without transfection (Mock I). The relative 
mutant transcript levels were analyzed using a paired two-sided Student t test. Differences 
were considered signifi cant when P < 0.05.
qPCR, Calculations and Sequencing. The qPCR was performed using 1 μl of 5x diluted cDNA, 
2x FastStart Universal SYBR Green Master mix (Roche), 2.5 pmol forward primer, 2.5 pmol 
reverse primer and PCR grade water to a total volume of 10 μl. Primer pairs for 6 transcripts 
containing long uninterrupted CAG repeats were selected for qPCR by BLAST analysis and 
ACTB and RPL22 were used as reference genes. (For primer list, see Table S1). The qPCR 
was performed using the LightCycler 480 (Roche). Initial denaturation was 10 min. at 95°C, 
followed by 45 cycles of 10 sec. denaturation at 95°C, 30 sec. annealing at 59°C and 20 sec. 
elongation at 72°C. The fi nal elongation was performed 5 min. at 72°C. Next, we performed 
a melting curve analysis of all samples from 60°C to 98°C with a ramp rate of 0.02°C per sec.
Relative expression of the transcript levels was calculated as described previously (PFAFFL, 
2001). All samples were run in triplicate on a plate and two independent experiments were 
performed for each sample. On all plates both reference genes were included to correct for 
inter-plate variance. 
Primer effi ciencies were determined using LinRegPCR v11.1 (RUIJTER et al., 2009) with the 
raw data amplifi cation curves as input and Mock II was used as reference. Values from the 
mock water transfected cells (Mock I) were set on 100%. The relative transcript levels were 
analyzed using a paired two-sided Student t test. Differences between groups were considered 
signifi cant when P < 0.05.
CAG repeats of the CAG enclosing transcripts were amplifi ed using primers fl anking 
the CAG repeat (see Table S1). PCR products were loaded on an agarose gel and bands 
were extracted using the QIAquick Gel Extraction Kit (QIAgen). The purifi ed products were 
sequenced by Sanger sequencing, using the Applied Biosystems 96-capillary 3730XL system 
(Life Technologies Corporation, Carlsbad, USA) with the Applied Biosystems BigDyeTerminator 
v3.1 kit.
Protein isolation and Western blotting
Cells were detached from the culture surface with a 0.5% Trypsin/EDTA solution. After 
washing twice with 1x HBSS, cells were resuspended in 200 μl ice cold lysis buffer, containing 
1x PBS, 0.4% Triton-X100, and 1 tablet Complete mini protease inhibitor EDTA free (Roche) 
per 10 ml buffer. Next, samples were sonicated 3 times for 5 seconds using ultrasound with 
an amplitude of 60 at 4°C. After incubation in a head-over-head rotor at 4°C for 1 hour, the 
extract was centrifuged for 15 min at 10,000g and 4°C and supernatant was isolated. Protein 
concentrations were determined by the bicinchoninic acid kit (Thermo Fisher Scientifi c, 
Waltham, USA) using Bovine Serum Albumin as a standard. Samples were snap frozen and 
stored at -80°C. 
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Protein extracts were separated by SDS-PAGE, with 4-15% acryl/bisacrylamide 1:37.5 
separating gels and 30 μg (human fi broblasts) of protein lysate loaded. For each sample the 
Spectra Multicolor High Range Protein Ladder (Fermentas) was used as a marker. Electrophoresis 
was performed for 30 min at 100V through the stacking gel and 5 hours at 150V through the 
running gel. Gels were blotted onto a polyvinylidene fl uoride (PVDF) membrane for 3 hours 
at 300mA. Membranes were blocked with 1x Tris Buffered Saline + 0.5% Tween 20 (TBST) 
containing 5% non-fat milk powder (Profi tar Plus, Nutricia, Zoetermeer, the Netherlands). The 
antibodies used for detection were mouse 4C8 for htt (Eurogentec, Liege, Belgium) dilution 
1:1000, mouse 1C2 specifi c for expanded poly glutamine stretches (Eurogentec) dilution 1:500, 
mouse ataxin-3 (Eurogentec) 1:1000, rabbit TBP (Santa Cruz Biotechnology, USA) 1:1000, 
and mouse β-actin, diluted 1:5000. Secondary antibodies were goat α-mouse-horseradish 
peroxidase (Santa Cruz) and goat α-rabbit-horseradish peroxidase (Santa Cruz), both diluted 
1:10.000 in 1x TBST. Horseradish peroxidase was activated by ECL+ reagent (GE Healthcare, 
Buckinghamshire, United Kingdom) to visualize positive staining on fi lm. 
Protein bands were quantifi ed using ImageJ software. The percentage of inhibition was 
calculated as a relative value to a non-treated control sample and was normalized using β-actin.
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 AON shows most pronounced reduction of HTT transcript levels
Patient-derived human fi broblasts were transfected with AONs with 3, 7 and 12 consecutive 
CUGs ((CUG)3, (CUG)7, and (CUG)12, respectively) and total RNA was isolated after 48 hours. In 
the HTT gene the glutamine repeat consists of a CAG stretch, followed by one CAA and a fi nal 
CAG triplet. The HD cell line GM04022 contained a (CAG)n CAA CAG repeat with n = 18 and 44. 
As a control fi broblasts cell line FLB73 was used where n = 17 and 21. To avoid infl uences of 
CAG repeat length, reductions in total 
HTT mRNA levels were measured by 
quantitative PCR (qPCR) with primers 
within the CAG containing exon but 
amplifying a transcript fragment 
upstream of the repeat (Table S1). 
The most signifi cant reduction in 
total HTT transcript of 81% (± 4%) 
in the HD and 76% (± 4%) in the 
control fi broblasts was found after 
(CUG)7 treatment (Figure 1). (CUG)12 
transfection resulted in a signifi cant 
reduction of total HTT transcript 
of 78% (± 5%) in the HD and 61% 
(± 18%) in the control cell line. The 
(CUG)3 did not show signifi cant 
reduction of HTT mRNA levels. The 
(CUG)7 AON was selected for further 
testing since it was the shortest AON 
resulting in the most signifi cant 
reduction in HTT mRNA levels.
Reduction of mutant HTT mRNA levels in HD cells after (CUG)
7
 treatment
Since regular htt expression is important for normal cellular function, our approach is to lower 
mutant htt protein levels, while maintaining suffi cient levels of normal protein. To examine the 
effect of (CUG)7 treatment on both HTT transcripts an allele-specifi c PCR with primers fl anking 
the CAG repeat was performed in quadruplo (Figure 2a). The mutant transcript was decreased 
by 83% (± 13%, measured by Lab-on-a-Chip analysis) in (CUG)7 treated cells compared to 
controls, while normal transcript was reduced to a lesser extent with 43% (± 32%) (Figure 2b). 
Treatment of the control cell line with (CUG)7 showed a reduction for both alleles of 21% (± 
38%) and 40% (± 38%) respectively. 
Figure 1. Number of CUGs of AON infl uences the 
reduction of HTT transcript levels. Total RNA was isolated 
48 hours after transfection. Quantitative RT-PCR was used 
to measure HTT mRNA levels in control and HD fi broblasts 
after treatment with 100nM (CUG)3, (CUG)7, (CUG)12 
AON, 100nM non-htt specifi c h40AON2 (Control AON), 
transfection agent only (Mock II), or non-transfected cells 
(Mock I, not included in this fi gure). ACTB and RPL22 are 
used as reference genes. The expression level of Mock I 
transfections are set to 100%. For all transfections n = 6 and 
*** P < 0.001. 
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We repeated this experiment in duplo in patient-derived Epstein Barr Virus transformed 
control and HD lymphoblasts (Figure 2c). (CUG)7 transfection of the HD cell line gave a 
reduction of the mutant transcript of 53% (± 10%), while only a small decrease of 22% (± 11%) 
for the normal transcript was detected (Figure 2d). No apparent reduction in the control cell 
line was found (data not shown).
Figure 2. Effect of (CUG)7 AON on HTT mRNA levels in HD patient derived cell lines 48 hours after 
transfection. Cells were transfected with 100nM (CUG)7, non-htt specifi c h40AON2 (Control AON), 
transfection agent only (Mock II), or non-transfected cells (Mock I). (a) Agarose gel analysis of the 
HTT transcript with primers fl anking the CAG repeat of control (FLB73) and HD (GM04022) fi broblasts 
treated with various AONs. Transfection with (CUG)7 shows a decrease of the upper band, representing 
the transcript from the mutant allele. The lower band, representing the normal HTT transcript, is also 
reduced, but to a lesser extent. Control cells treated with (CUG)7 only show a slight reduction compared 
to the control transfections. PCR products with primers for ACTB were used as loading control. gDNA 
was taken along to control for the PCR reaction over the CAG repeat. (b) Lab-on-a-Chip analysis of 
HTT transcripts after (CUG)7 treatment in a HD fi broblast cell line. The mutant transcript, with 44 CAGs, 
is signifi cantly reduced by 83% after (CUG)7 treatment, compared to transfection controls. The normal 
HTT transcript with 18 CAGs is reduced by 43%. Expression levels are corrected for loading differences 
with ACTB. The mRNA level of the Mock I transfection was set on 100% (* P < 0.05, *** P < 0.001, n = 
4). (c) Agarose gel analysis of HTT transcripts after (CUG)7 treatment in EBV transformed control and 
HD human lymphoblasts. After transfection with (CUG)7 the mutant HTT transcript with 45 CAGs is 
decreased compared to the Mock transfection. No changes in intensity of the HTT transcripts from the 
control lymphoblasts are seen after (CUG)7 treatment. (d) Lab-on-a-Chip analysis of HTT transcripts 
after PS57 treatment of human HD lymphoblasts. Mutant HTT transcript is reduced by 46% after (CUG)7 





















































































































Reduction of mutant htt protein levels in a HD cell line after (CUG)
7
 treatment
Since mRNA levels of the HTT transcript were substantially reduced after treatment with 
(CUG)7, in both experiments, we investigated htt protein levels (Figure 3a). Antibody 4C8 
can be used to detect total htt protein (TROTTIER et al., 1995A), while antibody 1C2 specifi cally 
recognizes the expanded polyQ tract (TROTTIER et al., 1995B). Patient-derived human fi broblasts 
were transfected and protein isolated (see Materials and Methods). 96 hours after fi rst 
treatment of HD fi broblasts with 100nM (CUG)7 4C8 antibody showed a clear reduction of 
54% (± 34%) in htt protein level, while a less pronounced reduction of 16% (± 28%) was 
observed in the control fi broblasts (Figure 3a and data not shown). With 1C2 antibody a 
signifi cant reduction of 58% (± 16%) of mutant htt protein was seen in the HD fi broblasts 
following 100nM (CUG)7 treatment (Figure 3b). Thus, reduction of mutant htt protein was 
more pronounced than normal htt.
(CUG)
7
 AON effi  ciency is concentration dependent
To test if (CUG)7 AON concentration is related to effi cacy, various AON concentrations were 
used to transfect HD and control fi broblasts. Lab-on-a-Chip analysis (Figure 4a and b) showed 
a reduction of mutant HTT with an IC50 value between 2.5nM and 5nM (Figure 4b). At 10nM 
(CUG)7 the mRNA expression of mutant HTT was reduced by 89% (± 5%), whereas normal 
HTT transcript was reduced by 38% (± 9%) in the HD fi broblasts. HTT mRNA reduction was 
less pronounced for both alleles (16% (± 6%) and 36% (± 5%)) in the control cells, suggesting 
that at lower concentrations the (CUG)7 AON is more specifi c at reducing HTT transcripts with 
expanded CAG repeats (Figure 4a).
Figure 3. (CUG)7 AON reduces mutant htt protein levels in HD patient fi broblast cell lines. Cells 
were transfected with 10nM and 100nM (CUG)7, non-htt specifi c h40AON2 (Control AON), or non-
transfected cells (Mock I). (a) Western blot of control (FLB73) and HD (GM04022) fi broblasts treated 
with (CUG)7 and controls. Total (4C8) and mutant (1C2) htt protein expression is reduced 72 hours after 
treatment with (CUG)7. No mutant htt could be detected in the control fi broblasts with 1C2. β-actin is 
used as loading control. (b) Mutant htt protein levels in HD (GM04022) fi broblasts after 100nM (CUG)7 
transfection were quantifi ed by ImageJ software. A signifi cant reduction of 58% of mutant htt protein was 
seen after (CUG)7 transfection as compared to control transfections (* P < 0.05, n = 2). Mutant protein 







































AON directed against the CAG repeat reduces mutant ataxin-3 levels
Since CAG repeat expansions are a hallmark of several neurodegenerative disorders, we 
tested the molecular effi cacy of our AON approach to reduce the expression of other genes 
as well. SCA3 patients have a CAG triplet repeat expansion in the ATXN3 gene, we examined 
the effect of (CUG)7 treatment in patient-derived SCA3 fi broblasts with a CAG CAA (CAG)n 
repeat where n = 18 and 72. As for htt, the (CUG)7 treatment reduced the transcript from the 
expanded ataxin-3 allele, while reduction in transcript levels from the normal allele was less 
pronounced (Figure 5a).
PCR with primers amplifying a product containing the CAG repeat in ATXN3 showed a 
signifi cant 97% (± 1%) down regulation of mutant ATXN3 after both 10nM and 100nM (CUG)7 
AON transfection (Figure 5b). The wild-type allele was reduced by respectively 27% (± 17%) 
and 33% (± 6%) by 10nM and 100nM after (CUG)7 AON treatment.
Reduction on other expanded CAG transcripts by (CUG)
7
 treatment
We next tested SCA1 and DRPLA fi broblasts. Allele-specifi c PCRs with primers fl anking the 
CAG repeat were performed to examine the effect of (CUG)7 treatment in both the normal 
and mutant allele. The mutant ataxin-1 (ATXN1) transcript was decreased by 89% (± 14%) in 
100nM (CUG)7 treated SCA1 cells compared to control transfections (Figure 6a and c), while 
the normal transcript was not reduced. (The SCA1 and DRPLA cell lines served as each other’s 
control.) Mutant atrophin-1 (ATN1) in DRPLA was also reduced after 100nM (CUG)7 treatment 
by 98% (± 2%), whereas there was only a 30% (± 6%) reduction in the normal allele (Figure 
6b and d).
Figure 4. Effect of vari-
ous (CUG)7 AON concen-
trations on HTT mRNA 
expression. Cells were 
transfected with 1-20nM 
(CUG)7. PCR products 
with primers fl anking the 
CAG repeat of HTT were 
quantifi ed by Lab on a 
Chip. (a) In the control cell 
line (FLB73) both alleles 
(17 and 21 CAGs) show 
a comparable concentra-
tion dependent reduction of HTT mRNA quantifi cation after (CUG)7 transfection. (b) In HD fi broblasts 
(GM04022) the mutant transcript, with 44 CAGs, shows a strong reduction of mutant HTT mRNA ex-
pression with increasing (CUG)7 AON concentrations, whereas the normal HTT transcript with 18 CAGs 
is reduced to a lesser degree. Expression levels are corrected for loading differences with ACTB and 

































































 does not aff ect other endogenous CAG-enclosing transcripts
The human genome contains several proteins that contain polyQ tracts, usually encoded 
by a combination of CAG and CAA triplets. Most of these transcripts are essential for normal 
cellular function (MOLLA et al., 2009) so reducing those transcripts could impair normal cellular 
function. To verify whether other uninterrupted CAG repeat containing transcripts were 
affected, 5 other transcripts were selected after a BLAST search: androgen receptor (AR), 
ataxin-2 (ATXN2), glutaminase (GLS), TBP, and zinc fi nger protein 384 (ZNF384). For the cells 
used in the present study the exact CAG tract length of these 5 transcripts was fi rst determined 
by Sanger sequencing (Table 1). Primers for qPCR were designed within the CAG containing 
exon but amplifying a fragment downstream of the CAG repeat in the transcript (Table S1). For 
technical reasons primers for ATXN2 were designed upstream of the CAG repeat.
Figure 5. (CUG)7 AON reduces mutant 
ATXN3 mRNA expression in patient-derived 
fi broblasts. Cells were transfected with 10 
or 100nM (CUG)7, non-htt specifi c h40AON2 
(Control AON), transfection agent only (Mock 
II), or non-transfected cells (Mock I). (a) 
Agarose gel analysis with primers fl anking the 
CAG repeat in the ATXN3 transcript of control 
(FLB73) and SCA3 (GM06151) fi broblasts 
after (CUG)7 treatment. After transfection 
with (CUG)7 the upper band, representing 
the mutant ATXN3 transcript, is greatly 
decreased in intensity, while the lower band, 
representing the wild-type transcript, is only 
slightly reduced. β-actin was used as loading 
control. (b) Lab-on-a-Chip analysis of ATXN3 
transcripts after 10nM and 100nM (CUG)7 
treatment in a SCA3 (GM06151) fi broblast 
cell line. The mutant transcript, with 72 CAGs, is signifi cantly reduced by 97% after (CUG)7 treatment, 
compared to transfection controls. The normal ATXN3 transcript with 18 CAGs is reduced by 27% and 
33% after 10nM and 100nM (CUG)7 AON treatment, respectively. Expression levels are corrected for 
loading differences with β-actin. The mRNA level of the Mock I transfection was set on 100% (* P < 0.05, 

































































Figure 6. (CUG)7 AON reduces mutant ATXN1 and ATN1 transcripts in SCA1 and DRPLA 
fi broblasts. SCA1 (GM06927) and DRPLA (GM13716) patient derived fi broblasts were transfected with 
10 and 100nM (CUG)7, 10nM non-htt specifi c h40 AON2 (Control AON), transfection agent only (Mock 
II), or non-transfected cells (Mock I). (a) Agarose gel analysis with primers fl anking the CAG repeat in 
the ATXN1 transcript. After transfection with both 10nm and 100nM (CUG)7 the upper band, representing 
the mutant ATXN1 transcript, is greatly decreased in intensity, while the lower band, representing the 
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All tested CAG-enclosing transcripts were unaffected by 100nM (CUG)7 treatment (Figure 
7), including the AR transcript that contained CAG repeats of 21 and 23 CAGs. Endogenous 
ataxin-3 (with 17:18 Qs) and TBP (37:38 Qs) protein levels were unaffected by 100nM (CUG)7 
treatment (Figure 8). From the above results we can conclude that (CUG)7 does not signifi cantly 
reduce endogenous CAG containing transcripts and does not decrease endogenous polyQ-
containing protein levels.
primers fl anking the CAG repeat in the ATN1 transcript. After transfection with both 10nM and 100nM 
(CUG)7, the upper band representing the mutant ATN1 transcript, is greatly decreased in intensity, 
while the lower band representing the wild-type transcript, is not reduced. β-actin was used as loading 
control. (c) Lab-on-a-Chip analysis of ATXN1 transcripts in SCA1 cells after control AON and 10nM 
(CUG)7 treatment. The mutant transcript, with 72 CAGs, is signifi cantly reduced by 89% after (CUG)7 
treatment, compared to transfection controls. The normal ATXN1 transcript with 27 CAGs is not reduced. 
(d) ImageJ analysis of ATN1 transcripts in DRPLA cells after control AON and 10nM (CUG)7 treatment. 
The 66 CAGs containing mutant ATN1 transcript is signifi cantly reduced by 98% after (CUG)7 treatment, 
while normal ATN1 transcript with 16 CAGs is not signifi cantly reduced by 30%. Expression levels are 
corrected for loading differences with β-actin. The mRNA level of the Mock I transfection was set on 




The present study shows that an 
AON targeting CAG repeats and 
consisting of 7 CUGs signifi cantly 
reduces protein and RNA levels 
of mutant htt in patient-derived 
fi broblast cell lines. This reduction 
was also seen, but to a lesser 
extends with (CUG)12 but not with 
(CUG)3. Although there was also a 
reduction of normal HTT transcript 
levels, the results show a preferential 
allele-specifi c reduction of mutant 
HTT in patient derived HD cells and 
this allele specifi city was improved 
when AON concentration was 
lowered from 100nM to 10nM. 
Furthermore, other non-
expanded CAG-containing 
transcripts that were investigated 
were not affected by (CUG)7 
treatment. There was no reduction 
after (CUG)7 treatment of the AR 
transcript that contained the longest 
tested uninterrupted CAG repeat, 
namely 21 and 23 CAGs. Normal 
HTT that contained 17 and 21 CAG 
repeats did show a reduction after 
(CUG)7 treatment, suggesting that 
there are other factors besides the 
number of consecutive CAG triplets 
that determine (CUG)7 effi cacy. 
The results with mutant ATXN1, 
ATXN3, and ATN1 confi rmed the 
specifi city of (CUG)7 for transcripts 
with an expanded CAG tract 
in SCA1, 3, and DRPLA patient 
derived cells, respectively. Our 
results suggest that (CUG)7 could 
Figure 7. (CUG)7 AON does not affect other CAG-
containing transcripts. Quantitative real-time PCR was 
used to measure androgen receptor (AR), ataxin-2 (ATXN2), 
glutaminase (GLS), TATA box binding protein (TBP), and zinc 
fi nger protein 384 (ZNF384) mRNA levels in control and HD 
fi broblasts after treatment with 100nM (CUG)7, non-htt specifi c 
h40AON2 (Control AON), transfection agent only (Mock II), 
or non-transfected cells (Mock I). All tested CAG-enclosing 
transcripts were unaffected by (CUG)7 treatment. ACTB and 
RPL22 are used as reference genes. The expression level of 
Mock I transfections were set on 100% (n= 6) 
Control HD
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be effective in reducing expanded CAG repeat 
containing transcripts in all polyQ diseases.
In HD there is a gain of toxic function of the 
mutant htt protein, while regular htt expression is 
important for normal cellular function. Knockout 
of the homologous htt mouse gene was found to 
be early embryonic lethal (ZEITLIN et al., 1995) and 
previous studies have shown that approximately 
50% of htt protein level is required to maintain cell 
functionality (DRAGATSIS et al., 2000; RIGAMONTI et al., 
2000; CATTANEO et al., 2001; CATTANEO et al., 2005). In 
addition, increased clearance of mutant htt protein 
by autophagy in a Drosophila model and blockage 
of mutant htt in a conditional knock-out mouse 
model of HD resulted in a reduction in aggregates 
and an ameliorated phenotype (YAMAMOTO et al., 
2000; SARKAR et al., 2007). Reduction of mutant 
protein levels will therefore most likely result in 
amelioration of the toxic HD phenotype but total 
knockdown of htt protein expression would not be advantageous (SAH AND ARONIN, 2011).
For other polyQ disorders the role of wild-type polyQ proteins in adult brain is still poorly 
understood. In a SCA3 Drosophila model expressing normal and mutant human ataxin-3, 
loss of normal ataxin-3 contributed to neurodegeneration (WARRICK et al., 2005). In contrast, 
non-allele-specifi c reduction of endogenous ataxin-3 was not found to be detrimental in 
rodents (SCHMITT et al., 2007; ALVES et al., 2010). Ataxin-1 knockout mice resulted in cerebellar 
transcriptional changes resembling SCA1 pathology, suggesting a neuroprotective role of 
normal ataxin-1 (CRESPO-BARRETO et al., 2010). In contrast, atrophin-1 knockout mice were viable 
and did not show a clear phenotype (SHEN et al., 2007), suggesting that non-allele-specifi c 
reduction of both alleles in DRPLA is not harmful. Future research is necessary to determine the 
signifi cance of wild-type polyQ protein levels for normal cellular function and the importance 
of AON-mediated allele-specifi c transcript reduction.
Several papers have shown allele-specifi c silencing of mutant htt with SNP-specifi c siRNAs 
(van Bilsen et al., 2008; Zhang et al., 2009b). Indeed HD patients carry different SNPs, requiring 
the development of at least fi ve different siRNAs, to target 75% of the European and United 
States HD population (LOMBARDI et al., 2009; PFISTER et al., 2009). However, the advantage of 
the approach described in the current paper is that it requires only 1 AON to treat all HD 
patients and would be applicable in other polyQ diseases. Furthermore, siRNAs are double 
stranded oligonucleotides and these have been described to cause off-target effects by the 
sense strand, (FEDOROV et al., 2006) as well as striatal toxicity (GRIMM et al., 2006; MCBRIDE et al., 
2008). In addition, RNA interference is an endogenous process; addition of siRNAs might cause 
toxicity due to an overload of the endogenous system. Recently, nucleic acids conjugates, with 
Figure 8. (CUG)7 AON does not reduce 
other polyQ-containing proteins. Western 
blot of control (FLB73) fi broblasts treated with 
100nM (CUG)7, non-htt specifi c h40AON2 
(Control AON), and non-transfected (Mock 
I). TATA box binding protein (TBP) and 
ataxin-3 are not reduced 72 hours after 













different chemistries than the AONs used in the current study, were used for allele-specifi c 
silencing of mutant htt. PNAs consisting of 1 guanine, followed by 6 CTGs, complementary 
to the CAG repeat, were found to specifi cally reduce mutant htt and ataxin-3 protein levels in 
patient-derived cells (HU et al., 2009A; HU et al., 2011). Although the reduction in protein levels 
by PNA transfection was highly effi cient with very long stretches of CAGs, there was only a 
minor decrease when the number of CAG repeats that occur most frequently in the patient 
population was targeted (HU et al., 2009A; HU et al., 2009B). Testing a variety of modifi cations 
resulted in oligonucleotides with a thymine (T) LNA nucleotide at every third base (LNA(T)) and 
2’O,4’O-C-ethyl nucleic acid (cET) which show higher selectivity (2.9 and 3.7 fold) for mutant 
alleles with 41 CAG repeats (GAGNON et al., 2010).
Table 1. Number of uninterrupted CAGs and codons that encode for glutamine in CAG 
repeat enclosing transcripts as determined by Sanger sequencing and a summary of 
the effect of (CUG)7 treatment in those transcripts. 
Transcript 
Name Cell Line









AR Control 22 24 21 23 No
HD 23 24 22 23 No
ATN1 Control 19 20 15 16 No
HD 12 19 8 15 No
DRPLA 20 70 16 66 Yes
SCA1 20 20 16 16 No
ATXN1 DRPLA 29 31 14 15 No
SCA1 29 52 14 37 Yes
ATXN2 Control 20 20 8 8 No
HD 20 20 8 8 No
ATXN3 Control 17 19 15 17 Yes
HD 19 23 17 21 No
SCA3 20 74 18 72 Yes
GLS Control 8 14 8 14 No
HD 7 18 7 18 No
HTT Control 19 23 17 21 Yes
HD 20 46 18 44 Yes
TBP Control 37 38 17 18 No
HD 35 36 16 17 No
ZNF384 Control 15 16 14 15 No
HD 15 16 14 15 No
Abbreviations: AR, androgen receptor; ATN1, atrophin-1; ATXN1, ataxin-1; ATXN2, ataxin-2; ATXN3, 
ataxin-3; GLS, glutaminase; HTT, huntingtin; TBP, TATA box binding protein; ZNF384, zinc fi nger protein 
384. Reduced transcripts after (CUG)7 treatment are depicted in bold.
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AONs are a promising therapeutic tool, as was recently shown by phase I and phase I/II 
clinical trials in Duchenne muscular dystrophy (DMD) boys carrying specifi c deletions in the 
DMD gene (GOEMANS et al., 2011). Local and systemic (subcutaneous) delivery of a specifi c 2OMe 
modifi ed AON induced exon 51 skipping in the DMD gene on transcript level allowing the 
synthesis of novel, internally deleted, but likely (semi-) functional, dystrophin proteins without 
clinically apparent adverse events (van Deutekom et al., 2007). AONs have also been used for 
the treatment of neurodegenerative disorders and are found to be taken up by neurons when 
delivered into the cerebral lateral ventricles. As treatment for ALS 2’-O-methoxyethyl modifi ed 
deoxynucleotides infused intraventricularly were found to reduce both SOD1 transcript and 
protein levels in rats and rhesus monkeys, which resulted in a slower disease progression (SMITH 
et al., 2006). Similarly modifi ed oligonucleotides for spinal muscular atrophy (SMA) resulted 
in putative therapeutic levels in all regions of the spinal cord after intrathecal infusion in non-
human primates (PASSINI et al., 2011). 
The exact mechanism by which the AONs are used in the current study to reduce transcript 
levels and why they show both an allele and gene preference is not known. This selective 
repeat-length dependent reduction was also seen in myotonic dystrophy type 1 after (CAG)7 
AON treatment (MULDERS et al., 2009). Since 2OMe PS modifi ed AONs are nuclease and RNase 
H resistant, RNase H-induced cleavage or RISC mediated degradation of dsRNA is not likely 
to be involved (MULDERS et al., 2009). Another explanation could be RNase H-independent 
translational blocking by (CUG)7 AON binding to the transcript, preventing binding or steric 
blockage of the ribosomal units. However, translational blocking is not likely to be involved 
since htt transcript levels are also reduced (HU et al., 2009A). Reduction of transcript levels are 
not thought to be caused by interference of the (CUG)7 AON during cDNA synthesis. Addition 
of (CUG)7 AON just prior to the mRNA before cDNA synthesis did not result in reduced htt 
transcript levels (data not shown). A more likely explanation for the allele-specifi c effect of 
the (CUG)7 AON shown in the current paper could be caused by structural differences in 
transcripts with normal and expanded repeats. Expanded CAG repeats are known to from 
hairpin structures (DE MEZER et al., 2011). (CUG)7 AON binding could stabilize this CAG RNA 
hairpin, resulting in selective breakdown of the mutant transcripts. Another explanation could 
be that the expanded CAG repeats have a more open structure, making them more accessible 
for AON binding, thereby leading to induction of selective breakdown, resulting in a lower 
mRNA expression. These two models are not mutually exclusive and other mechanisms may 
as well be involved.
However, these results show that reduction of the mutant mRNA and/or its translation 
are promising generic routes towards therapy of triplet expansion diseases. Our future plans 
would be unraveling the exact mechanism of the reduction of HTT transcripts by the AON and 
in vivo testing of the toxicity and delivery of the (CUG)7 in animal models of polyQ diseases.
Here we show the fi rst evidence of a specifi c reduction of mutant huntingtin, ataxin-
1 and -3, and atrophin-1 transcript levels using 2OMe PS modifi ed AONs that recognizes 
pure CAG repeat stretches, suggesting that a single AON is potentially applicable to polyQ 
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Table S1. Used primers for Sanger sequencing and (quantitative) RT-PCR.
Transcript Direction Amplifying the CAG repeat Without CAG repeat 
HTT Forward ATGGCGACCCTGGAAAAGCTGAT ATGGCGACCCTGGAAAAG
Reverse TGAGGCAGCAGCGGCTG CTGCTGCTGGAAGGACTTG




ATXN2 Forward CCTCACCATGTCGCTGAAG CTCCGCCTCAGACTGTTTTG
Reverse GGAGACCGAGGACGAGGAC GAGAAGGAGGACGACGAAGG
ATXN3 Forward GAGCTTCGGAAGAGACGAGA GGGGACCTATCAGGACAGAG
Reverse GATCACTCCCAAGTGCTCCT CAAGTGCTCCTGAACTGGTG
ATN1 Forward CACCCACCAGTCTCAACACA TCACAGCCAGGTGTCCTACA
Reverse GAGACATGGCGTAAGGGTGT GTAGCCGAAGAGGTGGTGAC
GLS Forward TAGGCGGAGCGAAGAGAAC ACCCAAGTAGCTGCCCTTTC
Reverse GCTCAACAGGGGAGGATG GCTCAACAGGGGAGGATG
TBP Forward GACCCCACAGCCTATTCAGA CCACAGCTCTTCCACTCACA
Reverse TTGACTGCTGAACGGCTGCA GCGGTACAATCCCAGAACTC






All primer sequences are from 5’ - 3’. Abbreviations are as follows: AR, androgen receptor; ATN1, 
atrophin-1; ATXN1, ataxin-1; ATXN2, ataxin-2; ATXN3, ataxin-3; GLS, glutaminase; HTT, huntingtin; 
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Preventing formation of 
toxic N-terminal huntingtin 
fragments through antisense 
oligonucleotide-mediated 
protein modifi cation




Huntington’s disease (HD) is a progressive autosomal dominant disorder, caused by a CAG 
repeat expansion in the HTT gene, which results in expansion of a polyglutamine stretch at 
the N-terminal end of the huntingtin protein. Several studies have implicated the importance 
of proteolytic cleavage of mutant huntingtin in HD pathogenesis and it is generally accepted 
that N-terminal huntingtin fragments are more toxic than full-length protein. Important 
cleavage sites are encoded by exon 12 of HTT. Here we report proof of concept using antisense 
oligonucleotides to induce skipping of exon 12 in huntingtin pre-mRNA, thereby preventing 
the formation of a 586 amino acid N-terminal huntingtin fragment implicated in HD toxicity. In 
vitro studies showed successful exon skipping and appearance of a shorter huntingtin protein. 
Cleavage assays showed reduced 586 amino acid N-terminal huntingtin fragments in the 
treated samples. In vivo studies revealed exon skipping after a single injection of antisense 
oligonucleotides in the mouse striatum. Recent advances to inhibit the formation of mutant 
huntingtin using oligonucleotides seem promising therapeutic strategies for HD. Nevertheless, 
huntingtin is an essential protein and total removal has been shown to result in progressive 
neurodegeneration in vivo. Our proof of concept shows a completely novel approach to 










4.2. Introduc  on
Polyglutamine (polyQ) diseases are a group of autosomal dominant neurodegenerative 
disorders caused by a CAG triplet repeat expansion in protein coding regions of the genome. 
The most prevalent polyQ disorder, Huntington’s disease (HD), is caused by a CAG repeat 
expansion in the fi rst exon of the HTT gene on chromosome 4p16. The expanded CAG 
transcript is translated into a mutant huntingtin (htt) protein with an expanded polyQ tract at 
the N-terminus. Carriers of 40 or more CAG repeats will develop HD, whereas people with 35 
to 39 repeats show reduced penetrance (MCNEIL et al., 1997). The disease is characterized by 
motor, psychiatric and cognitive impairments and the typical age of onset lies between 30 and 
50 years and is inversely correlated to the number of CAGs (ANDREW et al., 1993). 
In HD, insoluble protein aggregates are found in the nucleus and cytoplasm of cells, 
indicating that htt protein misfolding is a common feature (ROSS AND TABRIZI, 2011). Major 
neuropathology occurs in the striatum but degeneration is seen throughout the brain when the 
disease progresses (VONSATTEL AND DIFIGLIA, 1998). Many cellular processes are affected in HD, as 
is evident from transcriptional de-regulation, mitochondrial dysfunction, and impaired vesicle 
transport (ROSS AND TABRIZI, 2011). Several studies have implicated the importance of apoptosis 
and specifi cally proteolytic cleavage of mutant htt in HD pathogenesis (EHRNHOEFER et al., 2011). 
Exon 1 of the HTT gene with an expanded CAG repeat is suffi cient to induce symptoms in the 
R6/2 mouse model of HD (MANGIARINI et al., 1996), also shorter htt fragments seems to be more 
pathogenic than longer htt fragments (CROOK AND HOUSMAN, 2011). Aggregates in brains of HD 
patients can be stained with antibodies directed at N-terminal epitopes but not C-terminal 
epitopes of htt (LUNKES et al., 2002), suggesting that aggregates contain truncated N-terminal 
htt fragments. In apoptotic cells, htt is cleaved by cysteine aspartic acid proteases, called 
caspases (GOLDBERG et al., 1996). Mutations in caspase-3 at amino acid positions 513 and 552 
and caspase-6 motifs at position 586 in mutant htt resulted in cleavage-resistant neuronal and 
non-neuronal cells with reduced toxicity and less aggregates in vitro (WELLINGTON et al., 2000). 
In vivo it was also shown that mutation of amino acid position 586 in the caspase-6 cleavage 
motif resulted in reversal of the HD phenotype in a YAC128 mouse model (GRAHAM et al., 2006; 
POULADI et al., 2009). These mice express the full human genomic HTT, which is translated into 
a mutant htt protein with 128 glutamines. Using the same YAC128 model, no improvement 
of HD phenotype was seen after mutations in the caspase-3 cleavage sites at amino acid 
positions 513 and 552. This suggests that cleavage at position 586 is an important step in HD 
neuropathology and results in neuronal dysfunction and neurodegeneration (GRAHAM et al., 
2006). 
Recent advances to inhibit the formation of mutant htt using oligonucleotides seem 
promising therapeutic strategies for HD (SAH AND ARONIN, 2011). These approaches make use 
of RNA interference (RNAi), RNAi-like mechanisms using single-stranded RNAs (ssRNAs) or 
antisense oligonucleotides (AONs) (SAH AND ARONIN, 2011; YU et al., 2012). Lowering mutant 
htt protein levels would prevent all downstream toxic effects, but complete suppression of 
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htt may not be desirable since wild-type htt has numerous cellular functions. Htt is reported 
to act as protector of brain cells from apoptotic stimuli (RIGAMONTI et al., 2000) and is required 
in adult neurons and testis (DRAGATSIS et al., 2000). Knock-out of the homologous htt mouse 
gene was found to be early embryonic lethal (ZEITLIN et al., 1995) and htt inactivation in adult 
mice was shown to result in progressive neurodegeneration (DRAGATSIS et al., 2000). However, 
non-allele-specifi c reduction of both normal and mutant htt transcripts up to 75% was found 
to be well tolerated in HD rodents and non-human primates (BOUDREAU et al., 2009; DROUET et 
al., 2009; MCBRIDE et al., 2011; KORDASIEWICZ et al., 2012) and resulted in phenotypic reversal up 
to 4 months post treatment (KORDASIEWICZ et al., 2012). Although studies so far have shown that 
lowering of htt levels can be well tolerated, safety and specifi city of htt transcript lowering 
drugs after long-term exposure need to be assessed.
Allele-specifi c reduction would be preferred since this would leave the wild-type htt protein 
levels unchanged. This was achieved with oligonucleotides directed against single nucleotide 
polymorphisms (SNPs) unique to the mutant htt transcript (VAN BILSEN et al., 2008; LOMBARDI et 
al., 2009; PFISTER et al., 2009; WARBY et al., 2009; ZHANG et al., 2009; CARROLL et al., 2011). Another 
approach for an allele-specifi c reduction of mutant htt is targeting the expanded CAG repeat. 
Oligonucleotides complementary to the CAG repeat were found to result in allele-specifi c 
reduction of htt transcript and protein levels in patient derived cells (Krol et al., 2007; Hu et al., 
2009; Gagnon et al., 2010; Yu et al., 2012; Chapter 3). 
A novel way to alter toxicity of the mutant htt protein is through protein modifi cation. The 
major advantage of this approach is that htt transcript and protein levels are unchanged. 
Using AONs it is possible to mask exons from the splicing machinery resulting in exclusion of 
the targeted exon (SPITALI AND AARTSMA-RUS, 2012). When the reading frame is intact or restored 
after exon skipping there is subsequent translation of a modifi ed protein. This exon skipping is 
a promising therapeutic tool that is already in phase II/III clinical trial for Duchenne muscular 
dystrophy (DMD) (CIRAK et al., 2011; VAN PUTTEN AND AARTSMA-RUS, 2011). 
In this study we use 2’O-methyl modifi ed AONs with a phosphorothioate backbone to 
induce an in-frame partial exon 12 skip in human htt pre-mRNA. This resulted in a shorter 
htt protein lacking the 552 caspase-3 and 586 caspase-6 cleavage site, while total htt protein 
levels were unaltered. Using in vitro caspase-6 cleavage assay, AON treated samples showed 
less 586 N-terminal htt fragments implied in expanded htt toxicity. Injection of a single dose 
of AONs in the mouse striatum also resulted in removal of the same 552 caspase-3 and 586 
caspase-6 cleavage sites, further supporting the concept that proteolytic site removal by exon 
skipping could be a potential therapeutic approach to prevent formation of toxic N-terminal 
htt fragments. 
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4.3. Materials and Methods
Antisense oligonucleotide design
Our AONs were designed following the guidelines described by Aartsma-Rus (AARTSMA-RUS, 
2012). In short, the AONs were designed to anneal to in silico predictions of potential exonic 
splicing enhancer sites (ESEs) (DESMET et al., 2009), which have been shown to be an effi cient 
modulator of splicing (AARTSMA-RUS et al., 2005; WILTON et al., 2007). Primarily, AON design was 
based on targeting an open region in the secondary structure of the target exon as predicted 
by m-fold (ZUKER, 2003) and ensuring favorable thermodynamic properties (AARTSMA-RUS et 
al., 2009). Furthermore, cytosine-phosphate-guanine (CpG) dinucleotides were avoided in 
the AON design, as these potentially 
activate the Toll-like receptor-9 
infl ammatory response (BAUER et al., 
2001). Finally, sequences were BLAST-
verifi ed using megablast general 
algorithm parameters and short input 
sequence for the absence of stretches 
more than 15 homologous nucleotides 
to the entire genomic sequence of the 
relevant species.
Cell culture and transfection
Patient derived fi broblasts from HD patients (GM04022, purchased from Coriell Cell 
Repositories, Camden, USA) and controls (FLB73, a kind gift from Dr. M.P.G. Vreeswijk, LUMC) 
were cultured at 37°C and 5% CO2 in Minimal Essential Medium (MEM) (Gibco Invitrogen, 
Carlsbad, USA) with 15% heat inactivated fetal bovine serum (FBS) (Clontech, Palo Alto USA), 
1% Glutamax (Gibco) and 100 U/ml penicillin/streptomycin (Gibco). 
AON transfection was performed in a 6-wells plate with 3 μl of Lipofectamine 2000 (Life 
Technologies, Paisley, UK) per well. AON and Lipofectamine 2000 were diluted in MEM to a 
total volume of 500 μl and mixtures were prepared according to the manufacturer’s instruction. 
Four different transfection variables were used: 1) transfection with 1-200 nM AON12.1, 2) 
transfection with h40AON2 directed against exon 40 of the DMD gene (Control AON) (AARTSMA-
RUS et al., 2002), 3) transfection without AON (Mock). For AON sequences, see Table 1. Mixtures 
were added to a total volume of 1 ml of MEM. Four hours after transfection, medium was 
replaced with fresh medium containing 5% FBS. A control AON with a 5’ fl uorescein label 
was used to ascertain optimal transfection effi ciencies by counting the number of fl uorescent 
nuclei (in general, over 80% of all nuclei). All AONs consist of 2’-O-methyl RNA and contain a 
full-length phosphorothioate backbone (Eurogentec, Liege, Belgium). 
Table 1. Antisense oligonucleotides sequences 
used for transfection and injection.










Twenty four hours after the fi rst transfection total RNA was isolated from cells using the 
Aurum Total RNA Mini Kit (BioRad, Hercules, USA), with an on-column DNase treatment for 30 
minutes. RNA was eluted in 40 μl elution buffer and cDNA was synthesized from 500ng total 
RNA using the Transcriptor First Strand cDNA Synthesis Kit with Random Hexamer primers at 
65°C (Roche, Mannheim, Germany).
PCR was performed using 2 μl cDNA, 10x PCR buffer with 1.5 mM MgCl2 (Roche), 0.25 
mM dNTPs, 10 pmol of both forward and reverse primer (Eurogentec), 1U FastStart Taq DNA 
Polymerase (Roche), and PCR grade water to a fi nal volume of 20 μl. PCR was performed with 
primers fl anking exon 9 to 16 of the human sequence (see Table 2). The PCR program started 
with a 4 min initial denaturation at 95°C, followed by 35 cycles of 30 sec denaturation at 95°C, 
30 sec annealing at 59°C, 70 sec elongation at 72°C, after which a fi nal elongation step was 
performed at 72°C for 7 min. 
Lab-on-a-Chip was performed on the Agilent 2100 Bioanalyzer (Agilent Technologies, 
Waldbronn, Germany), using the Agilent DNA 1000 Kit.
The qPCR was performed on RNA extracted from striatal tissue isolated from mouse brain, 
using 2 μl of 5x diluted cDNA, 20x EvaGreen-qPCR dye (Biotium, Hayward, USA), 10x PCR 
buffer with 1 mM MgCl2 (Roche), 0.25 mM dNTPs (Roche), 2.5 pmol forward primer, 2.5 pmol 
reverse primer, 0.35U FastStart Taq DNA Polymerase (Roche), and PCR grade water to a total 
volume of 10 μl. Primer pairs located in various exons of htt were selected for qPCR using 
Primer3 software (ROZEN AND SKALETSKY, 2000) and tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, zeta polypeptide (Ywhaz) and ribosomal protein L22 
(Rpl22) were used as reference genes. (For primer list, see Table 2). The qPCR was performed 
using the LightCycler 480 (Roche). Initial denaturation was 10 min. at 95°C, followed by 45 
cycles of 10 sec. denaturation at 95°C, 30 sec. annealing at 59°C and 20 sec. elongation at 72°C. 
The fi nal elongation was performed 5 min. at 72°C.
Primer effi ciencies were determined using LinRegPCR v2012.0 with the raw data amplifi cation 
curves as input. The raw data were baseline corrected and absolute transcript level expressions 
(N0) were calculated as described previously (RUIJTER et al., 2009). All samples were run in 
triplicate on a plate. On all plates both reference genes were included to correct for inter-plate 
variance. 
Sanger sequencing
Full-length and skipped products were amplifi ed using exon 9 forward or htt exon 16 reverse 
primer (see Table 2). PCR products were loaded on agarose gel and bands were extracted using 
the QIAquick Gel Extraction Kit (QIAgen). The purifi ed products were re-amplifi ed, purifi ed, 
and analyzed by Sanger sequencing, using the Applied Biosystems 96-capillary 3730XL system 
(Life Technologies Corporation, Carlsbad, USA) with the Applied Biosystems BigDyeTerminator 
v3.1 kit.
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Protein isolation, caspase-6 assay and Western blotting
Cells were detached from the culture surface with a 0.5% Trypsin/EDTA solution three 
days after transfection. After washing twice with HBSS, cells were resuspended in 200 μl ice 
cold caspase lysis buffer, containing 50 mM Hepes, 50 mM NaCl, 10 mM EDTA, 10 mM DTT, 
0.1% CHAPS. Next, samples were sonicated 3 times for 5 seconds using ultrasound with an 
amplitude of 60 at 4°C. After 1 hour incubation in a head-over-head rotor at 4°C, the extract was 
centrifuged for 15 min at 10,000 g and 4°C and supernatant was isolated. Protein concentrations 
were determined by the bicinchoninic acid kit (Thermo Fisher Scientifi c, Waltham, USA) using 
Bovine Serum Albumin as a standard. Samples were snap frozen and stored at -80°C. 
For in vitro caspase cleavage, 30 μg protein lysate was incubated with 0.5 to 1.5 U human 
recombinant caspase-6 (Calbiochem, Darmstadt, Germany) for 5 hours at 37°C.
Protein extracts were separated by Criterion XT Tris-Acetate Gel, 3–8%, 12-wells (BioRad). 
For each sample both the PageRuler prestained and Spectra Multicolor High Range 
protein ladders (Thermo Fisher Scientifi c) were used as markers. Gels were blotted onto a 
nitrocellulose membrane using the Transblot Turbo (BioRad) for 30 min at 2.5 A. Membranes 
were blocked with Tris Buffered Saline (TBS) containing 5% non-fat milk powder (Profi tar Plus, 
Nutricia, Zoetermeer, the Netherlands). The antibodies used for detection of htt were 4C8 
(MAB2166) for htt (Millipore, Billerica, USA) dilution 1:1,000. A β-actin antibody (mouse AC-15 
(Abcam,Cambridge, UK) , dilution 1:2000) was used as loading control. Secondary antibody 
was goat α-mouse-IRDye800 (LI-COR Biosciences, Lincoln, USA), diluted 1:5,000 in block 
buffer. Odyssey scanner (LI-COR) was used to visualize infrared bands. Intensities of protein 
Table 2. Primer sequences used for Sanger sequencing and (quantitative) RT-PCR. 
Target gene Species Primer Name Application Sequence (5’ - 3’)
HTT Human hHttEx9Fw1 RT-PCR GAGCTTCTGCAAACCCTGAC
HTT Human hHttEx16Rev1 RT-PCR CTTCACGCTGACCCTCACAT
Htt Mouse mHttEx11Fw1 RT-PCR TCCAGGTCAGATGTCAGCAG
Htt Mouse mHttEx14Rev1 RT-PCR CTATGGCCCATTCTTTCCAA
Htt Mouse mHttEx12Fw1 qRT-PCR CCACTCCTGGTTCTGTTGGT
Htt Mouse mHttEx12Rev1 qRT-PCR TGGGATCTAGGCTGCTCAGT
Htt Mouse mHttEx13Fw1 qRT-PCR GTTAGATGGTGCCGATAGCC
Htt Mouse mHttEx13Rev1 qRT-PCR GTCCTCCTGTGGCTGTCCTA
Htt Mouse mHttEx27Fw1 qRT-PCR ACGGAAAGGGAAGGAGAAAG
Htt Mouse mHttEx27Rev1 qRT-PCR CACCAACTTTCTTGGGACTCA
Rpl22 Mouse mRpl22Ex3Fw1 qRT-PCR AGGAGTCGTGACCATCGAAC
Rpl22 Mouse mRpl22Ex3Rev1 qRT-PCR TTTGGAGAAAGGCACCTCTG
Ywhaz Mouse mYwhazEx4Fw1 qRT-PCR TCTGGCCCTCAACTTCTCTG
Ywhaz Mouse mYwhazEx4Rev1 qRT-PCR AGGCTTTCTCTGGGGAGTTC
Abbreviations: HTT, huntingtin; Rpl22, ribosomal protein L22; Ywhaz, tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, zeta polypeptide.
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bands were quantifi ed using Odyssey software. The skipping effi ciencies were calculated as 
described in calculations and statistical analysis paragraph.
In vivo injection into mice
Mouse htt specifi c AONs (mAON12.1, mAON12.2, and mAON13) and scrambled control 
AONs were injected in anesthetized C57bl/6j male mice between the ages of 12-14 weeks 
(Janvier SAS, France). For AON list, see Table 1. Animals were singly housed in individually 
ventilated cages (IVC) at a 12 hour light cycle with lights on at 7 am. Food and water were 
available ad libitum. All animal experiments were carried out in accordance with European 
Communities Council Directive 86/609/EEC and the Dutch law on animal experiments and 
were approved by the Leiden University animal ethical committee (protocol number: 11203). 
Animals were anesthetized with a cocktail of Hypnorm-Dormicum-demineralized water in a 
volume ratio of 1.33:1:3. The depth of anesthesia was confi rmed by examining the paw and tail 
refl exes. When mice were deeply anesthetized they were mounted on a Kopf stereotact (David 
Kopf instruments, Tujunga, USA). A total of 30 μg AON mix diluted in 2.5 μl sterile saline was 
bilaterally injected at the exact locations 0.50mm frontal from bregma, ±2.0mm medio-lateral, 
and -3.5mm dorso-ventral. For injections, customized borosilicate glass micro-capillary tips 
of approximately 100 μm in diameter, connected to a Hamilton needle (5 μl, 30 gauge) were 
used. The Hamilton syringe was connected to an injection pump (Harvard apparatus, Holliston, 
MA, USA) which controlled the injection rate set at 0.5 μl/min. After surgery the animals were 
returned to the home cage and remained undisturbed until sacrifi ce, with the exception of daily 
weighing in order to monitor their recovery from surgery. After 7 days the mice were sacrifi ced 
by intraperitoneal injection of overdose Euthasol (ASTfarma, Oudewater, the Netherlands) and 
brain tissue isolated and snap frozen till further analysis. 
Calculations and statistical analysis
RNA and protein skipping percentages were calculated using the following formula: Skipping 
% = (Molarity skipped product / (Total molarity full length product + skipped product)) * 
100%. The 586 N-terminal htt fragment levels were calculated using β-actin as reference. The 
skipping percentages were analyzed using a paired two-sided Student t test. Differences were 
considered signifi cant when P < 0.05.
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Exon 12 skipping resulted in a shorter htt protein resistant to caspase-6 cleavage 
The fi rst amino acid of the 586 caspase-6 site previously implicated in disease pathology 
(GRAHAM et al., 2006), is encoded in exon 12 and the last three amino acids are encoded in exon 
13. Exon 12 also encodes two caspase-3 sites at amino acids 513 and 552 (WELLINGTON et al., 
1998; WELLINGTON et al., 2000). Our initial aim was to generate a shorter htt protein lacking these 
3 caspase sites by skipping both exon 12 and 13. This double exon skip would be necessary 
to maintain the open reading frame and subsequently protein translation. Therefore, we 
transfected various AONs (Table 1) in patient derived fi broblasts, total RNA was isolated after 
24 hours and cDNA was amplifi ed using htt primers fl anking the skipped exon to examine 
skipping effi ciencies.
However, after transfection of one of the exon 12 AONs, AON12.1, that targets an ESE 
in the 3’ part of exon 12, a 135 base pair partial skip of exon 12 was observed (Figure 1a). 
This in-frame skip was confi rmed by Sanger sequencing (Figure 1b). The highest skipping 
percentage of AON12.1 in patient derived fi broblasts was 59.9% (±0.7%) at a concentration 
of 50 nM (Figure 1c). The partial exclusion of the 3’ part of htt exon 12 can be explained by 
activation of a cryptic 5’ splice site present in exon 12 (AG|GTCAG (ZHANG, 1998)) (Figure 1d). 
A thus modifi ed htt protein also lacks the active caspase-3 site at amino acid 552 (DLND), 
and the isoleucine (I) of the active caspase-6 site at amino acid 586 (IVLD) is replaced by a 
glutamine (Q).
Western blot analysis using the 4C8 antibody indeed revealed a 5 kDa shorter htt protein 
(Figure 2a), which is in concordance with the predicted 45 amino acid skip. Three days after a 
single AON12.1 transfection, 27.7% (±5.4%) of total htt protein levels consisted of this shorter 
htt protein (Figure 2b). There was no decreased cell viability after AON transfection in vitro 
(Figure S1).
To show a reduction in the amount of the 586 N-terminal htt protein fragments that are 
normally formed after caspase-6 cleavage, we performed an in vitro caspase-6 assay. Protein 
was isolated from human fi broblasts three days after treatment with 50 nM of AON12.1. After 
samples were incubated with recombinant active caspase-6, the 586 N-terminal htt protein 
fragment was detected at 98 kDa by Western blot (Figure 2a). Samples treated with AON12.1 
resulted in a 48.9% (±11.2%) reduction of these 586 N-terminal htt protein fragments (Figure 
2c). Furthermore, changing the fi rst amino acid of the amino acid 583 to 586 caspase-6 motif 
is suffi cient to prevent the formation of the toxic 586 N-terminal htt protein fragments.
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In vivo htt exon 12 skipping 
To investigate the potential of htt exon skipping in vivo and to test if removal of the amino 
acid sequence surrounding the 586 caspase-6 cleavage site could be harmful in vivo, we 
designed AONs homologous to the mouse sequence. Since mice do not exhibit the cryptic 
splice site responsible for the partial skip in human cells, we could only investigate the in-
frame full skip of both exon 12 and 13. This required the combined application of three AONs: 
mAON12.1, mAON12.2, and mAON13.
As proof of principle, murine C2C12 cells were transfected with 200nM of mAON12.1, 
mAON12.2, and mAON13. This resulted in a skip of both exons with an effi ciency of 86.8% 
(±5.6) (Figure S2). 
Figure 1. In-frame partial skip of human htt exon 12. Patient-derived fi broblasts were transfected with 
a htt AON targeting exon 12 (AON12.1), control AON, and non-transfected cells (Mock) and RNA was 
isolated after 24 hours. (a) Agarose gel analysis of the htt transcript with primers fl anking exon 12 and 13. 
Transfection with 100 nM AON12.1 resulted in a product lacking the 3’ part of exon 12. (b) Partial skip of 
exon 12 by AON12.1 was confi rmed by Sanger sequencing. (c) Lab-on-a-Chip analysis was performed 
to calculate skip levels with AON12.1 concentrations ranging from 10 to 200 nM. Mean ± SD, data were 
analyzed using paired student t-test, * P < 0.05, ** P < 0.01, *** P < 0.001, relative to mock transfection, n 
= 4. (d) Schematic representation of partial htt exon 12 skipping and subsequent changes in the 552 and 
586 caspase cleavage motifs on the htt protein. AON12.1 targets an exonic splicing enhancer site (ESE) 
cluster in the 3’ part of htt exon 12, activating a 5’ cryptic splice site and an in-frame exclusion of the 3’ 
part of exon 12. Skipping of the distal part of exon 12 results in the translation of a modifi ed htt protein, 
lacking the caspase-3 site at amino acid 552 (DLND), and the isoleucine (I) of the active caspase-6 site 
at amino acid 586 (IVLD) is replaced by a glutamine (Q).
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Next, a single dose of 30 μg scrambled AON or 30 μg mAON12.1, mAON12.2, and mAON13 
(10 μg per AON) was injected bilaterally into the mouse striatum. After 7 days the mice were 
sacrifi ced and expression levels of exon 12 and 13 in the mouse htt transcript were assessed 
by qRT-PCR (Figure 3). Exon 12 was signifi cantly reduced by 21.5% (±8.5%) and exon 13 was 
signifi cantly reduced by 23.1% (±8.3%). Exon 27, downstream of the area targeted for skipping, 
was not reduced.
This reduction in htt exon 12 and 13 after single injection in the mouse striatum further 
supports the concept that exon skipping could be a potential therapeutic approach to prevent 
formation of toxic 586 N-terminal htt fragments.
Figure 2. Modifi ed htt protein after partial exon 12 skipping is resistant to caspase-6 cleavage. 
Patient-derived fi broblasts were transfected with 50nM AON12.1 and control AONs. (a) Transfection 
with AON12.1 resulted in the appearance of a modifi ed htt protein of approximately 343 kDa. In vitro 
caspase-6 cleavage assay shows that the 586 N-terminal htt fragment (98 kDa) increases with increasing 
concentration of caspase-6. In samples from cells treated with AON12.1 this 586 N-terminal htt fragment 
is reduced, while the loading control β-actin remains unchanged. (b) Levels of modifi ed htt protein after 
transfection with AON12.1 determined by Odyssey software quantifi cation, normalized for β-actin. (c) 
Quantifi cation of the 586 N-terminal htt fragment, determined by Odyssey software, normalized for 
β-actin. Mean ± SD, data were evaluated using paired student t-test, * P < 0.05, ** P < 0.01, *** P < 
0.001, n = 6.
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Our results provide proof of 
concept that AON-mediated exon 
skipping can remove the caspase-3 
and caspase-6 motifs from the htt 
protein, both in vitro and in vivo. 
In vitro skipping, at least in the 
human transcript, counteracted the 
formation of the 586 N-terminal 
htt protein fragment implicated in 
toxicity of expanded htt. This htt 
protein modifi cation is therefore 
a novel potential therapeutic 
approach. Our results in patient-
derived fi broblasts show that a 
single AON can remove the 3’ part of 
exon 12 from the human htt mRNA 
through activation of a cryptic splice 
site in exon 12. This results in the 
formation of a shorter htt protein 
resistant to caspase-6 cleavage. A 
single injection of AONs targeting htt exon 12 and 13 into the striatum of control mice already 
resulted in a 22% reduction of htt exon 12 and 13. In vivo skipping effi ciencies are known to 
be lower than in vitro and 20 to 25% AON-induced splicing already has been shown to result 
in phenotypic improvements in DMD (TANGANYIKA-DE WINTER et al., 2012) and Usher syndrome 
mice (LENTZ et al., 2013).
Possibly, not only this 586 N-terminal htt fragment, but smaller fragments may be toxic 
entities (SATHASIVAM et al., 2013; LUNKES et al., 2002; WALDRON-ROBY et al., 2012). However, the 
formation of the 586 N-terminal mutant htt protein fragments by caspase-6 cleavage was found 
to be crucial in the pathogenesis of HD (GRAHAM et al., 2006; WELLINGTON et al., 2000). Notably, 
caspase-6 is activated in the striatum and frontal cortex of (pre-symptomatic) HD patients and 
this activation inversely correlates with the age of disease onset, as well as with the CAG repeat 
size (GRAHAM et al., 2010). Mice expressing the 586 N-terminal htt expanded polyQ fragment 
develop symptoms similar to mouse models with shorter N-terminal polyQ fragments (WARBY 
et al., 2008; TEBBENKAMP et al., 2011; WALDRON-ROBY et al., 2012) and removal of the 586 caspase-6 
site from the full-length mutant htt protein, prevents this phenotype (GRAHAM et al., 2006; 
POULADI et al., 2009), underscoring the signifi cance of this particular htt protein fragment, 
and suggesting that modifying the htt protein using AONs to prevent the formation of the 
N-terminal 586 htt fragment would be benefi cial. That caspase-6 is not exclusively responsible 
Figure 3. Reduction of mouse htt exon 12 and 13 after a 
single local injection into the mouse striatum. A single 
injection consisting of mAON12.1, mAON12.2 and mAON13 
(10 μg each) or 30 μg scrambled AON was injected 
bilaterally into the mouse striatum. After 7 days the mice 
were sacrifi ced and the presence of exon 12, 13 and 27 in 
the htt transcript was examined by qRT-PCR. Mean + SD, 







































for the formation of the 586 N-terminal htt fragment was concluded from experiments where 
a transgenic HD mouse model was crossed with a caspase-6 knock-out mouse. These mice did 
show the same 586 amino acid N-terminal htt fragment, suggesting that other proteases can 
also cleave the caspase-6 motif (GAFNI et al., 2012). Our exon skip approach does not target the 
proteases, but removes the proteolytic motif proper, implicated in enhanced toxicity from the 
htt protein (WARBY et al., 2008; TEBBENKAMP et al., 2011; WALDRON-ROBY et al., 2012).
A key question for translating genetic therapies into clinical applications for neurodegenerative 
disorders is how to administer AONs into the human brain. Since AONs do not cross the 
blood-brain-barrier, a more invasive delivery method was applied by intracranial injection 
(MILLER et al., 2013). AONs thus infused have been shown to diffuse throughout the non-human 
primate brain and could be detected in the nuclei and cell bodies of neurons and glial fi brillary 
acidic protein (GFAP)-positive astrocytes in the striatum, hippocampus, cerebellum, cortex, 
and spinal cord (KORDASIEWICZ et al., 2012). The stability, potency, and broad distribution of 
AONs in the brain marks them as good candidate for potential htt lowering therapeutic for HD. 
In our approach, AON-mediated reduction of the toxic N-terminal htt fragment is achieved 
without lowering of overall htt expression. This would be an advantage over non-allele-specifi c 
htt reduction approaches. In HD there is a gain of toxic function of the mutant htt protein, 
but regular htt is important for normal cellular function (DRAGATSIS et al., 2000) and is essential 
during development (ZEITLIN et al., 1995). Kordasiewicz et al. showed that 4 months repression 
of total htt of around 50% to 75% did not produce side effects in rats and non-human primates 
(KORDASIEWICZ et al., 2012). However, the effects of non-allele-specifi c lowering of htt over longer 
time periods has not yet been studied. This is important since HD carriers or patients probably 
have to be treated lifelong. 
For this AON-mediated htt protein modifi cation a single AON would be applicable to the 
entire HD patient population. Furthermore, by specifi cally removing critical caspase motifs 
in htt, there is less chance of unwanted side effects that could result from pharmacological 
inhibition of overall caspase-6 activity. On the other hand, while it is plausible to expect that 
the removal of a small stretch of 45 internal amino acids from htt will not, or only modestly, 
affect htt function - and only after the start of treatment - the extent of this remains to be 
established. We aim to study this further, as well as the effect on the HD-phenotype, by 
sustained intraventricular infusion of exon skipping AONs in HD animal models.
In conclusion, in the current manuscript we provide proof of principle for a novel approach 
to reduce mutant htt toxicity by modifying the protein proper, without changing its protein 
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Supplementary Materials and Methods
Cell culture mouse cells 
Mouse myoblasts C2C12 (ATCC, Teddington, UK) were cultured in Dulbecco’s Modifi ed Eagle 
Medium (DMEM) (Gibco) with 10% FBS, 1% glucose, 2% Glutamax and 100 U/ml P/S. For AON 
sequences, see Table 1.
PCR mouse huntingtin
PCR was performed with forward and reverse primer in respectively exon 9 and 14 of the 
mouse htt sequence (see Table 2).
Cell viability assay
Two days after transfection in a 96-wells plate, cells were prepared for Cellomics 
multiparameter cytotoxicity version 3 (Thermo Fisher Scientifi c) measurements, according to 
manufacturer’s instructions. Cell viability was analyzed on the Array Scan VTI reader (Thermo 
Fisher Scientifi c) using the following absorption/emission fi lter sets: (1) total nuclear intensity: 
350/461 nm, (2) lysosomal mass: 646/674 nm, and (3) cell permeability: 491/509 nm. All 
transfections were performed in triplicates on one plate.
Supplementary Figures
Figure S1. No negative effect htt AON treatment on cell viability in vitro. Control fi broblasts were 
transfected with htt AONs inducing partial skip of exon 12 (AON12.1), control AON, and non-transfected 
(mock). Mean ± SD, n = 2. The (a) total nuclear intensity, (b) lysosomal mass, and (c) cell permeability 

































































Figure S2. Skipping murine htt exon 12 and 13 in vitro. Mouse C2C12 cells were transfected with 
murine htt AONs, control AON, scrambled AON, and not transfected (Mock). (a) Agarose gel analysis 
of the htt transcript with primers fl anking exon 12 and 13. Skipping of htt exon 12 and 13 is seen after 
transfection with mAON12.1, mAON12.2, and mAON13. (b) Lab-on-a-Chip analysis of double-exon 
skipping after AON treatment. Mean ± SD, data were evaluated using paired student t-test, *** P<0.001, 
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Ataxin-3 protein modifi ca  on 
as a treatment strategy for 
spinocerebellar ataxia type 3: 
Removal of the
CAG containing exon




Spinocerebellar ataxia type 3 is caused by a polyglutamine expansion in the ataxin-3 protein, 
resulting in gain of toxic function of the mutant protein. The expanded glutamine stretch in the 
protein is the result of a CAG triplet repeat expansion in the penultimate exon of the ATXN3 
gene. Several gene silencing approaches to reduce mutant ataxin-3 toxicity in this disease 
aim to lower ataxin-3 protein levels but since this protein is involved in deubiquitination and 
proteasomal protein degradation, its long-term silencing might not be desirable. Here, we 
propose a novel antisense oligonucleotide-based protein modifi cation approach to reduce 
mutant atxin-3 toxicity by removing the toxic polyglutamine repeat from the ataxin-3 protein 
through antisense mediated exon skipping and maintaining important wild-type functions 
of the protein. In vitro studies showed that the ubiquitin binding capacity of ataxin-3 was 
unaffected after exon skipping and in vitro. Our in vivo studies showed no toxic properties of 
the novel truncated ataxin-3 protein. These results suggest a novel therapeutic approach to 
reduce polyglutamine-induced toxicity in spinocerebellar ataxia type 3.
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5.2. Introduc  on
Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is one 
of nine known polyglutamine (polyQ) disorders. PolyQ disorders are autosomal dominant 
neurodegenerative disorders caused by expansion of a CAG triplet in the coding region of a 
gene. This CAG repeat is translated into an extended glutamine stretch in the mutant protein, 
which causes a gain of toxic function inducing neuronal loss in various regions throughout 
the brain (BAUER AND NUKINA, 2009). A hallmark of all polyQ disorders is the formation of large 
insoluble protein aggregates containing the expanded disease protein. Whether these large 
aggregates are neurotoxic or neuroprotective is still under debate (TAKAHASHI et al., 2010).
In SCA3, the CAG repeat is located in the penultimate exon of the ATXN3 gene on 
chromosome 14q32.1. Healthy individuals have a CAG repeat ranging from 10 to 51, whereas 
SCA3 patients have an expansion of 52 repeats or more (CUMMINGS AND ZOGHBI, 2000). Transgenic 
mice expressing either a mutant ataxin-3 cDNA fragment (IKEDA et al., 1996) or the mutated 
full-length genomic sequence (CEMAL et al., 2002; GOTI et al., 2004), showed a clear ataxic 
phenotype with a more severe phenotype in the animals carrying larger repeats (BICHELMEIER et 
al., 2007), demonstrating a relationship between CAG repeat length and disease severity. The 
ATXN3 gene codes for the ataxin-3 protein of 45 kDa, which acts as an isopeptidase and is 
thought to be involved in deubiquitination and proteasomal protein degradation (BURNETT et 
al., 2003; SCHEEL et al., 2003; SCHMITT et al., 2007). The ataxin-3 protein contains an N-terminal 
Josephin domain that displays ubiquitin protease activity and a C-terminal tail with 2 or 3 
ubiquitin interacting motifs (UIMs), depending on the isoform (GOTO et al., 1997). Although in 
the past decade there has been extensive research into the SCA3 disease mechanisms (MATOS 
et al., 2011), it is still not completely understood how the ataxin-3 polyQ expansion results in 
the observed pathology.
The most promising recent therapeutic strategy under development for polyQ disorders 
is reducing levels of mutant polyQ proteins using RNA interference (RNAi) and antisense 
oligonucleotides (AONs). As potential gene silencing treatment for SCA3, non-allele-specifi c 
reduction of ataxin-3 has been tested in both mice (SCHMITT et al., 2007) and rats (ALVES et al., 
2010). The treated rodents were viable and displayed no overt phenotype, suggesting that 
ataxin-3 is a non-essential protein. However, ataxin-3 might also have a protective role, since 
in fl ies ataxin-3 was found to alleviate neurodegeneration induced by mutant polyQ proteins 
(WARRICK et al., 2005). Whether this is also true in humans is not known. The results in fl ies 
favors selective inhibition of mutant ataxin-3 protein levels over a total reduction of ataxin-3 
protein levels. Successful allele-specifi c reduction of the mutant ataxin-3 transcript was shown 
using lentiviral small hairpin RNAs directed against a single nucleotide polymorphism (SNP) in 
the ATXN3 gene in vitro (MILLER et al., 2003) and in vivo (ALVES et al., 2008; NOBREGA et al., 2013). 
However, this approach is limited to SCA3 patients carrying a heterozygous SNP in the ATXN3 
gene. Semi-allele-specifi c reduction of mutant ataxin-3 has also been achieved by targeting 




We here introduce a novel way to reduce toxicity of the ataxin-3 protein through protein 
modifi cation. Using AONs it is possible to mask exons in the pre-mRNA from the splicing 
machinery resulting in exclusion of the targeted exon (SPITALI AND AARTSMA-RUS, 2012). If the 
reading frame remains intact, subsequent translation yields an internally truncated protein. 
This has the major advantage that the polyQ-containing part of the protein is removed, 
while maintaining global ataxin-3 protein levels. AON-mediated exon skipping is a promising 
therapeutic tool that is already in phase II/III clinical trial for Duchenne muscular dystrophy 
(DMD) (CIRAK et al., 2011; VAN PUTTEN AND AARTSMA-RUS, 2011). 
In this study we used 2’O-methyl modifi ed AONs with a phosphorothioate backbone to 
induce an in-frame exon skip in the ataxin-3 pre-mRNA. This resulted in a modifi ed ataxin-3 
protein lacking the polyQ repeat, while total ataxin-3 protein levels were unaltered and its 
functional domains remained intact. We showed that this modifi ed protein retains its ubiquitin 
binding capacity. No cell death was seen after exon skipping, suggesting this modifi ed protein 
did not induce in vitro toxicity. Injection of a single dose of AONs in the mouse cerebral 
ventricle resulted in exon skipping in the cerebellum, the brain area most affected in SCA3. 
These results suggest exon skipping could be a promising novel therapeutic approach to 
reduce polyglutamine-induced toxicity in SCA3.
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5.3. Materials and Methods
Cell culture and transfection
Patient derived fi broblasts from SCA3 patients (GM06151, purchased from Coriell Cell 
Repositories, Camden, USA) and controls (FLB73, a kind gift from Dr. M.P.G. Vreeswijk, LUMC) 
were cultured at 37°C and 5% CO2 in Minimal Essential Medium (MEM) (Gibco Invitrogen, 
Carlsbad, USA) with 15% heat inactivated fetal bovine serum (FBS) (Clontech, Palo Alto USA), 
1% Glutamax (Gibco) and 100 U/ml penicillin/streptomycin (Gibco). Mouse myoblasts C2C12 
(ATCC, Teddington, UK) were cultured in Dulbecco’s Modifi ed Eagle Medium (DMEM) (Gibco) 
with 10% FBS, 1% glucose, 2% Glutamax and 100 U/ml P/S.
AON transfection was performed in a 6-well plate with 3 μl of Lipofectamine 2000 (Life 
Technologies, Paisley, UK) per well. AON and Lipofectamine 2000 were diluted in MEM to 
a total volume of 500 μl and mixtures were prepared according to the manufacturer’s 
instruction. Four different transfection conditions were used: 1) transfection with 1-200 nM 
AONs, 2) transfection with non-relevant h40AON2 directed against exon 40 of the DMD gene 
(Control AON) (AARTSMA-RUS et al., 2002), 
3) transfection with scrambled AON 
(Scrambled), and 4) transfection without 
AON (Mock). For AON sequences, see 
Table 1. Mixtures were added to a total 
volume of 1 ml of MEM. Four hours 
after transfection, medium was replaced 
with fresh medium containing 5% FBS. 
All AONs consisted of 2’-O-methyl 
RNA and contained a full-length 
phosphorothioate modifi ed backbone 
(Eurogentec, Liege, Belgium).
Plasmids and mutations
Full length as well as AON9.2 and AON10 induced skipped ataxin-3 fragments were PCR-
amplifi ed with ATXN3-specifi c primers (see Table 2) and cloned into pIVEX 1.4 WG vector that 
contained 6 His tags (His6-ataxin-3 full length and His6-ataxin-3Δ59aa, respectively). Three 
μg of vector DNA was used as template for cell free protein production using the RTS 100 kit 
together with the RTS ProteoMaster (Roche). His6-tagged beta-glucuronidase (GUS) (5 Prime) 
was taken along as control vector.
Leucine to alanine mutations in the UIMs were performed using the QuickChange II Site-
Directed Mutagenesis kit (Agilent Technologies, Waldbronn, Germany) following manufacturer’s 
instructions, using forward and reverse primers containing the desired mutation (see Table 2).
Table 1. Antisense oligonucleotides sequences 
used for transfection and injection.











Twenty four hours after the fi rst transfection, total RNA was isolated from cells using the 
Aurum Total RNA Mini Kit (BioRad, Hercules, USA), with an on-column DNase treatment for 30 
minutes. Brain tissue was homogenized using ceramic MagNA Lyser beads (Roche, Mannheim, 
Germany) by grinding in a Bullet Blender (Next Advance, Averill Park, USA) according to 
manufacturer’s instructions. RNA was eluted in 40 μl elution buffer and cDNA was synthesized 
from 1 μg total RNA using the Transcriptor First Strand cDNA Synthesis Kit with Random 
Hexamer primers at 65°C (Roche).
PCR was performed using 2 μl cDNA, 10x PCR buffer with 1.5 mM MgCl2 (Roche), 0.25 
mM dNTPs, 10 pmol of both forward and reverse primer (Eurogentec), 1U FastStart Taq DNA 
Polymerase (Roche), and PCR grade water to a fi nal volume of 20 μl. PCR was performed 
with primers for human and mouse ataxin-3 (see Table 2). The PCR program started with 
a 4 min initial denaturation at 95°C, followed by 35 cycles of 30 sec denaturation at 95°C, 
30 sec annealing at 59°C, 45 sec elongation at 72°C, after which a fi nal elongation step was 
performed at 72°C for 7 min. Lab-on-a-Chip was performed on the Agilent 2100 Bioanalyzer 
(Agilent Technologies), using the Agilent DNA 1000 Kit.
The qPCR was performed on RNA extracted from tissue isolated from mouse brain, using 
2 μl of 5 times diluted cDNA, 20 times EvaGreen-qPCR dye (Biotium, Hayward, USA), 10 times 
PCR buffer with 1 mM MgCl2 (Roche), 0.25 mM dNTPs (Roche), 2.5 pmol forward primer, 2.5 
pmol reverse primer, 0.35U FastStart Taq DNA Polymerase (Roche), and PCR grade water to 
a total volume of 10 μl. Primer pairs located in various exons of ataxin-3 were selected for 
qRT-PCR using Primer3 software (ROZEN AND SKALETSKY, 2000) and tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, zeta polypeptide (Ywhaz) and ribosomal 
protein L22 (Rpl22) were used as reference genes. (For primer list, see Table 2). The qRT-PCR 
was performed using the LightCycler 480 (Roche). Initial denaturation was 10 min. at 95°C, 
followed by 45 cycles of 10 sec. denaturation at 95°C, 30 sec. annealing at 60°C and 20 sec. 
elongation at 72°C. The fi nal elongation was performed 5 min. at 72°C.
Primer effi ciencies were determined using LinRegPCR v2012.0 with the raw data amplifi cation 
curves as input. The raw data were baseline corrected and absolute transcript level expressions 
(N0) were calculated as described previously (RUIJTER et al., 2009). All samples were run in 
triplicate on a plate. On all plates both reference genes were included to correct for inter-plate 
variance. 
Sanger sequencing
Full length and skipped products were amplifi ed using primers fl anking ataxin-3 exon 9 
and 10 (see Table 2). PCR products were loaded on agarose gel and bands were extracted 
using the QIAquick Gel Extraction Kit (QIAgen, Valencia, USA). The purifi ed products were 
re-amplifi ed, purifi ed, and analyzed by Sanger sequencing, using the Applied Biosystems 
96-capillary 3730XL system (Life Technologies Corporation, Carlsbad, USA) with the Applied 
Biosystems BigDyeTerminator v3.1 kit.
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Protein isolation, ubiquitin binding assay and Western blotting
Cells were detached from the culture surface with a 0.5% Trypsin/EDTA solution. After 
washing twice with HBSS, cells were resuspended in 200 μl ice cold lysis buffer, containing 15 
mM Hepes, pH 7.9, 200 mM KCl, 10 mM MgCl2, 1% NP40, 10% glycerol, 20 μg/ml BSA, and 
1 tablet Complete mini protease inhibitor EDTA free (Roche) per 10 ml buffer. Next, samples 
were sonicated 3 times for 5 seconds using ultrasound with an amplitude of 60 at 4°C. After 
1 hour incubation in a head-over-head rotor at 4°C, the extract was centrifuged for 15 min 
at 10,000 g and 4°C and supernatant was isolated. Protein concentrations were determined 
by the bicinchoninic acid kit (Thermo Fisher Scientifi c, Waltham, USA) using Bovine Serum 
Albumin (BSA) as a standard. Samples were snap frozen and stored at -80°C.
His6-ataxin-full length and His6-ataxin-3Δ59aa proteins were bound to TALON metal 
affi nity beads (Clontech) for 30 minutes. The ataxin-3-bound beads were incubated at 4°C with 
5 μg poly-ubiquitin chains (Enzo Life Sciences, Farmingdale, USA). Binding reactions contained 
15 mM Hepes, pH 7.9, 200 mM KCl, 10 mM MgCl2, 1% NP40, 10% glycerol, and 20 μg/ml 
BSA. Beads were washed extensively and bound proteins were removed from the beads by 2 
Table 2. Primer sequences used for Sanger sequencing, mutagenesis, and 
(quantitative) RT-PCR. 
Target gene Species Primer Name Application Sequence (5’ - 3’)
ATXN3 Human hATXN3Ex8Fw1 RT-PCR CCATAAAACAGACCTGGAACG
ATXN3 Human hATXN3Ex11Rev1 RT-PCR ACAGCTGCCTGAAGCATGTC
ATXN3 Human hATXN3_SDM_L229AFw Mutagenesis ACGAAGATGAGGAGGATGCGCAGAGGGCTCTGGC
ATXN3 Human hATXN3_SDM_L229ARev Mutagenesis GCCAGAGCCCTCTGCGCATCCTCCTCATCTTCGT
ATXN3 Human hATXN3_SDM_L249AFw Mutagenesis ACATGGAAGATGAGGAAGCAGATGCCCGCAGGGCTAT
ATXN3 Human hATXN3_SDM_L249ARev Mutagenesis ATAGCCCTGCGGGCATCTGCTTCCTCATCTTCCATGT
Atxn3 Mouse mAtxn3Ex7Fw1 RT-PCR AAGAGCAGAGTGCCCTCAAA
Atxn3 Mouse mAtxn3Ex11Rev1 RT-PCR TTTCTAAAGACATGGTCACAGC
Atxn3 Mouse mAtxn3Ex4Fw1 qRT-PCR TGCTTTGAAAGTTTGGGGTTT
Atxn3 Mouse mAtxn3Ex4Rev1 qRT-PCR CTGAGCCTCTGGTACTCTGGA
Atxn3 Mouse mAtxn3Ex9Fw1 qRT-PCR GTCCACAGACATCAAGTCCAGA
Atxn3 Mouse mAtxn3Ex9Rev1 qRT-PCR GTCTCCTCCGCAGCTCTTC
Atxn3 Mouse mAtxn3Ex10Fw1 qRT-PCR AGCAGCAGCAGGAGGTAGAC
Atxn3 Mouse mAtxn3Ex10Rev1 qRT-PCR CGTCCTCCTGAACTTGTGGT
Atxn3 Mouse mAtxn3Ex11Fw1 qRT-PCR ACCGACCACAAGTTCAGGAG
Atxn3 Mouse mAtxn3Ex11Rev2 qRT-PCR CCGAAGCATGTCCTCTTCAC
Rpl22 Mouse mRpl22Ex3Fw1 qRT-PCR AGGAGTCGTGACCATCGAAC
Rpl22 Mouse mRpl22Ex3Rev1 qRT-PCR TTTGGAGAAAGGCACCTCTG
Ywhaz Mouse mYwhazEx4Fw1 qRT-PCR TCAGCAAAAAGGAGATGCAG
Ywhaz Mouse mYwhazEx4Rev1 qRT-PCR TTTCTCTGGGGAGTTCAGGA
Abbreviations: ATXN3, ataxin-3; Rpl22, ribosomal protein L22; Ywhaz, tyrosine 3-monooxygenase/tryp-
tophan 5-monooxygenase activation protein, zeta polypeptide.
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hours incubation at 23°C with 2 μg Factor Xa Protease (New England Biolabs, Ipswich, United 
Kingdom) per reaction. 
Protein extracts were separated by SDS-PAGE, with 10% acryl/bisacrylamide 1:37.5 
separating gels, or Any kD precast TGX gels (BioRad). For each gel the PageRuler prestained 
protein ladder (Thermo Fisher Scientifi c) was used as marker. Electrophoresis was performed 
until the lowest marker reached the bottom of the gel. Gels were blotted onto nitrocellulose 
membranes using the Transblot Turbo (BioRad) for 30 min at 2.5 A. Membranes were blocked 
with Tris Buffered Saline (TBS) containing 5% non-fat milk powder (Profi tar Plus, Nutricia, 
Zoetermeer, the Netherlands). 
The mouse SCA3-1H9 antibody was used for detecting ataxin-3 (Millipore, Billerica, 
USA), dilution 1:1000, or rabbit His-tag 2365 (Cell Signaling Technology, Danvers, USA). To 
detect expanded polyQ stretches we used mouse 1C2 (Eurogentec), dilution 1:500. To detect 
ubiquitin chains, we used rabbit ubiquitin-protein conjugates (Enzo Life Sciences), diluted 
1:2000. Secondary antibodies were goat α-mouse-IRDye800, goat α-rabbit-IRDye800 (LI-COR 
Biosciences, Lincoln, USA), or goat α-mouse-horseradish peroxidase (HRP) (Santa Cruz 
Biotechnology, USA), diluted 1:5,000 in block buffer. Horseradish peroxidase was activated by 
ECL+ reagent (GE Healthcare, Buckinghamshire, United Kingdom) to visualize positive staining 
on fi lm or Odyssey scanner (LI-COR) was used to visualize infrared bands. Intensities of protein 
bands were quantifi ed using Odyssey software. The skipping effi ciencies were calculated as 
described in the calculations and statistical analysis paragraph.
AON injection into mice
Mouse ataxin-3 specifi c AONs (mAON9.1 and mAON10) and scrambled control AONs (Table 
1) were injected in anesthetized 12-14 week old C57bl/6j male mice (Janvier SAS, France). 
Animals were singly housed in individually ventilated cages (IVC) at a 12 hour light cycle with 
lights on at 7 am. Food and water were available ad libitum. All animal experiments were 
carried out in accordance with European Communities Council Directive 86/609/EEC and the 
Dutch law on animal experiments and were approved by the Leiden University animal ethical 
committee (protocol number: 12186). A total of 40 μg AON mix diluted in 5 μl sterile saline 
was injected into the left lateral ventricle at 0.22 mm anterior-posterior, 1.5 mm medio-lateral, 
and -2.5 mm dorso-ventral relative to bregma, using borosilicate glass micro-capillary tips 
connected to a Hamilton syringe (5 μl, 30 gauge). The Hamilton syringe was connected to an 
injection pump (Harvard apparatus, Holliston, MA, USA), which controlled the injection rate set 
at 0.5 μl/min. After 7 days the mice were sacrifi ced and brain isolated and frozen for qRT-PCR 
analysis.
Calculations and statistical analysis
RNA and protein skipping percentages were calculated using the following formula: 
Skipping% = (Molarity skipped product / (Total molarity full length product + skipped 
product)) * 100%. The skipping percentages were analyzed using a paired two-sided Student t 
test. Differences were considered signifi cant when P < 0.05.
121







AON mediated skipping of ataxin-3 exon 9 and 10 in vitro
The CAG repeat in the ATXN3 gene is located in exon 10, which is 119 nucleotides in 
length. Thus skipping will disrupt the reading frame. To preserve the reading frame exon 9 
(97 nucleotides) and 10 need to be skipped simultaneously. Various AONs were designed 
targeting exon internal sequences of ataxin-3 exon 9 and 10 and transfected in human 
fi broblasts (Table 1). PCR analysis revealed a 97 nucleotide skip after transfection with 100nM 
of AON9.1 (effi ciency = 59.2% ±1.0%) (Figure 1a and b). Sanger sequencing confi rmed that 
this was a skip of exon 9. Transfection with 100 nM AON9.2 resulted in a skip of 55 nucleotides 
(effi ciency = 62.3% ±3.7%) instead of the anticipated 97 nucleotides (Figure 1a and c). Sanger 
sequencing revealed that this fragment was a partial skip product that still contained the 5’ 
part of exon 9. In silico analysis showed the existence of a cryptic 5’ splice site AG|GTCCA in 
exon 9 that could explain the occurrence of this shorter fragment (ZHANG, 1998). Successful 
skipping of exon 10 was achieved with 50 nM AON10 (effi ciency = 96.3% ±0.3%) (Figure 1a 
and d), as confi rmed by Sanger sequencing.
Co-transfection of AON9.1 and AON10 and AON9.2 and AON10 resulted in a skip of 
respectively 216 and 174 nucleotides (Figure 2). The effi ciency of the AON9.1 and AON10 
induced double skip was 77.0% (±0.9%) in control fi broblasts (Figure 2d and e). The effi ciency 
of AON9.2 and AON10 co-transfection was 97.8% (±0.8%) in control fi broblasts (Figure 2d 
and e). The unexpected in-frame partial skip of exon 9 with AON9.2 resulted in an alternative 


















































































Figure 1. Single exon skipping of ataxin-3 pre-mRNA in vitro. Control fi broblasts were transfected 
with ataxin-3 AONs, control AON, and non-transfected (mock) and RNA was isolated after 24 hours. 
(a) Agarose gel analysis of the ataxin-3 transcript with primers fl anking exon 9 and 10 (full-length, grey 
arrowhead). Transfection with 50 nM AON against exon 9 resulted in a product lacking the entire exon 9 
(AON9.1, white arrowhead) or lacking the 3’ part of exon 9 (AON9.2, two white arrowheads). Transfection 
with 50 nM AON10 resulted in a product lacking exon 10 (three white arrowheads). Fibroblasts were 
transfected with concentrations ranging from 10 to 200 nM per ataxin-3 AON and Lab-on-a-Chip analysis 
was performed to calculate exon skip levels for (b) AON9.1, (c) AON9.2, and (d) AON10. Mean ± SD, 
data were evaluated using paired student t-test, * P < 0.05, ** P < 0.01, *** P < 0.001, relative to mock 
transfection, n = 4.
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Modifi ed ataxin-3 protein maintains its ubiquitin binding capacity
To investigate if AON transfection resulted in a modifi ed ataxin-3 protein, control and SCA3 
fi broblasts were transfected with AONs targeting exon 9 and 10 and protein was isolated three 
days after transfection. We did not see a negative effect on cell viability after AON treatment in 
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Figure 2. Double exon skipping of ataxin-3 pre-mRNA in vitro. (a) Schematic representation of two 
approaches to induce in-frame skipping of the CAG repeat-containing exon. (b) Skip of exon 9 and 10 
(AON9.1 + AON10) confi rmed by Sanger sequencing. (c) Partial skip of exon 9 and complete skip of 
exon 10 (AON9.2 + AON10) confi rmed by Sanger sequencing. (d) Agarose gel analysis of the ataxin-3 
transcript with primers fl anking exon 9 and 10. Transfection of control fi broblasts resulted in a product 
lacking both exon 9 and 10 (AON9.1 + AON10, black arrowhead) or lacking the 3’ part of exon 9 and 
exon 10 (AON9.2 + AON10, white arrowhead). (e) Lab-on-a-Chip analysis was performed to calculate 
exon skip levels in control cells. Mean + SD, data were evaluated using paired student t-test, ** P <0.01, 
*** P < 0.001, relative to mock, n = 4.
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either control or SCA3 fi broblasts (Figure S1). Western blot analysis using an ataxin-3-specifi c 
antibody revealed a modifi ed band of approximately 35 kDa after the complete skip of exon 9 
and 10 (ataxin-3 Δ72aa) (Figure 3a); 11.4% (±5.1%) and 6.2% (±1.9%) of total ataxin-3 protein 
levels consisted of this modifi ed ataxin-3 Δ72aa protein , in respectively control and SCA3 
fi broblasts (Figure 3b and c). 
The partial exon skip resulted in a novel 37 kDa protein (ataxin-3 Δ59aa) (Figure 3a). 27.1% 
(±9.0%) and 15.9% (±3.2%) of total ataxin-3 protein levels consisted of this 59 amino acids 
shorter ataxin-3 protein, in respectively control and SCA3 cells (Figure 3b and c). The ataxin-3 
Δ72aa protein was also formed, suggesting that AON9.2 and AON10 transfection also resulted 
in some ataxin-3 Δ72aa protein. The consistent lower percentage of exon skipping in SCA3 
cells were caused by the lower AON transfection effi ciencies in the diseased cells as compared 
to control cells.
A signifi cant reduction in expanded polyQ containing ataxin-3 was shown using the 1C2 
antibody, that recognizes long glutamine stretches (TROTTIER et al., 1995) (Figure 3a) in the 
Figure 3. Modifi ed ataxin-3 protein after exon 9 and 10 skipping. Human control and SCA3 fi broblasts 
were transfected with 50nM of each AON. (a) Transfection with AON9.1 and AON10, or AON9.2 and 
AON10 resulted in modifi ed ataxin-3 proteins of 35 kDa (ataxin-3 Δ72aa) and 37 kDa (ataxin-3 Δ59aa), 
respectively. The modifi ed protein products were shown using an ataxin-3 specifi c antibody. The 
reduction in polyQ-containing mutant ataxin-3 was shown with the polyQ antibody 1C2. Densitometric 
analysis was used after transfection with AONs. Ataxin-3 Δ72aa (white bars) and ataxin-3 Δ59aa (black 
bars) in (b) control and (c) SCA3 cells. Mean + SD, data were evaluated using paired student t-test, * P 































































































samples with the full and partial exon skip approaches. This indicates a reduction of expanded 
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Figure 4. Full-length and modifi ed ataxin-3 protein displays identical ubiquitin binding. 
(a) Schematic representation of the known functional domains of the ataxin-3 protein involved in 
deubiquitination. The ataxin-3 protein consists of an N-terminal (Josephin) domain with ubiquitin protease 
activity and a C-terminal tail with the polyQ repeat and 3 ubiquitin interacting motifs (UIMs). After exon 
skipping (ataxin-3 Δ59aa), the polyQ repeat is removed, leaving the Josephin domain and UIMs intact. 
(b) Overview of a leucine (L) to alanine (A) substitution in UIM 1 (L229A), UIM 2 (L249A) or both (L229A/
L249A) in full-length ataxin-3 and ataxin-3 Δ59aa. (c) Ubiquitin binding assay. HIS-tagged full-length 
ataxin-3 and ataxin-3 Δ59aa-bound ubiquitylated proteins were analyzed by Western blot. HIS control 
and beads only were taken along as negative control. The modifi ed ataxin-3 Δ59aa lacking the polyQ 
repeat showed identical ubiquitylated protein binding as unmodifi ed ataxin-3. (n = 3)
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The polyQ repeat in the ataxin-3 protein is located between the second and third UIM 
(Figure 4A). Both full and partial exon skip approaches resulted in removal of the polyQ 
repeat, preserving the Josephin domain, nuclear export signal (NES), and UIMs. To investigate 
whether the ubiquitin binding capacities of the UIMs in ataxin-3 are still intact after protein 
modifi cation, poly-ubiquitin chains were incubated with purifi ed cell free produced full-length 
ataxin-3 and ataxin-3 Δ59aa protein. As negative controls, we produced 3 different ataxin-3 
protein products containing 1 amino acid substitutions from leucine (L) to alanine (A) in UIM 
1 (L229A), UIM 2 (L249A), or both (L229A/L249A) (Figure 4b). Single amino acid changes in 
UIM 1 (L229A) already showed reduced binding of ataxin-3 to poly-ubiquitin chains, whereas 
double UIM mutated ataxin-3 (L229A/L249A) resulted in a nearly complete elimination poly-
ubiquitin binding (Figure 4c). This is consistent with previously described data (BURNETT et 
al., 2003). The negative HIS control protein did not bind ubiquitylated proteins as expected. 
Ataxin-3 Δ59aa bound poly-ubiquitin chains comparable to full-length ataxin-3, indicating 
that its ubiquitin binding capacity after protein modifi cation is still intact (Figure 4c). 
AON mediated skipping of ataxin-3 exon 9 and 10 in mouse
To examine ataxin-3 exon skipping in the mouse brain and to determine if the modifi ed 
protein is not harmful, we designed AONs specifi c to the mouse sequence. Since mice do 
not exhibit the cryptic splice site that is responsible for the partial exon 9 skip in the human 
transcript, we only investigated the full skip of exon 9 and 10. Transfection of 200 nM of 
each murine AON9 (mAON9) and AON10 (mAON10) in mouse C2C12 cells showed a skip of 
both exons with an effi ciency of 31.7% (±2.4%) (Figure 5a). Sanger sequencing confi rmed this 
in-frame double exon skip (Figure 5b). Transfection with mAON9 and mAON10 resulted in 
formation of a modifi ed protein of 34 kDa (Figure 5c). 
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Figure 5. Double exon skipping of murine ataxin-3 pre-mRNA in vitro. Mouse C2C12 cells were 
transfected with murine ataxin-3 AONs, control AON, scrambled AON, and not transfected (Mock). 
(a) Agarose gel analysis of the ataxin-3 transcript with primers fl anking exon 9 and 10. Skipping of 
ataxin-3 exon 9 and 10 was seen after transfection with mAON9.1 and mAON10. (b) Sanger sequencing 
confi rmed the precise skipping of exon 9 and 10. (c) Transfection with mouse AON9.1 and AON10 
resulted in the appearance of a modifi ed ataxin-3 protein of 34 kDa.
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Next, a single intra-cerebral ventricular 
(ICV) injection was administered of 40 μg 
ataxin-3 AON mix (20 μg per AON) or 40 
μg scrambled AON. After 7 days the mice 
were sacrifi ced and skipping effi ciency in 
the cerebellum was assessed by qRT-PCR 
(Figure 6). Exon 9 was found signifi cantly 
reduced by 44.5% (±7.6%) and exon 10 
was reduced by 35.9% (±14.1%) after a 
single ICV injection of AONs as compared 
to scrambled AON. Exon 4, upstream, 
and exon 11, downstream of the area 
targeted for skipping were not reduced, 
demonstrating a specifi c skip of ataxin-3 
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Figure 6. Reduction of mouse ataxin-3 exon 9 in 
vivo. Seven days after a single injection consisting of 
mAON9 and mAON10 (20 μg each) into the mouse 
cerebral ventricle. qRT-PCR analysis of cerebellar 
tissue showed reduced exon 9 and 10 transcript 
levels, whereas exon 4 and 11 levels were not 
affected. Mean + SD, data were evaluated using 
paired student t-test, * P < 0.05, n = 3.
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In the current study we show a novel approach to reduce toxicity of the mutant ataxin-3 
protein through skipping of the CAG repeat containing exon in the ataxin-3 transcript. The 
resulting modifi ed ataxin-3 protein lacks the polyQ repeat that is toxic when expanded, but 
maintains its ubiquitin binding properties. ICV administration of these AONs in mice resulted 
in skipping of the CAG repeat-containing exon in the cerebellum of control mice, proving 
distribution and effi ciency of ataxin-3 exon skipping after ICV injection in vivo. 
There was no negative effect on cell viability after AON treatment in both control and SCA3 
fi broblasts and also no overt toxicity in vivo. There are several known important functional 
domains in ataxin-3 that have been implicated to be involved in the SCA3 pathogenesis. 
Skipping of exon 9 and 10 described here resulted in removal of sequences encoding the 
calcium-dependent calpain cleavage and nuclear localization signal (NLS), both located in exon 
9. Following to the weak NLS located in the C-terminus (MACEDO-RIBEIRO et al., 2009), the ataxin-
3 protein has two strong NES located at the N-terminal part (MACEDO-RIBEIRO et al., 2009). In 
SCA3 it is thought that proteolytic cleavage of mutant ataxin-3 results in C-terminal fragments 
lacking the NES but containing the polyglutamine stretch, resulting in localization of the toxic 
C-terminal fragments into the nucleus and formation of nuclear inclusion bodies (BICHELMEIER 
et al., 2007; COLOMER GOULD et al., 2007). Recent studies in a mutant N-terminal ataxin-3 mouse 
model showed that N-terminal fragments, lacking the NLS, reside in the cytosol and form 
cytoplasmic inclusion bodies with subsequent neuronal degeneration (HUBENER et al., 2011). 
Both above described mutant C- and N-terminal ataxin-3 fragments could be the result of 
calpain cleavage at amino acid 260 (HAACKE et al., 2007). Skipping of exon 9 and 10 will also 
result in removal of an arginine/lysine-rich motif around amino acid 285 that was found to be 
a potential valosin containing protein (VCP) binding domain (DOSS-PEPE et al., 2003; BOEDDRICH et 
al., 2006). The ataxin-3-VCP complex is thought to be involved in assisting targeted proteins to 
the proteasome (WANG et al., 2006). In fl ies, co-expression of mutant ataxin-3 and VCP, resulted 
in alleviation of ataxin-3 aggregation and neurotoxicity in photoreceptor neurons (BOEDDRICH 
et al., 2006). Whether removal of the VCP binding domain by exon skipping causes impaired 
degradation of target substrates needs to be assessed in future studies.
As potential gene silencing treatment for SCA3, both non-allele and allele-specifi c reduction 
of (mutant) ataxin-3 have been tested. The main advantage of the AON-based protein 
modifi cation approach compared to existing gene silencing approaches is the preservation of 
overall ataxin-3 transcript and protein levels. Only the polyQ stretch and a small portion of the 
surrounding amino acids of the protein are removed and the N-terminal Josephine domain 
and C-terminal ubiquitin binding motifs are preserved. We validated this by showing that the 
modifi ed ataxin-3 protein retains its normal ubiquitin binding function. Furthermore, the exon 
skipping approach described here has the advantage that one set of AONs can be applied to 
all SCA3 patients. This in contrast with a previously described SNP-specifi c approach (MILLER 
et al., 2003; ALVES et al., 2008) that is only applicable for 70% of the patients who have the 
128
CHAPTER 5
targeted SNP in their ATXN3 gene (GASPAR et al., 2001).
That AONs are a promising therapeutic tool was recently shown in phase I and phase I/II 
clinical trials in DMD (CIRAK et al., 2011; GOEMANS et al., 2011). As treatment for neurodegenerative 
disorders, AONs with a phosphorothioate backbone are very promising and are currently 
tested in phase I and phase I/II clinical trials for amyotrophic lateral sclerosis (CLINICALTRIALS.GOV, 
2009) and, more recently, a phase I trial has been initiated for spinal muscular atrophy (RIGO 
et al., 2012). After injection into the cerebrospinal fl uid in non-human primates, AONs diffuse 
to the brain areas affected most in SCA3, which are the cerebellum, basal ganglia, and pons 
(KORDASIEWICZ et al., 2012). In transgenic HD mice, the most pronounced mutant huntingtin 
protein reduction was seen after AON infusion for a limited period of time. Furthermore, 
several months after the last AON infusions there were sustained phenotypic improvements 
(KORDASIEWICZ et al., 2012).
The above results are very promising but future experiments will have to determine the best 
route of administration to the brain, optimal dosage, and treatment regime. Future experiments 
are required to evaluate whether polyQ skipping improves the SCA3 induced phenotype using 
transgenic SCA3 mice. Furthermore, it will also be necessary to assess whether the modifi ed 
ataxin-3 protein is not toxic in vitro and in vivo and whether exon skipping results in altered 
localization, function, or aggregation.
In conclusion, we show that it is possible to remove the toxic polyQ repeat from a polyQ 
disease-causing protein and that this modifi ed ataxin-3 protein exhibits regular ubiquitin 
binding. We also show the in vivo potential of this approach as CAG repeat-containing exon 
skip in the cerebellum was seen after a single ICV injection.
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Figure S1. No negative effect on cell viability after ataxin-3 AON treatment in control fi broblasts. 
Control fi broblasts were transfected in a 96-wells plate with ataxin-3 AONs inducing partial skip of exon 
9 and complete skip of exon 10 (AON9.2 + AON10), control AON, and non-transfected (mock). Two days 
after transfection cells were prepared for Cellomics multiparameter cytotoxicity version 3 (Thermo Fisher 
Scientifi c) measurements, according to manufacturer’s instructions. Cell viability was analysed on the 
Array Scan VTI reader (Thermo Fisher Scientifi c) using the following absorption/emission fi lter sets: (a) 
total nuclear intensity: 350/461 nm, (b) lysosomal mass: 646/674 nm, and (c) cell permeability: 491/509 










































































Future perspec  ve
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CHAPTER 6
6.1. Introduc  on
In this thesis I have discussed various AON-mediated therapies to reduce polyQ-induced 
toxicity, particularly in HD and SCA3. These expanded polyQ proteins are known to undergo 
proteolytic processing and this results in polyQ-containing protein fragments that are 
considered to be the main toxic entities in polyQ disorders. By targeting the polyQ-encoding 
transcripts, translation of mutant polyQ protein is reduced or the polyQ protein is modifi ed. 
This is achieved by targeting the CAG repeat directly (chapter 3), removing the motifs that 
are implicated in the formation of polyQ fragments (chapter 4), or by removal of the CAG 
repeat-encoding exon (chapter 5).
Recently however, it has also been suggested that the polyQ pathogenesis is not only caused 
by polyQ protein toxicity. The signifi cance of these novel fi ndings will be assessed together 
with implication for the AON-mediated treatments proposed in this thesis. Subsequently, I will 
discuss the prospect of applying similar AON-mediated therapies to other polyQ disorders. 
Finally, using existing knowledge from preclinical studies with AONs in rodents and clinical 
trials with disease-modifying drugs, I will discuss what is required for the enrolment of future 
clinical trials of genetic therapies in polyQ diseased patients.
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6.2. Main fi ndings
In this thesis I propose various novel genetic therapies for polyQ disorders, aiming at reducing 
and/or modifying polyQ disease-causing proteins. While much research has been done on 
the underlying polyQ disease mechanisms, knowledge on mRNA and protein regulation and 
expression levels are limited. Chapter 2 describes differences in HTT RNA and htt protein 
expression in adult-onset HD with less mutant HTT mRNA, but equal wild-type and mutant 
htt protein levels. Juvenile HD subjects did show less mutant htt protein expression compared 
to wild-type, indicating subtle differences in htt protein expression between adult-onset and 
juvenile HD. 
In chapter 3, CUG triplet-repeat AONs are used to reduce mutant polyQ transcript and 
protein levels in several polyQ disorders. A slight reduction in wild-type CAG transcript levels 
was observed as well, showing that the (CUG)7 AON is not completely specifi c for the mutant 
allele. However, several other non-expanded CAG-containing transcripts investigated were 
not affected by (CUG)7 AON treatment, implying the preference of the (CUG)7 AON for the 
expanded transcript. Furthermore, chapter 2 describes that the basal levels of mutant HTT 
mRNA and protein are equal or lower than wild-type, providing feasibility for AONs such as 
the (CUG)7 AON described in chapter 3, that are not completely specifi c for the mutant HTT 
allele.
Next to specifi cally targeting the expanded CAG repeat transcripts to reduce the translation 
of mutant polyQ protein, chapter 4 reports on removing motifs that are implicated in the 
formation of toxic polyQ fragments. Preventing the formation of a 586 amino acid N-terminal 
htt fragment, implicated in HD toxicity, is achieved by AONs that induce skipping of exon 12 
in HTT pre-mRNA. This resulted in a shorter protein lacking the caspase-6 cleavage motif with 
subsequently reduced 586 amino acid N-terminal htt fragments. This proof of concept shows a 
completely novel approach to reduce mutant htt toxicity not by reducing its expression levels, 
but by modifying the protein.
A more direct genetic approach to reduce polyQ-induced toxicity is shown in chapter 5, 
where the toxic polyQ repeat is removed from the ataxin-3 protein through AON-mediated 
skipping of the CAG repeat-enclosing ATXN3 exon 10. A modifi ed ataxin-3 protein is formed 
that lacks the toxic polyQ repeat, but may well maintain many important wild-type functions 
of the protein. 
In chapter 4 and 5 the feasibility of the AONs is shown in vivo by ICV injections of the murine 
AONs into control mice. Above described results suggest that both targeting the CAG repeat 
directly, or AON-mediated exon skipping may be suitable therapeutic approaches to reduce 




Until recently it was believed that polyQ disorders are solely the result of gain of toxic 
protein function and to a lesser extent, loss of wild-type protein function. Recent fi ndings 
have shown that the molecular pathogenesis of these disorders is more complex. More and 
more observations suggest that next to polyQ protein toxicity, RNA toxicity and bidirectional 
transcription are also involved in the polyQ disease pathogenesis. These potential novel 
toxic mechanisms have to be taken into account when designing an AON-mediated disease-
modifying treatment.
CAG repeat-induced RNA toxicity
Recently, in patient-derived juvenile HD fi broblasts expanded CAG repeat-induced RNA foci 
were shown (DE MEZER et al., 2011), suggesting a RNA toxicity component in HD. Furthermore, 
overexpression of untranslated repeats with 200 CAGs showed clear nuclear RNA foci, 
progressive neural dysfunction, reduced breeding effi ciency, and premature death in various 
transgenes (LI et al., 2008; HSU et al., 2011; WANG et al., 2011). Although the exact mechanism 
of this expanded CAG repeat-induced toxicity remains elusive, there is some evidence that 
RNA toxicity may result from stable CAG hairpin structures which can sequester RNA binding 
proteins in nuclear foci, resulting in misregulation of alternative splicing (LI et al., 2008; MYKOWSKA 
et al., 2011; WANG et al., 2011). Next to CAG repeat-induced deregulation of splicing, short 
CAG repeat-containing RNAs of around 21 nucleotides, originating from mutant CAG repeat-
containing RNAs were found to induce cell death (BANEZ-CORONEL et al., 2012). The toxicity was 
CAG repeat dependent, since toxicity was blocked by AONs against the CAG repeat sequence, 
similar to the (CUG)7 AON described in chapter 3 (BANEZ-CORONEL et al., 2012). 
The size of the CAG repeat is probably critical for the contribution of mRNA aggregation 
from the expanded CAG repeat because overexpression of untranslated repeats with 83 and 
93 CAGs did not appear to result in a phenotype (MCLEOD et al., 2005; WANG et al., 2011). 
Likewise, in chapter 2 the levels of wild-type and mutant HTT mRNA and htt protein did not 
differ in adult-onset HD fi broblasts, suggesting that there is no mutant CAG repeat-induced 
mRNA aggregation in HD fi broblasts. To note, the repeat sizes of the adult-onset HD patients 
described in chapter 2 are shorter compared to the juvenile HD fi broblasts (with 68 and 151 
CAGs repeats) in which RNA foci were observed (de Mezer et al., 2011), and therefore CAG 
repeat-induced RNA toxicity could still play a role in patients with extremely expanded CAG 
repeat lengths.
In chapter 5 a novel protein modifi cation approach is proposed to reduce mutant ataxin-3 
toxicity by removing the toxic polyQ repeat from the ataxin-3 protein. In case of CAG repeat-
induced RNA toxicity, this AON-mediated exon skipping is still applicable, since the toxic CAG 
repeat is removed from the mRNA. In the same way the RNA toxicity component in polyQ 
disorders will be prevented by the (CUG)7 AON described in chapter 3, through direct binding 
of the (CUG)7 AON to the expanded CAG repeat. The potential RNA toxicity is not targeted by 
135







the AON-mediated htt protein modifi cation described in chapter 4. This potential therapeutic 
approach prevents the formation of toxic N-terminal htt fragments and leaves the hypothetical 
toxic RNA entities intact. However, removal of the 586 caspase-6 site from the full-length 
mutant htt protein was shown to alleviate the phenotype in transgenic HD mice (GRAHAM et al., 
2006; POULADI et al., 2009), supporting the signifi cance of this particular htt protein fragment. 
Therefore the role of RNA toxicity in the disease pathology remains to be assessed.
Bidirectional transcription in polyQ disorders
For many genes in the genome transcription occurs from both DNA strands (KATAYAMA et al., 
2005; HE et al., 2008). Several studies have shown that bidirectional transcription occurs from 
triplet repeat disorder genes (CHO et al., 2005; MOSELEY et al., 2006; WILBURN et al., 2011). Although 
bidirectional transcriptional tags have been identifi ed for all nine polyQ disease-causing loci 
(HE et al., 2008), only for HD and SCA7 antisense transcripts have been studied in more detail 
(CHUNG et al., 2011; SOPHER et al., 2011). The SCA7 antisense noncoding transcript 1 (SCAANT1) 
and HTT antisense (HTTAS) transcripts are thought to be involved in downregulation of the 
corresponding sense ATNX7 and HTT gene expression (CHUNG et al., 2011; SOPHER et al., 2011). 
In total 3 HTTAS versions have been identifi ed, of which one, HTTAS_v1 contained the CTG 
repeat whereas two other, HTTAS_v2.1 (CHUNG et al., 2011) and HTTAS_v2.2 (chapter 2), did not. 
It was hypothesized that HTTAS_v1 was downregulated in HD patients since HTTAS_v1 with an 
expanded CTG repeat was not detected in HD brains (CHUNG et al., 2011). However, in chapter 
2 we did show HTTAS_v1 expression in human-derived fi broblasts homozygous for the CAG 
repeat expansion, suggesting that there is bidirectional transcription from the expanded CAG 
repeat, questioning the role of HTTAS in HTT regulation.
Altogether, these novel fi ndings suggest that in some triplet repeat disorders bidirectional 
transcription could potentially play a role in the disease pathology. On the other hand, for 
only two out of nine polyQ disorders antisense transcripts have been characterized thus far, 
questioning the signifi cance of bidirectional transcription in deregulation of sense transcripts 
and disease manifestation.
Other potential toxic entities in polyQ disorders
A major line of thinking with regard to polyQ disorder pathogenesis termed the ‘toxic 
fragment hypothesis’ concerns the proteolytic cleavage of polyQ expanded protein. This 
proteolytic cleavage is thought to lead to generation of short cytotoxic and aggregation-prone 
fragments containing the expanded polyQ repeat. Most research on the formation of toxic 
entities has been performed on HD, for which various rodent models expressing full-length or 
N-terminal mutant htt fragments have been generated (HENG et al., 2008). 
Recently, it was shown in various knock-in and transgenic HD mouse models that alternative 
splicing of HTT pre-mRNA results in a short HTT transcript with a stop codon in the beginning 
of intron 1 and a polyA tail 700 nucleotides into intron 1. This HTT exon 1-intron 1 transcript 
was shown to be translated into a short polyQ-containing htt protein of 216 amino acids (with 
150Qs) (SATHASIVAM et al., 2013). Interestingly, this aberrantly spliced transcript occurred in a 
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repeat-dependent manner, probably by altered binding of splicing factors to the expanded 
CAG repeat (SATHASIVAM et al., 2013). While this alternative splicing of HTT pre-mRNA is 
interesting, it is diffi cult to assess the importance of this fi nding. Although the authors showed 
the aberrantly spliced transcript in patient-derived fi broblasts, they could only detect this HTT 
exon 1-intron transcript in two out of four post-mortem HD brain tissues. Neither did they show 
protein data from human brain samples, suggesting low abundance of this short N-terminal 
polyQ fragment in HD brain tissue. Still, these results show that not only posttranslational 
modifi cation, but also gene expression alteration can generate short toxic N-terminal htt 
fragments. If this would be the main or sole pathogenic mechanism, this would mean that 
the removal of the 586 caspase-6 site from the full-length mutant htt protein as proposed 
in in chapter 4 would not be therapeutically benefi cial. On the other hand, the (CUG)7 AON 
described in chapter 3 would still prevent the formation of these short polyQ-containing htt 
protein fragments.
Other toxic entities resulting from reading frame shifting have been suggested to be involved 
in the polyQ disease pathogeneses. Next to expanded polyQ repeats, also polyA stretches 
occur in cells derived from HD and SCA3 patients (GASPAR et al., 2000; DAVIES AND RUBINSZTEIN, 
2006). These polyA stretches in the full-length ataxin-3 protein were toxic when overexpressed 
in D. melanogaster and neuronal cell models (STOCHMANSKI et al., 2012). Next to reading frame 
shifting, repeat associated non-ATG translation was recently also proposed as a novel class of 
protein toxicity, in which coding RNA transcripts with mutant CAG repeats are translated in the 
absence of an ATG start codon (ZU et al., 2011). This repeat associated non-ATG translation was 
found in all three possible CAG repeat reading frames, resulting in the translation of proteins 
with polyQ, polyA, and polyserine (polyS) repeats (ZU et al., 2011). However, these non-ATG 
translated htt and ataxin-3 proteins were only shown in artifi cial overexpression systems with 
low expression levels and their contribution to the polyQ disease pathology is as yet unclear.
To conclude, although most evidence points towards a toxic gain of polyQ protein fragments, 
novel toxic entities have been described that are potentially involved in the pathogenesis 
of polyQ disorders. These toxic proteins could be the result of aberrant splicing, proteolytic 
cleavage, reading frame shifting, or repeat associated non-ATG translation. On transcriptional 
level bidirectional transcription and CAG repeat-induced RNA toxicity could also be involved. 
Although extensive research is necessary to assess the relevance of these novel toxic entities, 
in many cases AON-mediated protein lowering approaches would still have an effect as they 
interfere with mRNA levels and compositions.
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6.4. Future direc  ons
There are several neurodegenerative disorders where AON-mediated therapies moved from 
preclinical to clinical testing during the course of this PhD research. All completed clinical trials 
on AON-mediated therapies into the CSF reported thus far have been successful and no major 
adverse events were reported (RIGO et al., 2012; MILLER et al., 2013). Although recent preclinical 
results using non-allele-specifi c, SNP-specifi c and CAG repeat-targeting oligonucleotides look 
promising (GRAHAM et al., 2006; ALVES et al., 2008; HU et al., 2009B; KORDASIEWICZ et al., 2012; 
OSTERGAARD et al., 2013), no trials of genetic therapies in polyQ patients have been done thus far. 
Modulating splicing in polyQ disorders 
In chapter 3 an allele-specifi c silencing is achieved based on the common denominator of 
al polyQ patients, being their expanded CAG repeat. A reduction of the mutant transcript is 
shown in fi broblasts derived from patients with DRPLA, HD, SCA1, and SCA3. Unfortunately 
for the other 5 polyQ disorders the allele-specifi c effect of the (CUG)7 AON could not be 
investigated, because no fi broblasts were available. Still, based on the mutant CAG repeat 
sizes of SBMA, SCA2, SCA7 and SCA17, it is expected that these can also be targeted by the 
(CUG)7 AON. For SCA6 this could be more complicated since the pathogenic repeat size starts 
at already 19 CAGs.
Next to targeting the mutant CAG repeat directly, chapter 5 describes removal of the CAG 
repeat-containing exon 10 from ATXN3 pre-mRNA in SCA3. Recently, it was also shown that 
a (CUG)7 single-stranded silencing RNA (ss-siRNA), comparable to the (CUG)7 AON described 
in chapter 3, resulted in exon skipping of ataxin-3 exon 10 (LIU et al., 2013). The (CUG)7 ss-
siRNA was found to mask exon 10 from the splicing machinery, resulting in the activation of 
a downstream stop codon and subsequently the formation of a shorter, C-terminus-lacking 
ataxin-3 protein. CAG repeat-containing exon skipping could hypothetically also be used for 
other polyQ disorders, except for HD, SBMA, SCA2 and SCA6, where the CAG repeat is located 
in the fi rst or last exon of the transcript. In SCA7 the CAG repeat is located in the third exon of 
ATXN7, which is the fi rst coding exon. In this case therefore, the activation of an alternative start 
3’of the CAG repeat codon would be necessary for the translation of a polyQ lacking ataxin-7 
protein. In SCA1 the CAG repeat is also located in the fi rst coding exon, however, the ATXN1 
transcript only consists of 2 coding exons, making exon skipping unsuitable. As explained 
in chapter 4 and 5, it could be necessary to use more AONs to remove additional exons to 
preserve the reading frame. To remove the CAG repeat in DRPLA and SCA17 this would mean 
skipping of two exons to induce translation of a modifi ed polyQ-lacking atrophin-1 and TBP. 
Chapter 4 describes a proof of concept for AON-mediated exon skipping to remove 
proteolytic cleavage motifs from the htt protein. Proteolytically processed polyQ fragments 
are implicated in toxicity of HD and other polyQ disorders (SHAO AND DIAMOND, 2007). Removal 
of these coding regions that code for the proteolytic cleavage site would ideally reduce the 
formation of toxic fragments. For SCA3 this would mean removal of ATXN3 exon 8 and 9 to 
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subsequently remove calpain and caspase cleavage sites from the ataxin-3 protein (WELLINGTON 
et al., 1998; BERKE et al., 2004; HUBENER et al., 2012). For DRPLA, it is preferred that the caspase-3 
cleavage site near the N-terminus of the protein is removed from the protein. This is encoded 
by exon 5 of the ATN1 gene (WELLINGTON et al., 1998; ELLERBY et al., 1999A). Skipping of exon 5, 
and exon 6 to maintain the reading frame, would result in the removal of both the proteolytic 
cleavage encoding region as well as the CAG repeat. The known caspase-3 cleavage motif in the 
AR is encoded by the fi rst exon (ELLERBY et al., 1999B) and therefore AON-mediated skipping of 
this caspase-3 motif-encoding exon is not an option as treatment for SBMA. For the remaining 
polyQ disorders proteolytic processing has been implicated in disease pathogenesis, but the 
exact proteases and motifs are thus far unknown and therefore no AON-mediated therapy to 
remove proteolytic cleavage motifs can be designed for those disorders.
Towards clinical trials of genetic therapies for polyQ disorders
Some disease-modifying drugs were successful in small studies to prevent or even slow 
down the progression of polyQ disorders. But none of them were shown to be effective in 
larger, randomised, double-blind, placebo-controlled trials. For example, drugs aiming at 
correcting mitochondrial dysfunction, such as coenzyme Q10, ethyl-eicosapentaenoic acid, 
and antihistamine latrepirdine, were shown not to improve cognition or global function in 
HD patients in phase III placebo-controlled trials (HUNTINGTON STUDY GROUP, 2001; HUNTINGTON 
STUDY GROUP TREND-HD INVESTIGATORS, 2008; HORIZON et al., 2013). Likewise, the dopamine 
neurotransmission-stabilizing molecule pridopidine, which was promising in phase II, did 
not result in improved motor score in HD patients in a phase III clinical trial (de Yebenes et 
al., 2011). A phase II/III clinical trial with lithium carbonate was recently carried out in SCA3 
patients. The mechanism of lithium is thought to rely on upregulation of autophagy, though 
anti-apoptotic effects have also been implicated (JIA et al., 2013). Due to the limited group size, 
this did not show a signifi cant effect on disease progression as determined by the neurological 
examination score for spinocerebellar ataxia (SAUTE et al., 2013).
For potential genetic therapies it would be best to start treatment before onset of clinical 
symptoms, before irreversible brain atrophy has occurred. Indeed, in symptomatic transgenic 
HD mice, AON treatment did not lead to a signifi cant phenotypical improvement, whereas 
treatment of younger mice did show disease reversal (KORDASIEWICZ et al., 2012). Yet after 
disease onset there seems to be a window of opportunity for AON treatments. In a conditional 
knockout model of SCA1 it was shown that removal of mutant ataxin-1 in 6 week old mice 
with mild motor defi cits and some aggregation in Purkinje cells resulted in complete disease 
reversal (ZU et al., 2004). Likewise, knockdown of mutant ataxin-1 in more severe 12 week old 
transgenic SCA1 mice with clear signs of ataxia and Purkinje cell atrophy a partial recovery was 
seen (ZU et al., 2004), suggesting (partial) disease reversal in later stages.
The full penetrance of the polyQ mutation in combination with the availability of predictive 
genetic testing at the age of 18 provides the opportunity to start treatment in presymptomatic 
polyQ patients. The disease stage prior to onset of (typically motor) symptoms is variably 
called the presymptomatic, premanifest, preclinical or prodromal stage. The stage in which 
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subtle symptoms can be identifi ed upon refi ned comparisons is called the prodromal stage. 
To assess the therapeutic benefi t of disease-modifying compounds in polyQ patients who 
do not yet manifest signs of illness, there is a need for sensitive and stable clinical endpoints, 
such as subtle cognitive or motor improvement, brain imaging, or disease-specifi c biomarkers. 
As example, for HD the unifi ed HD rating scale (UHDRS) is thus far used in clinical trials to 
show improvements on disease phenotype after disease-modifying drugs (HUNTINGTON STUDY 
GROUP, 1996), whereas for ataxias, the scale for the assessment and rating of ataxia (SARA) 
clinical scale has been developed as clinical measurement for trials (SCHMITZ-HUBSCH et al., 2006). 
However, available rating scales can only be reliably employed after onset of clinical symptoms 
and are therefore inadequate to assess therapeutic potency in presymptomatic polyQ patients. 
Likewise, both scales require a large number of patients to show a possible signifi cant effect of 
treatment, which is not always feasible for the rare polyQ disorders.
Recently, much effort has been put into characterizing the polyQ disease stage before onset 
of symptoms. For HD, two extensive longitudinal observational studies are ongoing (TABRIZI et 
al., 2013; BIGLAN et al., 2013). Half-term reports showed that various motor and cognitive task 
scores were signifi cantly decreased over 3 year period in presymptomatic HD individuals (TABRIZI 
et al., 2013). Combining these individual measurements into a multidimensional diagnosis may 
result in a more sensitive diagnosis of presymptomatic HD (BIGLAN et al., 2013). For the SCAs 1, 
2, 3, and 6 a prospective observational study has also been enrolled to defi ne presymptomatic 
disease stage. The fi rst baseline data from the RISCA showed mild coordination defi cits in 
SCA1 and SCA2 patients respectively 10 to 20 years before age of onset (JACOBI et al., 2013). 
Follow-up studies of this cohort will hopefully gain more biological and clinical characteristics 
for SCA patients. 
In summary, polyQ pathology can be measured long before the onset of clinical symptoms 
and preferably disease-modifying drugs such as AON-mediated therapeutics need to be 
administered in the presymptomatic stage to prevent polyQ-induced toxicity and with best 




This thesis proposes various novel genetic therapies for polyQ disorders, aiming at reducing 
and/or modifying polyQ disease-causing proteins. Since AONs are never 100% effective, it is 
likely that a combination of lowering mutant polyQ protein levels and modifying the remaining 
mutant polyQ protein will be the most optimal therapy for polyQ disorders. Future experiments 
in small rodents are required to evaluate whether AON-mediated treatment improves the 
polyQ induced phenotype. Furthermore, it will also be necessary to assess (1) whether the 
novel modifi ed normal proteins retain their function and localization, and (2) whether the 
novel modifi ed mutant proteins are less toxic and less aggregation-prone. Also the best route 
of administration to the brain, optimal dosage, and treatment regime needs to be determined.
The ultimate aim should of course be to cure patients, but a more realistic short-term 
objective would be to delay the age of onset or reduce the progression and thereby increase 
the quality of life for both polyQ patients and their families. Although extensive in vitro and 
in vivo research is required to rule out toxic off-target effects of the various AONs and the 
resulting modifi ed proteins, these preclinical AON-mediated treatments look promising. 
Hopefully this thesis will help in the quest to develop treatments for individuals with one of 
the polyQ disorders.
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Polyglutamine (polyQ) diseases are a group of nine neurodegenerative disorders, which are 
all caused by a CAG triplet repeat expansion, resulting in a gain of toxic polyQ protein function. 
The longer the CAG repeat, the earlier the disease manifestation and in most cases the disease 
onset is around midlife. Although the disorders have a monogenic cause and much research 
has been done the last decades, no therapies are available to cure or slow down the disease. 
In chapter 1 a short overview of the polyQ disorders and insight in the disease-causing 
polyQ proteins is given and their role in known disease mechanisms is described. The most 
prevalent and best studied polyQ disorders, being Huntington disease (HD) and spinocerebellar 
ataxia type 3 (SCA3), and the molecular biology of the disease causing proteins, huntingtin and 
ataxin-3, are extensively reviewed. 
Furthermore, the opportunities for genetic therapies for polyQ disorders are discussed, 
focussing on what can be learned from other neurodegenerative disorders of which genetic 
therapies are in development or already used as therapy. Small molecules, called antisense 
oligonucleotides, are broadly used as potential treatment for neurodegenerative diseases. 
According to the specifi c chemical modifi cations and target binding site of the antisense 
oligonucleotide, they can either reduce expression or modify polyQ disease-causing proteins. 
Furthermore, the limitations and possibilities of the delivery of antisense oligonucleotides to 
the brain and into the affected neuronal cells are discussed.
While much research has been done on the underlying polyQ disease mechanisms, 
knowledge on regulation and expression of mRNA and protein expression are limited. Chapter 
2 describes subtle differences in huntingtin mRNA and protein expression in HD. In adult-
onset HD less mutant huntingtin mRNA, but equal wild-type and mutant huntingtin protein 
levels are found. In juvenile HD subjects less mutant huntingtin protein compared to wild-
type huntingtin protein is present. This indicates differences in huntingtin protein expression 
between adult-onset and juvenile HD.
In chapter 3 CUG triplet-repeat antisense oligonucleotides are used to effectively reduce 
mutant polyQ transcript and protein levels in polyQ patient-derived fi broblasts. Although a 
reduction in wild-type CAG transcript levels was observed as well. This reduction was less 
pronounced than for the mutant transcript. Expression levels of other non-expanded CAG 
triplet repeat-containing transcripts investigated were not affected, verifying the specifi city 
of the CUG triplet repeat antisense oligonucleotide for the mutant transcript. Chapter 2 
describes that the basal levels of mutant huntingtin mRNA and mutant huntingtin protein 
are equal or lower when compared to wild-type. This provides feasibility for genetic therapies 
like the CUG triplet-repeat antisense oligonucleotide that are not completely specifi c for the 







Next to specifi cally targeting the expanded CAG repeat transcripts to reduce the translation 
of mutant polyQ protein, chapter 4 reports on removing the motifs that are implicated in 
the formation of toxic polyQ fragments. Soluble polyQ fragments, generated by proteolytic 
cleavage during the aggregation process, are considered to be the main toxic entities, resulting 
in neurodegeneration. In HD, removing a proteolytic cleavage site, implicated in the formation 
of huntingtin fragments containing the polyQ repeat has been shown to result in reduced 
toxicity. Chapter 4 describes a potential therapeutic approach of preventing the formation of 
toxic huntingtin polyQ fragments by antisense oligonucleotides that induce skipping of exon 
12 in huntingtin pre-mRNA. This antisense oligonucleotide-mediated protein modifi cation 
resulted in a huntingtin protein lacking disease-implied cleavage motifs and subsequently 
reduced formation of toxic huntingtin polyQ fragments. This proof of concept shows a 
completely novel approach to reduce mutant huntingtin toxicity not by reducing expressing 
levels, but by modifying polyQ protein.
A more direct genetic approach to reduce polyQ-induced toxicity is shown in chapter 5. 
Here antisense oligonucleotide-mediated exon skipping is used to remove the toxic polyQ 
repeat from the ataxin-3 protein. Two different approaches are proposed with the same 
aim: removal of the CAG repeat-containing exon. Both approaches result in the formation 
of modifi ed ataxin-3 protein that lacks the toxic polyQ repeat. The modifi ed ataxin-3 protein 
lacks only a small part and maintains important wild-type functions of the protein. 
The feasibility of the in chapter 4 and 5 described antisense oligonucleotides was tested 
in vivo by injections of antisense oligonucleotides directly into the brain of mice. The in vivo 
and in vitro data described in this thesis suggest that both targeting the CAG repeat directly 
and antisense oligonucleotide-mediated exon skipping are promising potential therapeutic 
approaches to reduce polyQ-induced toxicity in HD, SCA3 and other polyQ disorders.
In chapter 6 the main fi ndings from this thesis are summarized. Recent developments are 
described and refl ected how they relate to the results reported in this thesis. In addition, 
a refl ection is given on how to get to clinical trials of genetic therapies like antisense 
oligonucleotide-mediated treatments for polyQ disease patients. 
This thesis proposes various novel genetic therapies for polyQ disorders, aiming at 
reducing and/or modifying polyQ disease-causing proteins. Although extensive in vitro 
and in vivo research is important to rule out toxic off-target effects of the various antisense 
oligonucleotides and resulting modifi ed proteins, these preclinical antisense oligonucleotide-
mediated treatments look promising as therapeutic candidates for polyQ disorders.
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Polyglutamine (polyQ) ziekten is een groep van negen neurodegeneratieve aandoeningen 
die allen worden veroorzaakt door een verlengde CAG herhaling resulterend in een extra 
schadelijke polyQ eiwitfunctie. Hoe langer deze CAG herhaling, des te eerder de ziekte zich 
manifesteert. In de meeste gevallen begint de ziekte rond middelbare leeftijd. Hoewel alle 
polyQ ziekten veroorzaakt worden door een mutatie in één gen, en er de laatste decennia veel 
onderzoek gedaan is, zijn er tot dusverre geen therapieën beschikbaar die de ziekte genezen 
of vertragen. 
In hoofdstuk 1 wordt een kort overzicht gegeven van de polyQ aandoeningen en worden de 
ziekte-veroorzakende polyQ eiwitten en hun rol in de ziektemechanismen beschreven. De meest 
voorkomende en best bestudeerde polyQ aandoeningen, de ziekte van Huntington (ZvH) en 
spinocerebellaire ataxie type 3 (SCA3) en de moleculaire biologie van hun ziekteverwekkende 
huntingtine en ataxine-3 worden beschreven. 
Vervolgens zijn in hoofdstuk 1 de mogelijkheden voor genetische therapieën voor 
polyQ aandoeningen besproken, met de nadruk op wat kan worden geleerd van andere 
neurodegeneratieve aandoeningen waarvoor genetische therapieën in ontwikkeling zijn of 
al worden gebruikt als therapie. Kleine moleculen, zogenaamde antisense oligonucleotiden, 
worden algemeen gebruikt als potentiële behandeling voor neurodegeneratieve ziekten. 
Afhankelijk van de specifi eke chemische modifi caties en plaats waarop het bindt kunnen 
antisense oligonucleotiden de expressie verlagen of polyQ eiwitten modifi ceren. De 
beperkingen en mogelijkheden van de toediening van antisense oligonucleotiden in de 
hersenen en het bereiken van de getroffen zenuwcellen wordt besproken.
Ondanks het vele onderzoek naar de onderliggende polyQ ziektemechanismen, blijft de 
kennis over regulering en expressie van mRNA en eiwit beperkt. Hoofdstuk 2 beschrijft subtiele 
verschillen in huntingtine mRNA en eiwit expressie in ZvH. In volwassen ZvH is iets minder 
mutant huntingtine mRNA, maar gelijke hoeveelheden wild-type en mutant huntingtin eiwit 
hoeveelheden gevonden. Juveniele ZvH proefpersonen vertoonden minder mutant huntingtin 
eiwit vergeleken met wild-type huntingtine eiwit. Dit duidt op verschillen in huntingtine 
eiwitexpressie tussen volwassen ZvH en juveniel ZvH.
In hoofdstuk 3 worden CUG triplet antisense oligonucleotiden gebruikt om, in van polyQ 
patiënten verkregen fi broblasten, specifi ek mutant polyQ transcripten en eiwit te verminderen. 
Een vermindering van wild-type CAG transcript niveaus werd ook waargenomen, maar deze 
afname was minder opvallend dan voor het mutant mRNA. Andere niet verlengde CAG 
triplet bevattende transcripten waren niet verminderd, wat de specifi citeit van de CUG triplet 
antisense oligonucleotide voor het mutant mRNA bevestigt. Hoofdstuk 2 beschrijft dat de 
basale niveaus van mutant huntingtin mRNA en mutant huntingtine eiwit gelijk of lager zijn 
in vergelijking met wild-type. Dit bevestigt de potentie van gentherapieën die niet geheel 







Naast het doelgericht aanpakken van verlengde CAG triplet transcripten om de translatie 
van mutant polyQ eiwit te verminderen, beschrijft hoofdstuk 4 het verwijderen van motieven 
die betrokken zijn bij de vorming van toxische polyQ fragmenten. Tijdens het aggregatieproces 
worden oplosbare polyQ fragmenten gegenereerd door het proteolytisch knippen van 
volledige polyQ eiwitten. Deze polyQ fragmenten worden beschouwd als de belangrijkste 
schadelijke entiteiten voor het ontstaan van neurodegeneratie. In de ZvH is reeds aangetoond 
dat het verwijderen van een proteolytische knipplaats, wat betrokken is bij de vorming van 
huntingtine polyQ fragmenten, leidt tot verminderde toxiciteit. Hoofdstuk 4 beschrijft een 
mogelijke therapeutische benadering door middel van antisense oligonucleotiden die ervoor 
zorgen dat exon 12 uit het huntingtine mRNA verwijderd wordt. Deze antisense oligonucleotide 
geïnduceerde eiwitmodifi catie resulteert in een huntingtine eiwit wat de knipplaats mist en wat 
vervolgens leidt tot verminderde vorming van toxische huntingtine polyQ fragmenten. Deze 
eerste studie beschrijft een compleet nieuwe aanpak voor het verminderen van de toxiciteit 
van mutant huntingtine door niet de expressieniveaus te verminderen, maar door het polyQ 
eiwit te modifi ceren.
Een meer directe genetische benadering om de polyQ geïnduceerde toxiciteit te verminderen 
is in hoofdstuk 5 beschreven. Hier wordt het verwijderen van de toxische polyQ herhaling uit 
het ataxine-3 eiwit door middel van het verwijderen van exonen met behulp van antisense 
oligonucleotiden beschreven. Twee verschillende benaderingen werden aangedragen 
met hetzelfde doel, het verwijderen van het verlengde CAG triplet bevattende exon. Beide 
benaderingen resulteren in gemodifi ceerd ataxine-3 eiwit wat de toxische polyQ verlenging 
mist. Het gemodifi ceerde ataxine-3 eiwit mist slechts een klein deel en behoudt belangrijke 
wild-type functies van het eiwit.
De haalbaarheid van de in hoofdstuk 4 en 5 beschreven antisense oligonucleotiden is in vivo 
aangetoond door antisense oligonucleotiden direct in de hersenen van muizen te injecteren. 
De in dit proefschrift beschreven in vivo en in vitro resultaten suggereren dat antisense 
oligonucleotiden gericht tegen de verlengde CAG triplet rechtstreeks en het verwijderen van 
exonen veelbelovende therapeutische benaderingen zijn om de polyQ geïnduceerde toxiciteit 
te verminderen in de ZvH, SCA3 en andere polyQ aandoeningen.
In hoofdstuk 6 zijn de belangrijkste bevindingen van dit proefschrift samengevat. Recente 
ontwikkelingen worden beschreven en gerelateerd aan de verkregen resultaten beschreven 
in dit proefschrift. Daarnaast wordt er een blik in de toekomst geworpen hoe voor polyQ 
patiënten klinische studies met genetische therapieën zoals antisense oligonucleotiden 
behandelingen op te zetten.
Dit proefschrift beschrijft enkele nieuwe genetische therapieën voor polyQ aandoeningen 
welke gericht zijn op het verminderen en/of modifi ceren van polyQ ziekte-veroorzakende 
eiwitten. Hoewel uitgebreid in vitro en in vivo onderzoek nodig is om toxische bijwerkingen 
van de verschillende antisense oligonucleotiden en de resulterende gemodifi ceerde eiwitten 
uit te sluiten, zijn deze preklinische antisense oligonucleotide behandelingen veelbelovend als 
mogelijke therapeutische behandelingen voor polyQ aandoeningen.
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List of abbrevia  ons
AAV adeno-associated virus
AD Alzheimer disease
ALS amyotrophic lateral sclerosis
AON antisense oligonucleotide






BBB blood brain barrier
BDNF brain-derived neurotrophic factor
CA1 Cornu ammonis area 1
CACNA1A alpha 1A subunit of the voltage-dependent P/Q type calcium channel (CaV2.1)
CBP cAMP response element-binding protein binding protein
CELF2 CUGBP, Elav-like family member 2
cET ethyl nucleic acid
CNS central nervous system
CSF cerebrospinal fl uid
DM1 myotonic dystrophy-1
DMD Duchenne muscular dystrophy
DMPK dystrophia myotonica protein kinase
DRPLA dentatorubro-pallidoluysian atrophy
EA-2 episodic ataxia type-2
ER endoplasmic-reticulum
ERAD endoplasmic-reticulum-associated protein degradation
ESE exonic splicing silencer
FHM familial hemiplegic migraine
FMRP fragile X mental retardation protein
FOXO forkhead box O (FOXO) transcription factor
FXTAS fragile X-associated tremor/ataxia syndrome
gDNA genomic DNA













hHR23 human homologues of yeast protein RAD23




ISS intronic splicing silencer
LNA locked nucleic acid







NCoR1 nuclear receptor co-repressor
NES nuclear export signal
NLS nuclear localisation signal
PCAF p300/CBP-associated factor
PMO phosphorodiamidate morpholino oligomer




PPMO peptide-linked phosphorodiamidate morpholino oligomer
PS phosphorothioate
qRT-PCR quantitative real-time polymerase chain reaction
REST RE1 silencing transcription factor
RNase H ribonuclease H
RT-PCR reverse transcription polymerase chain reaction
SARA scale for the assessment and rating of ataxia
SBMA bulbar muscular atrophy
SCA spinocerebellar ataxia
SCAANT1 SCA7 antisense noncoding transcript 1
shRNA short hairpin RNA
siRNA small interfering RNA
SLiC SNP linkage by circularization
SMA spinal muscular atrophy
SMN survival motor neuron
SNP single nucleotide polymorphism
SOD1 superoxide dismutase 1
ss-siRNA single-stranded silencing RNA
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TAF4 TBP-associated factor 4
TARDBP TAR DNA-binding protein
TBP TATA box-binding protein
UHDRS unifi ed Huntington disease rating scale




YAC yeast artifi cial chromosome
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